

University of New Orleans
ScholarWorks@UNO

University of New Orleans Theses and
Dissertations

Dissertations and Theses

Summer 8-13-2014

Synthesis and Biological Evaluation of N-heterocycles for Activity on Monoamine Transporters and Exploration of Iridium Chemistry for Synthesis of Medicinally Important Molecules

Tushar D. Apsunde
University of New Orleans, tapsunde@uno.edu

Follow this and additional works at: <https://scholarworks.uno.edu/td>

 Part of the [Medicinal-Pharmaceutical Chemistry Commons](#), and the [Organic Chemistry Commons](#)

Recommended Citation

Apsunde, Tushar D., "Synthesis and Biological Evaluation of N-heterocycles for Activity on Monoamine Transporters and Exploration of Iridium Chemistry for Synthesis of Medicinally Important Molecules" (2014). *University of New Orleans Theses and Dissertations*. 1862.
<https://scholarworks.uno.edu/td/1862>

This Dissertation is protected by copyright and/or related rights. It has been brought to you by ScholarWorks@UNO with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/or on the work itself.

This Dissertation has been accepted for inclusion in University of New Orleans Theses and Dissertations by an authorized administrator of ScholarWorks@UNO. For more information, please contact scholarworks@uno.edu.

Synthesis and Biological Evaluation of N-Heterocycles for Activity on Monoamine Transporters
and Exploration of Iridium Chemistry for Synthesis of Medicinally Important Molecules

A Dissertation

Submitted to the Graduate Faculty of the
University of New Orleans
In partial fulfillment of the
requirements for the degree of

Doctor of Philosophy
In
The Department of Chemistry

by

Tushar Dattu Apsunde

M. S. National Institute of Pharmaceutical research and education, Mohali 2007

M. S. University of New Orleans 2013

August 2014

ACKNOWLEDGMENTS

I would like to express sincere gratitude to my research advisor, Professor Mark L. Trudell for his guidance, support and encouragement throughout the period of my study and research. I would also like to thank my committee members, Professor Branko Jursic, Professor Steven Rick and Professor Dhruva Chakravorty.

In addition, I would like to acknowledge Dr. Ananthakrishnan Sankaranarayanan for his guidance and support in research of ion channel blockers. I would also like to thank Dr. Sari Izenwasser and Dean Wade from University of Miami for the biological tests included in this dissertation.

I wish to express many thanks and appreciation to my friends and family for their support and encouragement in my research. I would also like to thank Dr. Wurz Ryan (Senior Scientist, Amgen Inc.) and Prof. Vipin Nair (Professor, NIPER Mohali).

I would like to acknowledge Louisiana Board of Regents (Support fund-Contract LEQSF (2009-12)-RD-A-26), University of New Orleans and the National Institute of drug Abuse (DA11528) for providing the funding for the research.

Table of Contents

List of Tables.....	vi
List of Schemes.....	vi
List of Figures.....	vii
Abstract.....	ix
Chapter 1: Design, synthesis and evaluation of novel piperidine derivatives for monoamine transporter affinity	1
1.1. Abstract	1
1.2. Introduction.....	1
1.3. Design of new Pharmacophore.....	16
1.4. Objectives.....	17
1.5. Results and Discussion	19
1.6. Conclusion	22
1.7. Experimental	23
1.8. References.....	69
Chapter 2: Design, synthesis and pharmacological evaluation of 3-aryl-3-aryl pyrrolidines as monoamine transporter ligands.....	74
2.1. Abstract	74
2.2. Introduction.....	74
2.3. Results and discussion	75
2.5. Conclusion	78
2.6. Experimental	78
2.7. References.....	105
Chapter 3. Application of Iridium catalyzed N-heterocyclization for synthesis of Natural products.....	106

3.1. Abstract	106
3.2. Introduction	106
3.3. Pyridine alkaloids	107
3.4. Application of iridium catalysis	108
3.5. Results and discussion	110
3.6 Conclusion	116
3.7. Experimental	116
3.8. References	129
Chapter 4: Solvent free, base free microwave mediated iridium catalyzed N-alkylation of amides with alcohols	131
4.1. Abstract	131
4.2. Introduction	131
4.3. Result and discussion	133
4.4. Conclusion	141
4.5. Experimental	141
4.6. References	154
VITA	158

LIST OF TABLES

CHAPTER 1

Table 1.1. Preliminary Binding studies

CHAPTER 2

Table 2.1. Final pyrrolidine derivatives

CHAPTER 3

Table 3.1. Optimization of the N-Heterocyclization Reaction

Table 3.2. Synthesis of nor-nicotine derivatives

CHAPTER 4

Table 4.1. Reaction optimization for N-alkylation of benzamide with benzyl alcohol

Table 4.2. Reaction of variety of amides with various substituted primary alcohols

Table 4.3. Reaction of benzamide with secondary alcohols

LIST OF SCHEMES

CHAPTER 1

Scheme 1.1. Synthesis of intermediates **24a-24d**

Scheme 1.2. Synthesis of intermediates **26aa-26di**

Scheme 1.3. Synthesis of final compounds **27aa-27di**

CHAPTER 2

Scheme 2.1. Synthesis of Boc-pyrrolidin-3-one

Scheme 2.2. Synthesis of tert-alcohol using aryl lithium

Scheme 2.3. Alkylation of tert-alcohol using substituted benzyl bromides.

Scheme 2.4. Deprotection of Boc-group from tert-amine

CHAPTER 3

Scheme 3.1. N-alkylation of primary amines with primary alcohol

Scheme 3.2. N-heterocyclization of amines with alcohols using iridium catalyst

Scheme 3.3. Synthesis of 1, 4 and 1, 5- pyridine diols

Scheme 3.4. Synthesis of quinoline butan-1, 4-diol

Scheme 3.5. Development of method

Scheme 3.6. Synthesis of N-substituted nor-nicotine derivatives

Scheme 3.7. Synthesis of Nicotine from its N-benzyl derivative

CHAPTER 4

Scheme 4.1. N-alkylation of primary amides with primary alcohol using iridium catalysis

Scheme 4.2. N-alkylation of primary amides using primary alcohol with Ruthenium catalysis

Scheme 4.3. N-alkylation of primary amides using primary alcohol with copper catalysis

Scheme 4.4. Development of methodology

Scheme 4.5. Reaction of variety of amides with various substituted primary alcohols

Scheme 4.6. Reaction of benzamide with secondary alcohols

LIST OF FIGURES

CHAPTER 1

Figure 1.1. Illicit drug use profile in USA

Figure 1.2. Cocaine (1) and Methamphetamine (2)

Figure 1.3. Mechanism of cocaine action on the dopamine transporter

Figure 1.4. Mechanism of METH action

Figure 1.5. Dopamine agonist

Figure 1.6. Selective serotonin uptake inhibitors (SSRIs) - fluoxetine (**5**), paroxetine (**6**)

Figure 1.7. Meperidine analogues

Figure 1.8. GBR 12909 (**11**) and GBR-benztropine hybrid analogue (**12**)

Figure 1.9. 3-ethylidenyl-8-azabicyclo-[3.2.1] octane derivative (**13**) and Tropane congener (**14**)

Figure 1.10. 3-diarylmethoxymethyl-8-arylalkyl-8-azabicyclo [3.2.1] oct-2-ene (**15**) and its saturated analogues (**16**)

Figure 1.11. Design of Pharmacophore 1

Figure 1.12. Design of Pharmacophore 2

Figure 1.13. Radiolabelled ligands for the transporters for the binding studies

CHAPTER 2

Figure 2.1. Design of pyrrolidine pharmacophore

Figure 2.2. Radiolabelled ligands for the transporters for the binding studies

CHAPTER 3

Figure 3.1. Pyridine alkaloids- Nicotine derivatives

Figure 3.2. Mechanism of iridium catalysis

Figure 3.3. Quinoline analogue of Benzyl-nornicotine

Abstract

The focus of these studies was directed towards the synthesis of novel N-heterocyclic compounds and pharmacological evaluation of these compounds for activity at monoamine transporters. A series of novel piperidine and pyrrolidine analogues were prepared from commercially available starting material with a three and four step synthetic method, respectively. A variety of substituents on the aromatic ring were incorporated to achieve a diverse library of compounds. The preliminary binding studies of piperidine molecules showed strong affinity towards serotonin transporters and moderate affinity towards dopamine transporters. The focus of further studies was directed towards utilization of iridium catalysis for the development of new synthetic methods for biologically important molecules. This research has led to the development of a new synthetic strategy for the construction of nicotine and its analogues. In addition, the iridium catalysis was also used for alkylation of amides with primary and secondary alcohols under microwave conditions.

Key words: Dopamine, Serotonin, Methamphetamine, Cocaine, Iridium, *N*-Heterocyclization, Catalysis, Microwave, Nicotine, *N*-Alkylation

Chapter 1: Design, synthesis and evaluation of novel piperidine derivatives for monoamine transporter affinity

1.1. Abstract

In an effort to search for potential therapeutic agents for methamphetamine addiction, a novel class of compounds was synthesized and evaluated for *in vitro* dopamine and serotonin transporter affinities. These unique 4 β -aryl-4 α -arylmethoxypiperidine analogues incorporated the structure of previously designed dual monoamine transporter selective 3 β -aryl-3 α -arylmethoxytropane and serotonin selective meperidine derivatives.

The short three step methodology was developed for the synthesis of the target compounds. To study the effect of substitution of aryl group on dopamine and serotonin affinity, we substituted various derivatives with electron-donating, electron-withdrawing and halogen groups on the aryl ring. All the compounds were tested for affinity for dopamine and serotonin transporters by ability of these compounds to displace natural radiolabeled ligands from the transporters.

1.2. Introduction

Psychostimulants

Cocaine (**1**) and amphetamines are the most common illicit stimulants among drug abused individuals. According to data from the 2012 National Survey on Drug Use and Health (NSDUH), over 12 million people (4.7 percent of the population) have tried methamphetamine at least once. NSDUH also reports that approximately 1.2 million people used methamphetamine in the year leading up to the survey. The number of people who abused methamphetamine for the first time in the past year has increased by 62% from 2008 to 2009.¹ Since then, there has been

little deviation from this level of psychostimulant abuse. The U.S. Department of Justice's National Drug Threat Assessment continues to report that total 82% of state and local agencies in the Western states perceive methamphetamine and cocaine as their greatest drug threat (**Figure 1.1**).²




Figure 1.1. Illicit drug use profile in USA.²

Cocaine and Methamphetamine

Cocaine (1), (**Figure 1.2**) (street name: *Coke, snow, flake, blow*) is a tropane alkaloid that is obtained from the leaves of *Erythroxylum coca* plant. The genus *Erythroxylum* contains about 250 species and many of the members produce cocaine.³ The amount of cocaine in the plant is less than 1%. It is a weakly alkaline compound (an "alkaloid"), and can therefore combine with acidic compounds to form various salts. Cocaine hydrochloride in its purest form is a white, crystalline product.³




Figure 1.2. Cocaine (1) and Methamphetamine (2)

As a psychostimulant, methamphetamine (2) (**Figure 1.2**) (METH) (street name: *Speed, meth, chalk, ice, crystal, glass*) differs significantly from cocaine. METH is a phenyl-ethyl-amine and a member of the amphetamine class of psychostimulants. Methamphetamine can be readily synthesized by reduction of commercially available ephedrine or pseudoephedrine found in over the counter cold and allergy medicines.⁴ It is a white, odorless, bitter-tasting powder which dissolves in water or alcohol. METH was developed early last century from its parent drug, amphetamine, and was used originally as a nasal decongestant and in bronchial inhalers. Methamphetamine causes increased activity, decreased appetite and a general sense of well-being. In high concentration, high levels of methamphetamine get into the brain, making it a more potent stimulant drug with long lasting and harmful effects on the central nervous system. METH is a Schedule 2 stimulant, which means it is a drug that has been classified for having a

high potential for being abused, and it is available only by prescription. It is prescribed for the treatment for narcolepsy and attention deficit hyperactivity disorder but these medical uses are limited, and the doses prescribed are much lower than those typically abused. METH can exist in two enantiomeric forms, dextrorotatory and levorotatory. The (*d*)-methamphetamine elicits the psychostimulant effects of the drug, while levo form is inactive on central nervous system (CNS).³

Physiological effects of METH

Methamphetamine causes anorexia, hyperactivity, dilated pupils, flushed skin, excessive sweating, restlessness, dry mouth and bruxism, diarrhea, and constipation. In high doses, METH can cause convulsions, stroke, heart attack and death.⁵ Withdrawal symptoms of methamphetamine primarily consist of fatigue, depression, and increased appetite. Symptoms may last for days with occasional use, and weeks or months with chronic use. The severity is dependent on the length of time and the amount of methamphetamine used. Withdrawal symptoms may also include anxiety, irritability, headaches, agitation, restlessness, excessive sleep, vivid or lucid sleep, deep REM sleep and suicidal ideation.^{3,5}

Pharmacological actions of METH

Important differences exist between the neuropharmacological mechanisms of action of cocaine and METH. Cocaine mediates its effects at monoamine transporters. The stimulant and reinforcing effects of cocaine are primarily associated with the blockade of dopamine reuptake (Figure 1.3).^{4,6}

Cocaine binds to dopamine re-uptake transporters on the pre-synaptic membranes of dopaminergic neurones. This binding inhibits the removal of dopamine from the synaptic cleft and its subsequent degradation by monoamine oxidase in the nerve terminal. Dopamine remains in the synaptic cleft and is free to bind to its receptors on the post synaptic membrane, producing further nerve impulses. This increased activation of the dopaminergic reward pathway leads to the feelings of euphoria and the ‘high’ associated with cocaine use (**Figure 1.3**).




Figure 1.3. Mechanism of cocaine action on the dopamine transporter⁷

Alternatively, the mechanism of action of METH appears to be more complex. METH is a neurotransmitter releaser, triggering the release of monoamine neurotransmitters (dopamine,

serotonin, and norepinephrine) via the corresponding transporter system in the brain. At high doses, METH increases the concentration of dopamine in the synaptic cleft in 4 ways: (1) it can bind to the pre-synaptic membrane of dopaminergic neurons and induce the release of dopamine from the nerve terminal; (2) It can interact with dopamine containing synaptic vesicles, releasing free dopamine into the nerve terminal; (3) It can bind to monoamine oxidase in dopaminergic neurons and prevent the degradation of dopamine, leaving free dopamine in the nerve terminal; and (4) It can bind to the dopamine re-uptake transporter, causing it to act in reverse and transport free dopamine out of the nerve terminal. High-dose amphetamine has a similar effect on noradrenergic neurons; it can induce the release of noradrenaline into the synaptic cleft and inhibit the noradrenaline re-uptake transporter (**Figure 1.4**).

Releasers and uptake inhibitors have dissimilar outcomes at the synapses.⁶ Although both mechanisms increase synaptic neurotransmitter concentrations, releasers produce larger increases in extracellular neurotransmitter concentration. Moreover, the increased concentration effects are not regulated by neurotransmitter autoreceptor mechanisms. Thus releasers and uptake inhibitors produce significantly different cellular responses.⁴




Figure 1.4. Mechanism of METH action⁸

It has long been the assumption that disruption of dopaminergic circuitry is the primary mechanism of action of METH. Post-mortem studies of METH-users have shown that striatal (caudate and putamen) dopamine levels are severely depleted, suggesting that METH can cause release of stored dopamine in sufficient amounts to deplete tissue stores of the neurotransmitter.^{6,7} In addition, it has been reported that striatal concentrations of the dopamine transporter (DAT) in the post-mortem brains of METH-users are significantly decreased. In

contrast to dopamine, serotonin depletion is not observed to the same extent. However, recent positron emission tomography (PET) imaging studies indicate significant loss of the serotonin transporter (SERT) in both cerebral cortical and sub-cortical brain regions of chronic METH-users. Furthermore, the extent of the SERT binding decrease was more severely affected than the corresponding DAT binding or that reported for SERT in chronic users of ecstasy i.e. (3, 4-methylenedioxymethamphetamine (MDMA) a known serotonergic hallucinogen. These results are consistent with the behavioral effects associated with METH exposure (e.g., problems in cognition and aggression) and could well be explained by a disruption of serotonergic circuitry.

Treatment of METH dependence

To date there is no pharmacological therapy for METH-dependence or the adverse side effects associated with craving and withdrawal. A variety of medications have been investigated as potential treatment strategies, however, none have been identified as having significant promise.¹⁰

Dopamine agonists

Some modest success with dopamine agonist bupropion (**3**) has been reported.^{4, 11} Bupropion was reported to reduce METH use among “light “abusers but was not effective against “heavy” METH-users. Alternatively, modafinil (**4**) showed no clear evidence of efficacy in reducing METH use.¹² In addition, other clinical trials have shown that the dopamine partial agonist aripirizole (**5**) and GABAergic agent gabapentin (**6**) exhibited no efficacy toward reduction of METH-use (**Figure 1.5**).^{13, 14}




Figure 1.5. Dopamine agonists

Selective serotonin reuptake inhibitors

Studies have shown that some selective serotonin uptake inhibitors (SSRIs, e.g., fluoxetine (7), paroxetine (8)) block the effects of METH in animals,^{15, 16} but clinical studies with SSRIs have been much less promising.^{15, 17-19} Recent clinical findings have indicated that treatment of chronic METH-users with the SSRI sertraline (9) resulted in sustained METH-craving and an elevated likelihood of relapse (**Figure 1.6**).²⁰




Figure 1.6. Selective serotonin uptake inhibitors (SSRIs) - fluoxetine (7), paroxetine (8), Sertraline (9)

It is clear from the studies above that new medications are needed for METH–cessation. Currently available medications that have application to other abused substances fall short of being effective in treating the complex pharmacology of METH addiction.

Dual acting DAT/SERT approach

To date there is mounting evidence that in addition to dopaminergic systems, brain serotonergic systems also modulate responses in cocaine-induced behaviors and to a greater extent in methamphetamine-induced behaviors.²¹ However, it has become evident that a single dopaminergic or serotonergic agent cannot adequately attenuate the behavioral effects associated with psychostimulant abuse. The abuse liability of selective dopaminergic agents has diminished enthusiasm for an agonist based approach to medication development and clearly SSRIs have not been effective in the clinic. However, it has been suggested that the development of an appropriately calibrated dual acting DAT/SERT agent may be more effective as a medication than a singularly selective transporter agent. For METH addiction, a dual acting DAT/SERT agent could be used to attenuate the reinforcing effects while providing protection from the psychotic effects associated with METH cessation.²¹⁻²³

Based on the pharmacological evidence presented, it is clear that attenuation of dopaminergic and serotonergic pathways can affect the behaviors associated with METH abuse and addiction. However the question remains: What level of attenuation is required of each monoaminergic system to positively modify the behavioral effects of METH abuse? We believe that the proper balance of dopaminergic/serotonergic (and noradrenergic) reuptake inhibition can restore the monoaminergic tone of METH disrupted neuronal systems and lead to diminished craving, psychosis, depression and other symptoms of withdrawal.

Based on that approach in the past, our laboratory has focused upon the structure activity

relationships of meperidine (**10**) and related molecule. From the SAR of the meperidine derivatives and WIN analogues (**11**), it was found that the 3, 4-dichlorophenyl group is important moiety for the molecular recognition at the DAT.²⁴ Moreover, meperidine is more selective for the serotonin transporter over the dopamine transporter. Studies on aryl substituted meperidine analogues revealed that dopamine transporter affinity of these could be enhanced with predominant SERT activity. This effect of aryl substitution on the DAT affinity of meperidine analogues is paralleled with the SAR for reported tropane analogues and piperidine analogues. However unlike these piperidine and tropane analogues that are DAT selective 3, 4-dichloromeperidine (**12**), exhibit high potency at the SERT ($K_i = 19\text{nM}$) and was slightly SERT-selective (DAT/SERT=6.7) (**Figure 1.7**).²⁵




Figure 1.7. Meperidine analogues

Our group explored the structure activity relationships of 3, 4-dichloromeperidine analogues (**13**) at dopamine and serotonin transporters. It was found that chemical modification of the ester group generally led to compounds with increased SERT activity. The benzyl ester (**13b**) was

found to be the most potent and most selective ligand of this study.²⁶

The disubstituted piperazine GBR 12909 (**14**) is a selective high affinity dopamine transporter ligand and a selective dopamine uptake inhibitor. The behavioral studies with GBR 12909 and related derivatives have shown potential for the development of an agonist based medicinally important molecule for the cocaine addiction. GBR 12909 exhibited slower onset and duration of action than cocaine while possessing much higher affinity for the DAT with slower dissolution rate. It also shown to antagonize the cocaine induced elevation of extracellular dopamine levels, The favorable pharmacological profile of GBR 12909 resulted to in-vivo studies that demonstrated its ability to suppress the cocaine self-administration behavior in rhesus monkeys, and exhibit non stimulant properties in humans. Although the development of GBR 12909 as cocaine medication was halted after phase I, human safety studies identified problematic cardiovascular effects. Due to the unique pharmacological profile of GBR 12909, it has served as a template for the synthesis of high affinity selective dopamine transporter ligands. The further results showed that the piperazine ring is not necessary for the affinity of GBR 12909 for the dopamine transporters. The tropane and piperidine based derivatives of the GBR 12909 have been also found to exhibit moderate to high affinity for the DAT with improved selectivity over the serotonin transporter (**Figure 1.8**).²⁷





Figure 1.8. GBR 12909 (**14**) and GBR-benztropine hybrid analogue (**15**)

Rice and coworkers have reported the GBR-benztropane analogue (**15**) was found to be selective for DAT. The pharmacological profile of **15** was found to be more like the GBR compounds than benztropine.¹⁹ Further, our laboratories have synthesized 3-(2-(diarylmethoxyethylidene)-8-alkyl-aryl-8-azabicyclo[3.2.1]octane analogues and the dopamine transporter affinity was determined. The ethylidene analogues exhibited higher selectivity for binding at the DAT over the SERT, with **16** nearly 10-fold more selective than GBR-12909. It was evident from studies that 3-ethylidenyl-8-azabicyclo[3.2.1]octane ring system is an important structural feature for selective molecular recognition at the DAT. This compound also exhibited similar potency as that of corresponding 3 α -tropane congeners **15** but were significantly more selective for the DAT than **18**. The structure-activity relationship studies of **16** and related tropane analogues, suggest that the high selectivity of **16** resulted from either the rigid conformation of 3-ethylidenyltropane ring system or the stereochemical effects imparted by unsaturation at C3. (**Figure 1.9**).²⁸




3-ethylidenyl-8-azabicyclo[3.2.1]octane derivative (**16**)


Tropane congener (**17**)

Figure 1.9. 3-ethylidenyl-8-azabicyclo[3.2.1]octane derivative (**16**) and Tropane congener (**17**)

Our group investigated the effects of unsaturation and stereochemistry at C3 of these tropane-GBR 12909 hybrid analogues on DAT and SERT binding affinities. For investigation of this effect, our group designed and synthesized a series of 3-diarylmethoxymethyl-8-arylalkyl-8-azabicyclo [3.2.1] oct-2-enes (**18**). Furthermore, to address the question of stereochemical proximity effects of the benzhydryl ether moiety relative to DAT affinity, the 3 α - and 3 β -diarylmethoxymethyl-8-alkylaryl-8-azabicyclo-[3.2.1]-octane derivatives were synthesized (**19**) (**Figure 1.10**).²⁸



3-diarylmethoxymethyl-8-arylalkyl-8-azabicyclo [3.2.1] oct-2-ene (**18**)



Diarylmethoxymethyl-8-alkylaryl-8-azabicyclo [3.2.1] octane (**19**)


Figure 1.10. 3-Diarylmethoxymethyl-8-arylalkyl-8-azabicyclo [3.2.1] oct-2-ene (**18**) and its saturated analogues (**19**)

It was found that diarylmethoxytropane analogues exhibited similar DAT structure activity to that of 3 α -diarylmethoxyethyl and 3-diarylethylidienyltropane analogues. The results suggested that conformational strain imparted by unsaturation at C3 is important for selectivity at the dopamine transporter over the serotonin transporter. This is supported by SAR of 3 α -isomers in this series, which despite the reduced ether length between benzhydryl ether moiety and the tropane ring system exhibited similar DAT binding affinity to the 3-arylmethoxyethylidinyltropanes but were less selective for DAT over SERT. The compounds with 3 α -stereochemistry were not as well accommodated by transporter constraints for potent molecular recognition.^{27,28}

Our efforts to develop a novel scaffold for targeting monoamine transporter systems have led to the development of several class of DAT and SERT ligands. There have been a number of reports that describe 3-aryltropane derivatives exhibiting high affinity and selectivity for the DAT.²⁸ Furthermore, we also have reported on a series of piperidine derivatives that exhibit affinity and selectivity for SERT. Our group has devised a new pharmacophore by merging these two classes of molecules. Furthermore, the arylmethoxy moiety was also included which is common in many of the prototypical SSRIs and SNRIs.^{30,31}

The designed 3-arylmethoxy-3-aryltropane pharmacophore by merging two pharmacophore found active on DAT and SERT. It has showed SERT selectivity and exhibited high affinity for the SERT. The monochloro derivative exhibited good affinity for all three transporters. However, high lipophilicity of these compounds precluded its progress to further development into clinical trials. The 3-arylmethoxy-3-aryltropanes was a unique class of monoamine transporter ligands that possess tunable affinity for dopamine and serotonin transporters.³² This prompted us a broader examination of the structure-activity relationships of this molecular

scaffold in search of compounds with dual affinity for dopamine and serotonin transporters. It was of interest to explore condensed ring systems that would accommodate the pharmacophore requirements while reducing the overall molecular weight and lipophilicity inherent to the tropane derivatives (**Figure 1.11**).³²



Pharmacophore 1

Figure 1.11. Design of Pharmacophore 1

Recently, In order to devise novel molecular scaffolds targeting monoamine transporters, our group has identified the condensed ring system with low molecular weight and lipophilicity, 3-arylmethoxy-3-arylazetidines as viable targets for the synthesis and biological evaluation at monoamine transporters. It was found that the arylazetidines exhibited high affinity for the SERT and were generally selective for the SERT over the DAT. However, it was also clear that the DAT affinity can be improved with proper substitution of the 3-aryl group.³³

1.3. Design of new Pharmacophore

In search of a new pharmacophore we decided to merge structural characteristics of **Pharmacophore 1** and piperidine derivatives (which have been found to be active at SERT). Given the similar structural characteristics of these two classes of molecules it was of interest to explore the possibility of merging the two pharmacophores to develop a class of monoamine

transporter ligands that would have a unique profile of multiple transporter affinities. The new **pharmacophore 2** was designed (**Figure 1.12**).




Figure 1.12. Design of Pharmacophore 2

1.4. Objectives

Based on the pharmacological evidence presented, it is clear that attenuation of dopaminergic and serotonergic pathways can affect the behaviors associated with METH abuse and addiction. We believe that the proper balance of dopaminergic/serotonergic (and noradrenergic) reuptake inhibition can restore the monoaminergic tone of METH disrupted neuronal systems and lead to diminished craving, psychosis, depression and other symptoms of withdrawal.

Based on the above hypothesis, the objective of this study is to explore dual DAT/SERT inhibitor for treatment of METH addiction. The focus of this study will be to design a SAR for the novel set of aryl piperidine derivatives. The developed SAR will be utilized to optimize potency and alter selectivity at the various transporters. The results of this project will provide the foundation for future studies aimed at the development of new medications for

methamphetamine addiction.

The designed pharmacophore analogues will be prepared from commercially available starting material 1-Boc-4-piperidone. Further, the method will be standardized for the synthesis of final target molecules by optimizing various conditions. After standardization of the synthetic method, a variety of electron withdrawing and electron releasing substituents will be introduced on the aromatic ring to produce a library of derivatives for biological evaluation.

Biological evaluation will consist of in initial in vitro screening at DAT and SERT to determine the binding affinity. In-Vitro binding affinity for monoamine transporters will be determined by ability of compounds to displace the radiolabeled ligand from rat caudate-putmen tissue. The binding affinity for the DAT will be determined by inhibition of [³H] WIN35,428 (**20**) and at SERT by inhibition of [³H]Citalopram (**21**) (**Figure 1.13**).³²





Figure 1.13. Radiolabelled ligands for the transporters for the binding studies.

1.5. Results and Discussion


Synthesis of target compounds

The commercially available 1-(Boc)-4-piperidone (**21**) was used for the synthesis of the target molecules. The 4-aryl moiety was introduced with a preformed aryl lithium reagent by addition to the ketone of 1-(Boc) 4-piperidone. A variety of substituents were installed on the aryl moiety to furnish intermediates **24a-24d** (Scheme 1.1).³²




Scheme 1.1. Synthesis of intermediates **24a-24d**

The alcohols **24a-24d** were reacted with variety of substituted benzyl bromides (**25a-25i**) in the presence of sodium hydride to yield compounds **26aa-26di** with 70-90% yield (Scheme 1.2.).



Scheme 1.2. Synthesis of intermediates **26aa-26di**


Removal of the N-Boc group was attempted using trifluoroacetic acid but only a trace amount of deprotected product was observed after the overnight reaction. An alternate method using hydrochloric acid and methanol was attempted which gave rapid deprotection within 2 hours and a quantitative yield of product as the hydrochloride salts **27aa-27di** (Scheme 1.3.). The final compounds were then screened for binding affinity at monoamine transporters.



Scheme 1.3. Synthesis of final compounds **27aa-27di**

In-vitro screening of final compounds

The binding affinities of all the compounds listed in **Table 1.1** were determined for DAT and SERT.



Cmpd ^a	Code	R ₁	R ₂	DAT Ki (nM) ^b	SERT Ki (nM) ^b	DAT/SERT
27aa	TAV-12	H	H	403 ± 100	145 ± 16	2.77
27ab	TAV-09	H	4-F	1810 ± 1110	17.0 ± 0.90	106
27ac	TAV-52	H	4-CH ₃	3108 ± 376	2.5 ± 0.20	1243.2
27ad	TAV-18	H	4-CF ₃	10,000 ± 1960	2.6 ± 2.4	3846.1
27ae	TAV-19	H	3,4-Cl ₂	976 ± 316	15.8 ± 17.2	61.7
27af	TAV-51	H	2-F	502 ± 340	567 ± 453	0.0015
27ag	TAV-53	H	3-F	536 ± 139	85.3 ± 24.7	65.2
27ah	TAV-54	H	3,5-F ₂	1705 ± 785	40.5 ± 11.1	42
27ba	TAV-13	F	H	1494 ± 326	30.8 ± 2.90	48.5
27bb	TAV-07	F	4-F	3970 ± 356	44.5 ± 44.7	89.2
27bc	TAV-67	F	4-CH ₃	4693 ± 1552	2.1 ± 0.90	2234
27bd	TAV-15	F	4-CF ₃	8134 ± 54	433 ± 21.2	18.7
27be	TAV-46	F	3,4-Cl ₂	4110 ± 687	8.9 ± 10.6	461.7
27bf	TAV-68	F	2-F	1471 ± 663	327 ± 105	4.5
27bg	TAV-72	F	3-F	1470 ± 130	79.9 ± 28.1	18.4
27bh	TAV-71	F	3,5-F ₂	2836 ± 826	53.3 ± 14.1	53.2
27bi	TAV-45	F	4-Cl	2368 ± 789	1.3 ± 1.4	1821
27ca	TAV-25	Cl	H	1039 ± 476	133 ± 108	7.8
27cb	TAV-29	Cl	4-F	1960 ± 155	8.3 ± 4.5	236
27cc	TAV-34	Cl	4-CH ₃	2171 ± 458	1.5 ± 0.70	1447.3
27cd	TAV-28	Cl	4-CF ₃	5667 ± 2397	0.50 ± 0.50	11334
27ce	TAV-26	Cl	3,4-Cl ₂	2277 ± 1191	0.60 ± 0.6	3795
27cf	TAV-61	Cl	2-F	2035 ± 1006	193 ± 126	10.5
27cg	TAV-72	Cl	3-F	2520 ± 471	35.7 ± 33.8	70.6
27ch	TAV-63	Cl	3,5-F ₂	2835 ± 828	56.8 ± 39.9	49.9
27ci	TAV-64	Cl	4-Cl	26% @ 100 μM	199 ± 126	-
27da	TAV-37	CF ₃	H	1938 ± 139	135 ± 82	14.35
27db	TAV-40	CF ₃	F	2170 ± 263	35.8 ± 11.3	60.6
27dd	TAV-39	CF ₃	4-CF ₃	5686 ± 35	3.7 ± 2.6	1536.7
27de	TAV-38	CF ₃	3,4-Cl ₂	9183 ± 1472	7.5 ± 2.5	1224.4

^aAll compounds were tested as the HCl salts. ^bAll values are the mean ± SEM of three experiments performed in triplicate.

Table 1.1. Preliminary binding studies.

Structure-activity relationship studies

The preliminary binding studies show that the binding affinity varies with the type of substituent present on the aromatic ring. It was found that all the compounds showed strong affinity towards serotonin transporters. Transporter affinities of the 4-arylmethoxy-4-arylpiperidines were generally selective for the SERT over the DAT with exception of **27af** which displayed slight selectivity for the dopamine transporter over the serotonin transporter (DAT/SERT = 0.0015). Most notably, compounds **27cd** ($K_i = 0.05$ nM) and **27ce** ($K_i = 0.06$ nM) were the most potent ligands of the series at the serotonin transporter. The binding affinity of **27cd** and **27ce** exceeded the potency of the radiolabeled ligand citalopram, ($K_i = 2$ nM) used for obtaining this data. In general, the compounds with 4-trifluoromethyl, 4-methyl and 3, 4-dichloro groups on the aromatic ring of the benzyloxy group ring showed highest potency at the serotonin transporter. Therefore, it can be concluded that these groups are important substituents on the aryl ring of these piperidine analogues for molecular recognition at serotonin transporters.

The compound **27aa** ($K_i = 403$ nM) was most potent ligands of the series at the dopamine transporter. However, it is noteworthy that **27aa** also exhibited nearly equal affinity for both DAT and SERT (DAT/SERT = 2.77). This confirms that the 4-aryl-4 arylmethoxypiperidines are viable targets for the development of selective serotonin transporter ligands with variable DAT affinity.

1.6. Conclusion

A series of 4-aryl-4-arylmethoxypiperidine analogues were synthesized and evaluated as dopamine and serotonin transporter ligands. The *in vitro* affinity (K_i) for the dopamine transporter and the serotonin transporter of this series was determined by inhibition of [³WIN]-35,428 and [³H]citalopram, respectively, in rat caudate putamen tissue. The results of this study

clearly demonstrate that 4-aryl-4-arylmethoxypiperidines are selective ligands for the serotonin transporter over the dopamine transporter. The preliminary binding studies show that the 4-aryl-4-arylmethoxypiperidines exhibit high affinity for SERT and modest to low affinity for DAT. The analogue TAV-28 (**27cd**) showed highest affinity towards SERT transporters. Overall, this investigation suggested that the 4-trifluoromethyl, 4-methyl and 3, 4-dichloro group on the aromatic ring of the benzyloxy group ring is a key structural feature for molecular recognition at the serotonin transporter as well as differentiation between the serotonin transporter and the dopamine transporter.

1.7. Experimental


All chemicals were purchased from Aldrich Chemical Company and used as received unless otherwise noted. Anhydrous Ethyl ether (Et₂O), Dimethylformamide (DMF), Methanol (MeOH), Dichloromethane (DCM) was purchased from Mallinckrodt Baker, Inc. Thin layer chromatography (TLC) 20×20 cm aluminium plates pre-coated with silica gel purchased from EMD Millipore USA and used to monitor reactions via visualization with short-wave UV light. ¹H NMR (400 MHz) and ¹³C NMR (100 MHz) spectra were recorded on a Varian 400 MHz NMR spectrometer at ambient temperature in CDCl₃. ¹H NMR chemical shifts are reported as δ values (ppm) relative to tetramethylsilane. ¹³C NMR chemical shifts are reported as δ values (ppm) relative to CDCl₃ (77.0 ppm). Atlantic Microlab, Inc., Norcross, GA performed all CHN microanalyses.

General procedure A. Synthesis of tertiary alcohols (**24a-24d**)

In a clean, dry round-bottom flask was added substituted benzenes (2 equiv.) (**23a-23d**) in dry ethyl ether (20 ml). The solution of *n*-butyl lithium (2 equiv.) was added to the solution dropwise at -78 °C. The solution of 1-(Boc) 4-piperidone (1 equiv.) (**22**) in diethyl ether was added to the

solution at $-78\text{ }^{\circ}\text{C}$. The solution was warmed to room temperature and stirred for 2h. The reaction mixture was diluted with ammonium chloride solution. The reaction mixture was extracted with ethyl ether ($3\times 30\text{ ml}$). The organic extract was washed with brine solution (30 ml) and dried over sodium sulphate. The solvent was evaporated under reduced pressure. The crude mixture was purified using column chromatography to obtain compounds **24a-24d**.

Tert-butyl-4-hydroxy-4-phenylpiperidine-1-carboxylate (24a)




General procedure A: This compound was obtained as a white solid (2 g, 75%).

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.25-7.48 (m, 5H), 3.98 (s, 1H), 3.24 (s, 2H), 2.00 (d, $J=11.6$ Hz, 2H), 1.74 (d, $J=11.2$ Hz, 2H), 1.44-1.59 (m, 11H).

$^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 28.6, 34.8, 39.4, 76.3, 79.6, 127.9, 128.8, 129.5, 144.1, 155.1.

Tert-butyl-4-(4-fluorophenyl)-4-hydroxypiperidine-1-carboxylate (24b)




General procedure A: This compound was obtained as a white solid (2.4 g, 82%).

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.25-7.43 (m, 2H), 7.03-7.05 (t, $J=8.8$ Hz, 2H), 3.95 (s, 1H), 3.20 (s, 2H), 1.88 (d, $J=11.6$ Hz, 2H), 1.63 (d, $J=11.2$ Hz, 2H), 1.42-1.61 (m, 11H).

$^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 28.6, 34.8, 39.4, 76.3, 79.6, 125.4, 129.5, 143.2, 144.1, 155.1.

Tert-butyl-4-(4-chlorophenyl)-4-hydroxypiperidine-1-carboxylate (24c)




General procedure A: This compound was obtained as a white solid (2.3g, 78%).

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.32-7.45 (m, 4H), 3.98 (s, 1H), 3.18 (s, 2H), 1.88 (d, $J=10.8$ Hz, 2H), 1.64 (d, $J=11.6$ Hz, 2H), 1.40-1.59 (m, 11H).

$^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 28.4, 34.5, 39.5, 75.8, 79.7, 128.6, 128.9, 133.6, 143.3, 155.1.

Tert-butyl-4-hydroxy-4-(4-(trifluoromethyl)phenyl)piperidine-1-carboxylate (24d)



General procedure A: This compound was obtained as a white solid (1.8 g, 72%).


¹H NMR (400 MHz, CDCl₃): δ 7.66 (d, *J*=8.0Hz, 2H), 7.60 (d, *J*=8.0Hz, 2H), 4.01 (s, 1H), 3.14 (s, 2H), 2.00 (s, 2H), 1.74 (s, 2H), 1.44-1.63 (m, 11H).

¹³C NMR (100 MHz, CDCl₃): δ 28.6, 35.7, 40.1, 76.1, 79.7, 125.7, 125.8, 126.8, 128.6, 129.3, 155.1,

General procedure B. Benzylation of alcohols (26aa-26di)

The solution of alcohols (**24a-24d**, 1 equiv.) was stirred in dimethylformamide at 0 °C. To the solution was added sodium hydride at 0 °C. The benzyl bromide (**25a-25i**, 1.1 equiv.) was added to the solution and the reaction was stirred for 2 h. The reaction was quenched with water and extracted with ethyl acetate (3×20 ml). The organic solvent was washed with brine solution and dried over sodium sulphate. The crude product was purified using column chromatography to obtain compounds **26aa-26di**.

N-(*tert*-Butoxycarbonyl)-4-(phenylmethoxy)-4-phenyl-piperidine (**26aa**, TAV-08)




General procedure B: This compound was obtained as a colorless liquid (300 mg, 80%).

¹H NMR (100 MHz, CDCl₃): δ 7.40-7.43 (m, 3H), 7.25-7.34 (m, 5H), 7.08 (t, *J*=8.8Hz, 2H), 4.08 (s, 4H), 3.26 (s, 2H), 2.13 (d, *J*=6.0Hz, 2H), 1.88 (s, 2H), 1.46 (s, 9H).

¹³C NMR (400 MHz, CDCl₃): δ 28.6, 34.8, 39.4, 63.4, 76.3, 79.6, 125.4, 126.0, 127.4, 127.9, 128.8, 129.5, 143.2, 144.1, 155.1.

N-(*tert*-Butoxycarbonyl)-4-[(4-fluorophenyl)methoxy]-4-phenyl-piperidine (26ab, TAV-08)




General procedure B: This compound was obtained as a colorless liquid (315 mg, 79%).

¹H NMR (400 MHz, CDCl₃): δ 7.36-7.43 (m, 6H), 7.28-7.32 (m, 2H), 7.02-7.11 (m, 1H), 4.05 (s, 4H), 3.24 (s, 2H), 2.13 (d, *J*=12.4Hz, 2H), 1.93 (s, 2H), 1.47 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 28.6, 34.8, 39.4, 62.8, 76.4, 79.6, 126.0, 126.6, 128.0, 128.9, 129.2, 132.5, 139.4, 144.0, 155.1.

N-(*tert*-Butoxycarbonyl)-4-[(4-methylphenyl)methoxy]-4-phenyl-piperidine (26ac, TAV-47)




General procedure B: This compound was obtained as a colorless liquid (271mg, 68%).

¹H NMR (400 MHz, CDCl₃): δ 7.49 (d, *J*=12.0Hz, 2H), 7.41 (t, *J*=8.0Hz, 2H), 7.30 (t, *J*=8.0, 1H), 7.22 (d, *J*=8.0 Hz, 2H), 7.17 (d, *J*=8.0 Hz, 2H), 4.10 (s, 4H), 3.20 (s, 2H), 2.37 (s, 3H), 2.17 (d, *J*=10.8Hz, 2H), 1.95 (s, 2H), 1.51 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 155.2, 144.8, 137.2, 136.0, 129.3, 128.8, 127.8, 126.2, 79.6, 76.0, 64.2, 39.5, 34.6, 28.7, 21.4.

N-(*tert*-Butoxycarbonyl)-4-[(4-trifluoromethylphenyl)methoxy]-4-phenyl-piperidine (26ad, TAV-16)




General procedure B: This compound was obtained as a colorless liquid (350 mg, 89%).

¹H NMR (400 MHz, CDCl₃): δ 7.58 (d, *J*=8.0Hz, 2H), 7.36-7.45 (m, 6H), 7.29-7.32 (m, 1H), 4.17 (s, 2H), 4.03 (s, 2H), 3.26 (s, 2H), 2.15 (d, *J*=12.0Hz, 2H), 1.95 (s, 2H), 1.47 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 28.6, 34.8, 39.4, 63.4, 76.3, 79.6, 125.4, 126.0, 127.4, 127.9, 128.8, 129.5, 129.8, 143.2, 144.1, 155.1

N-(*tert*-Butoxycarbonyl)-4-[(4-chlorophenyl)methoxy]-4-phenyl-piperidine (26ae, TAV-17)




General procedure B: This compound was obtained as a colorless liquid (310 mg, 80%).

¹H NMR (400 MHz, CDCl₃): δ 7.36-7.43 (m, 5H), 7.28-7.32 (m, 2H), 7.02-7.11 (m, 1H), 4.05 (s, 4H), 3.24 (s, 2H), 2.13 (d, *J*=12.4Hz, 2H), 1.93 (s, 2H), 1.47 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 28.6, 34.8, 39.4, 62.8, 76.4, 79.6, 126.0, 126.6, 128.0, 128.8, 128.9, 129.2, 130.4, 131.2, 144.0, 155.1, 161.5.

N-(*tert*-Butoxycarbonyl)-4-[(2-fluorophenyl)methoxy]-4-phenyl-piperidine (26af, TAV-48)




General procedure B: This compound was obtained as a colorless liquid (280 mg, 72%).

¹H NMR (400 MHz, CDCl₃): δ 7.45-7.50 (m, 3H), 7.37 (t, *J*=7.2 Hz, 2H), 7.21-7.31 (m, 2H), 7.13 (t, *J*=7.2 Hz, 1H), 6.71 (t, *J*=8.4Hz, 1H), 4.18 (s, 2H), 4.02 (s, 2H), 3.29 (s, 2H), 2.15 (d, *J*=13.2Hz, 2H), 1.93 (s, 2H), 1.51 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 161.9, 159.5, 155.1, 144.3, 129.9, 129.2, 128.8, 127.8, 126.1, 124.3, 115.4, 79.5, 76.3, 58.1, 39.5, 34.8, 28.7.

N-(*tert*-Butoxycarbonyl)-4-[(3-fluorophenyl)methoxy]-4-phenyl-piperidine (26ag, TAV-49)




General procedure B: This compound was obtained as a colorless liquid (300 mg, 82%).

¹H NMR (400 MHz, CDCl₃): δ 7.45 (d, *J*=7.6 Hz, 2H), 7.38 (t, *J*=8.0Hz, 2H), 7.23-7.31 (m, 2H), 7.06 (t, *J*=7.6 Hz, 2H), 6.94 (t, *J*=8.0Hz, 1H), 4.11 (s, 4H), 3.29 (s, 2H), 2.15 (d, *J*=12.4Hz, 2H) 1.94 (s, 2H), 1.50 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 164.3, 161.9, 155.1, 144.3, 141.8, 130.0, 128.8, 127.9, 126.1, 122.8, 114.2, 79.6, 76.2, 63.4, 40.3, 34.5, 28.7.

N-(*tert*-Butoxycarbonyl)-4-[(3,5-difluorophenyl)methoxy]-4-phenyl-piperidine (26ah, TAV-50)




General procedure B: This compound was obtained as a colorless liquid (284 mg, 72%).

¹H NMR (400 MHz, CDCl₃): δ 7.28-7.43 (m, 5H), 6.82 (d, *J*=6.4Hz, 2H), 6.65-6.70 (m, 1H), 4.09 (s, 4H), 3.25 (s, 2H), 2.13-2.16 (m, 2H), 1.94 (s, 2H), 1.45-1.48 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 28.6, 34.4, 39.5, 63.0, 76.4, 79.7, 109.8, 126.0, 128.0, 128.9, 143.0, 143.9, 155.1, 162.0, 164.5.

N-(*tert*-Butoxycarbonyl)-4-benzyloxy-4-(4-fluorophenyl)-piperidine (26ba, TAV-11)




General procedure B: This compound was obtained as a colorless liquid (290 mg, 80%).

¹H NMR (400 MHz, CDCl₃): δ 7.40-7.43 (m, 2H), 7.25-7.34 (m, 5H), 7.08 (t, *J*=8.8Hz, 2H), 4.08 (s, 4H), 3.26 (s, 2H), 2.13 (d, *J*=6.0Hz, 2H), 1.88 (s, 2H), 1.46 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 28.6, 34.8, 39.4, 63.4, 76.3, 79.6, 125.4, 126.0, 127.4, 127.9, 129.5, 129.8, 143.2, 144.1, 155.1.

N-(*tert*-Butoxycarbonyl)-4-[(4-fluorophenyl)methoxy]-4-(4-fluorophenyl)piperidine (26bb, TAV-06)




General procedure B: This compound was obtained as a colorless liquid (275mg, 68%).

¹H NMR (400 MHz, CDCl₃): δ 7.36-7.40 (m, 2H), 7.21-7.26 (m, 2H), 7.00-7.04 (m, 4H), 6.88-6.93 (m, 1H), 4.06 (s, 4H), 3.24 (s, 2H), 2.12 (d, *J*=13.2Hz, 2H), 1.87 (s, 2H), 1.46 (s, 9H).

^{13}C NMR (100 MHz, CDCl_3): δ 28.6, 34.8, 39.4, 63.4, 75.8, 79.6, 114.0, 114.4, 115.7, 122.7, 127.9, 129.9, 140.1, 141.5, 163.6.

N-(*tert*-Butoxycarbonyl)-4-[(4-methylphenyl)methoxy]-4-(4-fluorophenyl)-piperidine (26bc, TAV-65)




General procedure B: This compound was obtained as a colorless liquid (280 mg, 72%).

^1H NMR (400 MHz, CDCl_3): 7.42-7.46 (m, 2H), 7.22 (d, $J=8.0\text{Hz}$, 2H), 7.16 (d, $J=8.0\text{Hz}$, 2H), 7.05-7.09 (m, 2H), 4.07 (s, 4H), 3.29 (s, 2H), 2.35 (s, 3H), 2.13 (d, $J=12.0\text{Hz}$, 2H), 1.90 (s, 2H), 1.51 (s, 9H).

^{13}C NMR (100 MHz, CDCl_3): 21.3, 28.7, 34.7, 39.5, 64.1, 75.6, 79.6, 115.4, 127.9, 129.3, 135.8, 137.3, 140.6, 155.1, 161.1, 163.5.

N-(*tert*-Butoxycarbonyl)-4-[(4-trifluoromethylphenyl)methoxy]-4-(4-fluorophenyl)-piperidine (26bd, TAV-14)




General procedure B: This compound was obtained as a colorless liquid (285 mg, 71%).

¹H NMR (400 MHz, CDCl₃): δ 7.57 (d, *J*=8.4Hz, 2H), 7.38-7.42 (m, 4H), 7.03 (t, *J*= 7.2Hz, 2H), 4.01 (s, 2H), 4.02 (s, 2H), 3.24 (s, 2H), 2.13 (d, *J*=12.4Hz, 2H), 1.91 (s, 2H), 1.47 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 28.5, 34.6, 40.2, 63.3, 76.0, 79.6, 115.7, 125.4, 127.2, 129.8, 140.0, 142.9, 155.1, 161.1, 163.6.

N-(tert-Butoxycarbonyl)-4-[(3,4-dichlorophenyl)methoxy]-4-(4-fluorophenyl)piperidine
(26be, TAV-42)




General procedure B: This compound was obtained as a colorless liquid (285 mg, 78%).

¹H NMR (400 MHz, CDCl₃): δ 7.32-7.38 (m, 4H), 7.00-7.08 (m, 3H), 4.01 (s, 4H), 3.21 (s, 2H), 2.09 (d, *J*=12.0Hz, 2H), 1.87 (s, 2H), 1.45 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 163.6, 161.1, 155.0, 139.1, 132.5, 131.3, 130.4, 129.1, 127.8, 126.6, 115.5, 79.7, 76.0, 62.8, 39.5, 35.8, 28.6.

N-(*tert*-Butoxycarbonyl)-4-[(2-fluorophenyl)methoxy]-4-(4-fluorophenyl)-piperidine (26bf, TAV-66)




General procedure B: This compound was obtained as a colorless liquid (310 mg, 84%).

¹H NMR (400 MHz, CDCl₃): δ 7.39-7.45 (m, 3H) 7.21-7.25 (m, 1H), 6.96-7.14 (m, 4H), 4.13 (s, 2H) 4.02 (s, 2H) 3.25 (s, 2H) 2.11-2.14 (d, *J*=12.0Hz, 2H) 1.88 (t, 2H) 1.47 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 28.6, 34.8, 39.3, 58.0, 75.9, 79.6, 115.2, 124.3, 125.8, 127.8, 128.3, 129.9, 140.3, 141.5, 155.1, 159.4, 163.6.

N-(*tert*-Butoxycarbonyl)-4-[(3-fluorophenyl)methoxy]-4-(4-fluorophenyl)-piperidine (26bg, TAV-70)




General procedure B: This compound was obtained as a colorless liquid (275mg, 68%).

¹H NMR (400 MHz, CDCl₃): δ 7.36-7.40 (m, 2H), 7.21-7.26 (m, 2H), 7.00-7.04 (m, 4H), 6.88-6.93 (m, 1H), 4.06 (s, 4H), 3.24 (s, 2H), 2.12 (d, *J*=13.2Hz, 2H), 1.87 (s, 2H), 1.46 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 28.6, 34.8, 39.4, 63.4, 75.8, 79.6, 114.0, 114.4, 115.7, 122.7, 127.9, 129.9, 140.1, 141.5, 155.1, 161.1, 163.6.

N-(*tert*-Butoxycarbonyl)-4-[(3,5-difluorophenyl)methoxy]-4-(4-fluorophenyl)-piperidine
(26bh, TAV-69)




General procedure B: This compound was obtained as a colorless liquid (268 mg, 64%).

¹H NMR (400 MHz, CDCl₃): δ 7.33-7.37 (m, 2H), 6.99 (t, *J*=8.4Hz, 2H), 6.75-6.80 (m, 2H), 6.59-6.64 (m, 1H), 4.03 (s, 4H), 3.20 (s, 2H), 2.07-2.10 (d, *J*=12.0Hz, 2H), 1.86 (s, 2H), 1.44 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 28.5, 34.4, 39.3, 62.9, 76.0, 79.6, 102.3, 109.5, 115.5, 127.7, 139.8, 142.9, 155.0, 162.0, 164.4.

N-(*tert*-Butoxycarbonyl)-4-[(4-chlorophenyl)methoxy]-4-(4-fluorophenyl)-piperidine (26bi, TAV-43)




General procedure B: This compound was obtained as a colorless liquid (274mg, 68%).

¹H NMR (400 MHz, CDCl₃): δ 7.36-7.39 (m, 2H), 7.18-7.26 (m, 4H), 7.02 (d, *J*=9.6Hz, 2H), 4.03 (s, 4H), 3.23 (s, 2H), 2.10 (d, *J*=12.8Hz, 2H), 1.87 (s, 2H), 1.46 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 28.6, 35.7, 40.2, 63.4, 75.8, 79.6, 115.4, 127.6, 128.6, 128.8, 133.2, 140.1, 155.0, 161.1, 163.5.

N-(*tert*-Butoxycarbonyl)-4-(phenylmethoxy)-4-(4-chlorophenyl)-piperidine (26ca, TAV-16)




General procedure B: This compound was obtained as a colorless liquid (280mg, 72%).

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.25-7.40 (m, 9H), 4.09 (s, 4H), 3.26 (s, 2H), 2.10 (s, 2H), 1.88 (s, 2H), 1.47 (s, 9H).

$^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 28.7, 34.5, 39.4, 64.3, 72.3, 75.8, 79.7, 127.5, 127.7, 128.0, 128.6, 128.9, 133.6, 138.7, 143.3, 155.1.

N-(tert-Butoxycarbonyl)-4-[(4-fluorophenyl)methoxy]-4-(4-chlorophenyl)piperidine (26cb, TAV-26)




General procedure B: This compound was obtained as a colorless liquid (268 mg, 65%).

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.36-7.39 (m, 2H), 7.18-7.26 (m, 4H), 7.02 (d, $J=9.6\text{Hz}$, 2H), 4.03 (s, 4H), 3.23 (s, 2H), 2.10 (d, $J=12.8\text{Hz}$, 2H), 1.87 (s, 2H), 1.46 (s, 9H).

^{13}C NMR (100 MHz, CDCl_3): δ 28.6, 35.7, 40.2, 63.4, 75.8, 79.6, 115.4, 127.6, 128.6, 128.8, 133.2, 137.3, 140.1, 155.0, 161.1.

N-(*tert*-Butoxycarbonyl)-4-[(4-methylphenyl)methoxy]-4-(4-chlorophenyl)-piperidine (26cc, TAV-33)




General procedure B: This compound was obtained as a colorless liquid (238 mg, 64%).

^1H NMR (400 MHz, CDCl_3): 7.42-7.46 (m, 2H), 7.22 (d, $J=8.0\text{Hz}$, 2H), 7.16 (d, $J=8.0\text{Hz}$, 2H), 7.05-7.09 (m, 2H), 4.07 (s, 4H), 3.29 (s, 2H), 2.35 (s, 3H), 2.13 (d, $J=12.0\text{Hz}$, 2H), 1.90 (s, 2H), 1.51 (s, 9H).

^{13}C NMR (100 MHz, CDCl_3): 21.3, 28.7, 34.7, 39.5, 64.1, 75.6, 79.6, 115.4, 127.9, 129.3, 135.8, 137.3, 140.6, 155.1, 161.1, 163.5.

N-(*tert*-Butoxycarbonyl)-4-[(4-trifluoromethylphenyl)methoxy]-4-(4-chlorophenyl)-piperidine (26cd, TAV-24)




General procedure B: This compound was obtained as a colorless liquid (275mg, 68%).

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.57 (d, $J=8.0\text{Hz}$, 2H), 7.32-7.41 (m, 6H), 4.15 (s, 2H), 4.05 (s, 2H), 3.24 (s, 2H), 2.13 (d, $J=13.2\text{Hz}$, 2H), 1.90 (s, 2H), 1.47 (s, 9H).

$^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 28.6, 34.8, 39.4, 63.5, 76.1, 79.7, 123.0, 125.4, 127.5, 129.0, 129.6, 129.9, 133.8, 142.3, 142.8, 155.1.

N-(tert-Butoxycarbonyl)-4-[(3,4-dichlorophenyl)methoxy]-4-(4-chlorophenyl)piperidine
(26ce, TAV-23)




General procedure B: This compound was obtained as a colorless liquid (310mg, 82%).

¹H NMR (400 MHz, CDCl₃): δ 7.34-7.39 (m, 5H), 7.25 (s, 1H), 7.08 (dd, *J*=2.0Hz, 8.0Hz, 1H), 4.03 (s, 4H), 3.21(s, 2H), 2.09 (d, *J*=12.0Hz, 2H), 1.88 (s, 2H), 1.46 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 28.6, 34.4, 39.3, 62.9, 76.1, 79.8, 126.6, 127.5, 129.0, 129.2, 130.5, 131.5, 132.6, 133.8, 138.9, 142.6, 155.1.

N-(*tert*-Butoxycarbonyl)-4-[(2-fluorophenyl)methoxy]-4-(4-chlorophenyl)-piperidine (26cf, TAV-57)




General procedure B: This compound was obtained as a colorless liquid (285mg, 74%).

¹H NMR (400 MHz, CDCl₃) : δ 7.32-7.45 (m, 5H), 7.21-7.25 (m, 1H) 7.12 (t, *J*= 7.2Hz, 1H), 7.00 (t, *J*=8.8Hz, 1H), 4.14 (s, 2H), 4.02 (s, 2H), 3.24 (s, 2H), 2.12 (m, 2H), 1.87 (m, 2H), 1.47 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 28.6, 34.7, 39.4, 58.2, 76.0, 79.7, 115.2, 124.3, 125.7, 128.9, 129.3, 129.9, 133.6, 141.4, 143.0, 155.1, 159.4.

N-(*tert*-Butoxycarbonyl)-4-[(3-fluorophenyl)methoxy]-4-(4-chlorophenyl)-piperidine (26cg, TAV-58)




General procedure B: This compound was obtained as a colorless liquid (278mg, 72%).

¹H NMR (400 MHz, CDCl₃): δ 7.36-7.21 (m, 5H), 7.00-7.03 (m, 2H), 6.89-6.94 (m, 1H), 4.72-4.75 (m, 4H), 3.23 (s, 2H), 2.08-2.12 (m, 2H), 1.87 (s, 2H), 1.46 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 28.6, 34.5, 39.4, 63.5, 75.9, 79.7, 114.2, 122.7, 127.6, 129.0, 130.0, 133.7, 141.3, 142.9, 155.1, 161.9, 164.3.

N-(tert-Butoxycarbonyl)-4-[(3,5-fluorophenyl)methoxy]-4-(4-chlorophenyl)-piperidine
(26ch, TAV-59)




General procedure B: This compound was obtained as a colorless liquid (280 mg, 75%).

¹H NMR (400 MHz, CDCl₃): δ 7.28-7.33 (m, 4H), 6.80 (d, *J*=7.2Hz, 2H), 6.64 (t, *J*=8.8Hz, 1H), 4.05 (s, 2H), 3.20 (s, 2H), 2.11 (d, *J*=12.0Hz, 2H), 1.87 (s, 2H), 1.45 (s, 9H).

^{13}C NMR (100 MHz, CDCl_3): δ 28.5, 34.4, 39.3, 62.9, 76.0, 79.6, 102.3, 109.5, 115.5, 127.7, 139.8, 142.9, 155.0, 162.0, 164.4.

N-(*tert*-Butoxycarbonyl)-4-[(4-chlorophenyl)methoxy]-4-(4-chlorophenyl)-piperidine (26ci, TAV-60)




General procedure B: This compound was obtained as a colorless liquid (264 mg, 63%).

^1H NMR (400 MHz, CDCl_3): δ 7.32-7.37 (m, 4H), 7.29 (d, $J=8.8\text{Hz}$, 2H), 7.20 (d, $J=8.0\text{Hz}$, 2H), 4.05 (s, 4H), 3.23 (s, 2H), 2.10 (d, $J=12.0\text{Hz}$, 2H), 1.88 (s, 2H), 1.47 (s, 9H).

^{13}C NMR (100 MHz, CDCl_3): δ 28.6, 34.8, 39.4, 63.6, 75.9, 79.8, 127.6, 128.7, 128.8, 129.0, 133.4, 133.7, 137.1, 143.0, 155.1.

N-(*tert*-Butoxycarbonyl)-4-(phenylmethoxy)-4-(4-trifluoromethyl)-phenyl-piperidine (26da, TAV-32)




General procedure B: This compound was obtained as a colorless liquid (280mg, 75%).

¹H NMR (400 MHz, CDCl₃): δ 7.65 (d, *J*=8.0Hz, 2H), 7.59 (d, *J*=8.0Hz, 2H), 7.28-7.37 (m, 5H), 4.14 (s, 4H), 3.30 (s, 2H), 2.16 (d, *J*=8.8Hz, 2H), 1.94 (s, 2H), 1.51 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 28.6, 22.8, 35.7, 40.1, 64.5, 76.1, 79.7, 125.7, 125.8, 125.8, 126.6, 127.5, 127.7, 128.6, 138.5, 148.9, 155.1.

N-(*tert*-Butoxycarbonyl)-4-[(4-fluorophenyl)methoxy]-4-(4-trifluoromethylphenyl)-piperidine (26db, TAV-36)




General procedure B: This compound was obtained as a colorless liquid (265 mg, 70%).

¹H NMR (400 MHz, CDCl₃): δ 7.62 (d, *J*=8.4Hz, 2H), 7.55 (m, *J*=8.4Hz, 2H), 7.25 (m, 2H), 6.98 (t, *J*=8.4Hz, 2H), 4.06 (s, 4H), 3.25 (s, 2H), 2.12 (d, *J*=12.8Hz, 2H), 1.90 (s, 2H), 1.47 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 28.5, 35.6, 40.1, 63.8, 76.1, 79.7, 115.5, 125.7, 126.5, 129.1, 130.1, 134.2, 148.7, 155.0, 161.1, 163.6.

N-(*tert*-Butoxycarbonyl)-4-[(4-methylphenyl)methoxy]-4-(4-trifluoromethylphenyl)-piperidine (26dc, TAV-41)




General procedure B: This compound was obtained as a colorless liquid (285 mg, 75%).

¹H NMR (400 MHz, CDCl₃): δ 7.66 (d, *J*=8.4Hz, 2H), 5.60 (d, *J*=8.4Hz, 2H), 7.22 (d, *J*=8.0Hz, 2H), 7.17 (d, *J*=8.0Hz, 2H), 4.10 (s, 4H), 3.30 (s, 2H), 2.36 (s, 3H), 2.15 (d, *J*=12.0Hz, 2H), 1.93 (s, 2H), 1.50 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 155.1, 149.0, 137.5, 135.4, 130.1, 129.8, 129.3, 127.7, 126.6, 125.8, 79.7, 76.0, 64.4, 40.1, 35.9, 28.6, 21.3

N-(*tert*-Butoxycarbonyl)-4-[(4-trifluoromethylphenyl)methoxy]-4-(4-(trifluoromethyl)phenyl)piperidine (26dd, TAV-35)




General procedure B: This compound was obtained as a colorless liquid (268mg, 64%).

¹H NMR (400 MHz, CDCl₃): δ 7.63 (d, *J*=8.4Hz, 2H), 7.55-7.58 (m, 4H), 7.42 (d, *J*=8.0Hz, 2H), 4.18 (s, 2H), 4.06 (s, 2H), 3.26 (s, 2H), 2.15 (d, *J*=8.8Hz, 2H), 1.94 (s, 2H), 1.47 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 28.5, 34.6, 36.3, 63.6, 76.3, 79.8, 125.4, 125.5, 125.8, 126.4, 127.3, 129.6, 129.9, 130.2, 142.6, 148.6, 155.0.

N-(*tert*-Butoxycarbonyl)-4-[(3,4-dichlorophenyl)methoxy]-4-(4-trifluoromethylphenyl)-piperidine (26de, TAV-33)




General procedure B: This compound was obtained as a colorless liquid (314 mg, 82%).

¹H NMR (400 MHz, CDCl₃): δ 7.60 (d, *J*=8.0Hz, 2H), 7.52 (d, *J*=8.0Hz, 2H), 7.32-7.36 (m, 2H), 7.07-7.10 (d, *J*=8.0Hz, 1H), 4.04 (s, 4H), 3.21 (s, 2H), 2.09-2.13 (d, *J* =13.2Hz, 2H), 1.90 (s, 2H), 1.45 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 28.6, 34.5, 38.4, 63.0, 76.4, 79.8, 125.7, 125.8, 125.9, 126.4, 126.5, 129.1, 130.5, 131.4, 132.6, 138.3, 155.0, 160.3.

N-(*tert*-Butoxycarbonyl)-4-[(2-fluorophenyl)methoxy]-4-(4-trifluoromethylphenyl)-piperidine (26df, TAV-73)




General procedure B: This compound was obtained as a colorless liquid (264mg, 69%).

¹H NMR (400 MHz, CDCl₃): δ 7.64 (d, *J*=8.4Hz, 2H), 7.58 (d, *J*=8.0Hz, 2H), 7.46 (t, *J*=7.6Hz, 1H), 7.23-7.29 (m, 1H), 7.15 (t, *J*=7.6Hz, 1H), 6.99 (t, *J*=9.2Hz, 1H), 4.17 (s, 4H), 3.27 (s, 2H), 2.15 (d, *J*=12.0Hz, 2H), 1.92 (s, 2H), 1.48 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 161.9, 159.5, 155.1, 148.6, 130.2, 129.9, 126.5, 125.8, 125.5, 124.3, 115.5, 102.8, 79.7, 75.9, 63.5, 39.4, 34.5, 28.6.

N-(*tert*-Butoxycarbonyl)-4-[(3,5-difluorophenyl)methoxy]-4-(4-trifluoromethylphenyl)-piperidine (26dh, TAV-73)




General procedure B: This compound was obtained as a colorless liquid (285 mg, 78%).

¹H NMR (400 MHz, CDCl₃): δ 7.61 (d, *J*=8.0Hz, 2H), 7.53 (d, *J*=8.0Hz, 2H), 6.81 (d, *J*=6.4Hz, 2H), 6.63 (t, *J*=9.2Hz, 1H), 4.09 (s, 4H), 3.23 (s, 2H), 2.13 (d, *J*=12.0Hz, 2H), 1.92 (s, 2H), 1.45 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): δ 164.4, 161.9, 155.0, 148.2, 142.6, 130.3, 126.4, 125.8, 109.6, 102.7, 79.7, 76.4, 63.1, 39.3, 34.7, 28.5.

N-(*tert*-Butoxycarbonyl)-4-[(4-chlorophenyl)methoxy]-4-(4-trifluoromethylphenyl)-piperidine (26di, TAV-75)



General procedure B: This compound was obtained as a colorless liquid (270 mg, 65%).


¹H NMR (400 MHz, CDCl₃): δ 7.64 (d, *J*=8.4Hz, 2H), 7.55 (d, *J*=8.0Hz, 2H), 7.30 (d, *J*=8.4Hz, 2H), 7.23 (d, *J*=8.4Hz, 2H), 4.08 (s, 4H), 3.25 (s, 2H), 2.14 (d, *J*=12.0Hz, 2H), 1.92 (s, 2H), 1.48 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): 155.1, 148.6, 142.4, 137.0, 133.5, 130.2, 129.9, 128.8, 126.5, 125.8, 79.8, 76.2, 63.7, 39.3, 34.4, 28.6.

General procedure C. Synthesis of hydrochloride salts (27aa-27di)

To the solution of **23aa-23di** in methanol (10 ml) was added to concentrated HCl (2ml) and stirred for 1h. The solvent was evaporated under reduced pressure. To the crude product was added water (20 ml) at 0 °C. The solid formed was filtered and dried under vacuum to get the hydrochloride salt of compounds **24aa-24di**.

4-(Benzyloxy)-4-phenyl-piperidinium chloride (27aa, TAV-12)




General procedure C: This compound was obtained as a white solid (200 mg, 95%).

¹H NMR (400 MHz, CDCl₃): δ 7.48 (d, *J*=8.4Hz, 2H), 7.34 (t, *J*=7.6Hz, 3H), 7.30-7.34 (m, 4H), 7.27-7.28 (m, 1H), 4.11 (s, 2H), 3.16 (t, *J*=12.0Hz, 2H), 2.93 (d, *J*=12.0Hz, 2H), 2.15 (d, *J*=11.6Hz, 2H), 1.93 (t, *J*=12.0Hz, 2H), 1.72 (s, NH)

¹³C NMR (100 MHz, CDCl₃): δ 36.5, 42.5, 63.9, 76.4, 126.2, 127.4, 127.5, 127.6, 128.5, 128.6, 139.3, 145.4.

Anal. Calcd for C₁₈H₂₂ClNO. 2/3H₂O: C, 68.48; H, 7.45; N, 4.44 Found: C, 68.22; H, 7.47; N, 4.47.

4-(4-Fluorobenzyloxy)-4-phenyl-piperidinium chloride (27ab, TAV-09)




General procedure C: This compound was obtained as a white solid (194 mg, 94%).

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.40-7.42 (m, 2H), 7.23-7.40 (m, 2H), 6.97-7.01 (m, 4H), 4.03 (s, 2H), 3.14 (t, $J=11.6\text{Hz}$, 2H), 2.93 (d, $J=9.6\text{Hz}$, 2H), 2.10 (d, $J=13.2\text{Hz}$, 2H), 1.86-1.93 (m, 2H), 1.62 (s, NH)

$^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 36.5, 42.5, 63.1, 76.1, 115.2, 115.5, 127.9, 129.2, 134.8, 141.2, 161.1, 163.5.

Anal. Calcd for $\text{C}_{18}\text{H}_{21}\text{ClF}_2\text{NO} \cdot \text{H}_2\text{O}$: C, 60.54; H, 6.16; N, 4.05 Found: C, 60.42; H, 6.20; N, 3.91.

4-(4-Methylbenzyloxy)-4-phenylpiperidinium chloride (27ac, TAV-52)




General procedure C: This compound was obtained as a white solid (172 mg, 78%).

¹H NMR (400 MHz, CDCl₃): δ 7.41-7.45 (m, 3H), 7.19 (d, *J*=8.0Hz, 2H), 7.13 (d, *J*=7.6Hz, 2H), 7.03-7.07 (m, 2H), 4.03 (s, 2H), 3.15 (t, *J*=11.2Hz, 2H), 2.92-2.95 (m, 2H), 2.33 (s, 3H), 2.12 (d, *J*=13.2Hz, 2H), 1.85-1.92 (m, 2H), 1.70 (s, NH).

¹³C NMR (100 MHz, CDCl₃): δ 21.3, 36.6, 42.4, 63.7, 75.9, 115.2, 115.5, 127.7, 127.9, 128.0, 129.2, 136.1, 137.2.

Anal. Calcd for C₁₈H₂₁ClF₂NO. 2.1/4H₂O: C, 63.68; H, 8.02; N, 3.91 Found: C, 63.68; H, 8.02; N, 3.91.

4-(4-Trifluoromethylbenzyloxy)-4-phenyl-piperidinium chloride (27ad, TAV-18)




General procedure C: This compound was obtained as a white solid (165 mg, 87%).

¹H NMR (400 MHz, CDCl₃): δ 7.57 (d, *J*=8.4Hz, 2H), 7.45 (t, *J*=8.4Hz, 4H), 7.37 (t, *J*= 7.6Hz, 2H), 7.279 (t, *J*=7.6Hz, 1H), 4.16 (s, 2H), 3.15 (t, *J*=11.6Hz, 2H), 2.95 (s, *J*=12.0Hz, 2H), 2.15 (d, *J*=12.0Hz, 2H), 1.92-2.00 (m, 2H) 1.64 (s, NH).

¹³C NMR (100 MHz, CDCl₃): δ 36.4, 42.5, 63.1, 76.7, 125.4, 125.8, 126.1, 127.4, 127.6, 128.7, 129.4, 143.5, 145.1.

Anal. Calcd for C₁₉H₂₁ClF₃NO. H₂O: C, 58.54; H, 5.95; N, 3.59 Found: C, 58.55; H, 5.43; N, 3.55.

4-(3,4-Dichlorobenzoyloxy)-4-phenyl-piperidinium chloride (27ae, TAV-19)




General procedure C: This compound was obtained as a white solid (210 mg, 96%).

¹H NMR (400 MHz, CDCl₃): δ 7.44-7.35 (m, 6H), 7.29 (t, *J*=7.2Hz, 1H), 7.11 (dd, *J*=1.6Hz, 8.4Hz, 1H), 4.04 (s, 2H), 3.14 (t, *J*=12.0Hz, 2H), 2.95 (m, 2H), 2.15 (d, *J*=11.6Hz, 2H), 1.94 (t, *J*=12.0Hz, 2H), 1.71 (s, NH)

¹³C NMR (100 MHz, CDCl₃): δ 36.3, 42.5, 62.6, 76.7, 126.1, 126.6, 127.7, 128.7, 129.3, 130.4, 131.2, 132.5, 139.6, 144.9.

Anal. Calcd for C₁₈H₂₀Cl₃NO: C, 57.31; H, 5.48; N, 3.71 Found: C, 57.71; H, 5.57; N, 3.82

4-(2-Fluorobenzoyloxy)-4-phenyl-piperidinium chloride (27af, TAV-51)




General procedure C: This compound was obtained as a white solid (175 mg, 80%).

¹H NMR (400 MHz, CDCl₃): δ 7.46-7.52 (m, 3H), 7.37 (t, *J*=7.6Hz, 2H), 7.22-7.30 (m, 2H), 7.14 (t, *J*=8.4Hz, 1H), 6.99 (t, *J*=9.2Hz, 1H), 4.16 (s, 2H), 3.15 (t, *J*=12.0Hz, 2H), 2.95 (d, *J*=12.4Hz, 2H), 2.15 (d, *J*=12.4Hz, 2H), 1.94 (t, *J*=12.0Hz, 2H), 1.80 (s, NH).

¹³C NMR (100 MHz, CDCl₃): δ 161.8, 159.4, 145.2, 129.8, 129.0, 128.7, 127.5, 126.1, 124.2, 115.1, 76.6, 57.7, 42.4, 36.4.

Anal. Calcd for C₁₈H₂₁ClFNO: C, 64.47; H, 6.576; N, 4.18 Found: C, 64.51; H, 6.77; N, 4.25.

4-(3-Fluorobenzyloxy)-4-phenyl-piperidinium chloride (27ag, TAV-53)




General procedure C: This compound was obtained as a white solid (182 mg, 84%).

¹H NMR (400 MHz, CDCl₃): δ 7.46 (d, *J*= 7.2Hz, 2H), 7.37 (t, *J*=8.0Hz, 2H), 7.24-7.30 (m, 2H), 7.07 (t, *J*= 8.4Hz, 2H), 6.91-6.96 (m, 1H), 4.01 (s, 2H), 3.13-3.20 (m, 2H), 2.94-2.98 (m, 2H), 2.14 (d, *J*=12.0Hz, 2H), 1.92-1.99 (m, 2H), 1.81 (s, NH).

¹³C NMR (100 MHz, CDCl₃): δ 36.3, 42.4, 63.1, 76.5, 114.1, 114.2, 122.7, 126.1, 128.7, 142.0, 142.0, 145.1, 161.9, 164.0.

Anal. Calcd for C₁₈H₂₁ClFNO. 3/4H₂O: C, 67.18; H, 6.58; N, 4.35 Found: C, 64.47; H, 6.76; N, 4.18.

4-(3,5-Difluorobenzyloxy)-4-phenyl-piperidinium chloride (27ah, TAV-54)




General procedure C: This compound was obtained as a white solid (180 mg, 84%).

¹H NMR (400 MHz, CDCl₃): δ 7.63 (d, *J*=8.4Hz, 2H), 7.56 (d, *J*=8.0Hz, 2H), 7.24-7.30 (m, 2H), 7.03-7.07 (m, 2H), 6.91-6.96 (m, 1H), 4.09 (s, 4H), 3.26 (s, 2H), 2.15 (d, *J*=12.0Hz, 2H), 1.93 (s, 2H), 1.48 (s, NH).

¹³C NMR (100 MHz, CDCl₃): δ 164.3, 161.9, 155.1, 148.6, 125.8, 122.7, 114.2, 114.5, 79.8, 76.2, 63.6, 39.3, 35.7, 28.5.

Anal. Calcd for C₁₈H₂₀ClF₂NO · H₂O: C, 60.42; H, 6.20; N, 3.91. Found: C, 60.48; H, 6.18; N, 3.87.

4-Benzyloxy-4-(4-fluorophenyl)-piperidinium chloride (27ba, TAV-13)




General procedure C: This compound was obtained as a white solid (196 mg, 96%).

¹H NMR (400 MHz, CDCl₃): δ 7.46 (d, *J*=8.8Hz, 1H), 7.34-7.39 (m, 2H), 7.23-7.31 (m, 5H), 6.99 (t, *J*=8.4Hz, 1H), 4.06 (s, 2H), 3.16 (t, *J*=12.0Hz, 2H), 2.93 (d, *J*=12.0Hz, 2H), 2.15 (d, *J*=11.6Hz, 2H), 1.94 (t, *J*=12.0Hz, 2H), 1.66 (s, NH)

¹³C NMR (100 MHz, CDCl₃): δ 36.5, 42.5, 63.9, 76.4, 126.2, 127.4, 127.5, 127.6, 128.5, 128.6, 139.3, 145.4.

Anal. Calcd for C₁₈H₂₁ClFNO. 3/4H₂O: C, 67.18; H, 6.58; N, 4.35 Found: C, 66.25; H, 6.64; N, 4.29.

4-(4-Fluorobenzoyloxy)-4-(4-fluorophenyl)-piperidinium chloride (27bb, TAV-07)




General procedure C: This compound was obtained as a white solid (205 mg, 95%).

¹H NMR (400 MHz, CDCl₃): δ 7.40-7.43 (m, 2H), 7.23-7.26 (m, 2H), 6.97-7.01 (m, 4H), 4.03 (s, 3H), 3.14 (t, *J*=11.6Hz, 2H), 2.92 (d, *J*=12.0Hz, 2H), 2.10 (d, *J*=12.0Hz, 2H), 1.86-1.93 (m, 2H), 1.64 (s, NH).

¹³C NMR (100 MHz, CDCl₃): δ 36.5, 42.5, 63.1, 76.1, 115.3, 115.5, 127.8, 129.2, 134.8, 141.2, 161.1, 163.4.

Anal. Calcd for C₁₈H₂₁ClF₂NO. H₂O: C, 60.54; H, 6.16; N, 4.05 Found: C, 60.42; H, 6.20; N, 3.91.

4-(4-Methylbenzyloxy)-4-(4-fluorophenyl)-piperidinium chloride (27bc, TAV-67)




General procedure C: This compound was obtained as a white solid (172 mg, 78%).

¹H NMR (400 MHz, CDCl₃): δ 7.41-7.45 (m, 2H), 7.19 (d, *J*=8.0Hz, 2H), 7.13 (d, *J*=7.6Hz, 2H), 7.03-7.07 (m, 2H), 4.03 (s, 2H), 3.15 (t, *J*=11.2Hz, 2H), 2.92-2.95 (m, 2H), 2.33 (s, 3H), 2.12 (d, *J*=13.2Hz, 2H), 1.85-1.92 (m, 2H), 1.70 (s, NH).

¹³C NMR (100 MHz, CDCl₃): δ 21.3, 36.6, 42.4, 63.7, 75.9, 115.2, 115.5, 127.7, 127.9, 128.0, 129.2, 136.1, 137.2.

Anal. Calcd for C₁₉H₂₃ClFNO. H₂O: C, 64.49; H, 7.12; N, 3.96 Found: C, 62.61; H, 7.09; N, 3.99.

4-(4-Trifluoromethylbenzyloxy)-4-(4-fluorophenyl)-piperidinium chloride (27bd, TAV-15)




General procedure C: This compound was obtained as a white solid (185 mg, 90%).

¹H NMR (400 MHz, CDCl₃): δ 7.57 (d, *J*=12.0Hz, 2H), 7.39-7.43 (m, 4H), 7.05 (t, *J*=8.8Hz, 2H), 4.14 (s, 2H), 3.14 (t, *J*=12.0Hz, 2H), 2.95 (d, *J*=11.2Hz, 2H), 2.14 (d, *J*=12.0Hz, 2H), 1.89-1.96 (m, 2H), 1.77 (s, NH)

¹³C NMR (100 MHz, CDCl₃): δ 36.4, 42.4, 63.1, 76.3, 115.4, 115.6, 125.3, 127.4, 127.8, 140.8, 143.2, 161.0, 163.5.

Anal. Calcd for C₁₉H₂₀ClF₄NO. 3/4H₂O: C, 56.58; H, 5.37; N, 3.47 Found: C, 56.61; H, 5.31; N, 3.56.

4-(4-Fluorobenzoyloxy)-4-(3,4-dichlorophenyl)-piperidinium chloride (27be, TAV-46)




General procedure C: This compound was obtained as a white solid (210 mg, 96%).

¹H NMR (400 MHz, CDCl₃): δ 7.44-7.35 (m, 5H), 7.29 (t, *J*=7.2Hz, 1H), 7.11 (dd, *J*=1.6Hz, 8.4Hz, 1H), 4.04 (s, 2H), 3.14 (t, *J*=12.0Hz, 2H), 2.95 (d, *J*=12.0Hz, 2H), 1.86-1.94 (m, 2H), 1.42 (s, NH).

¹³C NMR (100 MHz, CDCl₃): δ 36.3, 42.5, 62.6, 76.7, 126.1, 126.6, 127.7, 128.7, 129.3, 130.4, 131.2, 132.5, 139.6, 144.9.

Anal. Calcd for C₁₈H₂₀Cl₂FNO. H₂O: C, 55.33; H, 4.90; N, 3.58 Found: C, 55.09; H, 4.75; N, 3.63.

4-(2-Fluoromethylbenzyloxy)-4-(4-fluorophenyl)-piperidinium chloride (27bf, TAV-68)




General procedure C: This compound was obtained as a white solid (175 mg, 80%).

¹H NMR (400 MHz, CDCl₃): δ 7.46-7.52 (m, 2H), 7.37 (t, *J*=7.6Hz, 2H), 7.22-7.30 (m, 2H), 7.14 (t, *J*=8.4Hz, 1H), 6.99 (t, *J*=9.2Hz, 1H), 4.16 (s, 2H), 3.15 (t, *J*=12.0Hz, 2H), 2.95 (d, *J*=12.4Hz, 2H), 2.15 (d, *J*=12.4Hz, 2H), 1.94 (t, *J*=12.0Hz, 2H), 1.80 (s, NH).

¹³C NMR (100 MHz, CDCl₃): δ 161.8, 159.4, 145.2, 129.8, 129.0, 128.7, 127.5, 126.1, 124.2, 115.1, 76.6, 57.7, 42.4, 36.4.

Anal. Calcd for C₁₈H₂₁ClF₂NO: C, 67.18; H, 6.58; N, 4.35 Found: C, 66.92; H, 6.60; N, 4.36.

4-(3-Fluoromethylbenzyloxy)-4-(4-fluorophenyl)-piperidinium chloride (27bg, TAV-72)




General procedure C: This compound was obtained as a white solid (182 mg, 84%).

¹H NMR (400 MHz, CDCl₃) : δ 7.46 (d, *J*=7.2Hz, 2H), 7.37 (t, *J*=8.0Hz, 2H), 7.24-7.30 (m, 2H), 7.07 (t, *J*=8.4Hz, 2H), 4.01 (s, 2H), 3.13-3.20 (m, 2H), 2.94-2.98 (m, 2H), 2.14 (d, *J*=12.0Hz, 2H), 1.92-1.99 (m, 2H), 1.81 (s, NH).

¹³C NMR (100 MHz, CDCl₃): δ 36.3, 42.4, 63.1, 76.5, 114.1, 114.2, 122.7, 126.1, 128.7, 142.0, 142.0, 145.1, 161.9, 164.

Anal. Calcd for C₁₈H₂₁ClF₂NO: C, 63.62; H, 5.93; N, 4.12 Found: C, 63.42; H, 5.90; N, 4.10.

4-(3, 4-Difluorobenzyloxy)-4-(4-fluorophenyl)-piperidinium chloride (27bh, TAV-71)




General procedure C: This compound was obtained as a white solid (180 mg, 84%).

¹H NMR (400 MHz, CDCl₃): δ 7.63 (d, *J*=8.4Hz, 2H), 7.56 (d, *J*=8.0Hz, 2H), 7.24-7.30 (m, 1H), 7.03-7.07 (m, 2H), 6.91-6.96 (m, 1H), 4.09 (s, 4H), 3.26 (s, 2H), 2.15 (d, *J*=12.0Hz, 2H), 1.93 (s, 2H), 1.48 (s, 2H).

¹³C NMR (100 MHz, CDCl₃): δ 164.3, 161.9, 155.1, 126.5, 125.8, 122.7, 114.2, 114.5, 79.8, 76.2, 63.6, 39.3, 35.7.

Anal. Calcd for C₁₈H₁₉ClF₃NO · H₂O: C, 57.53; H, 5.63; N, 3.73 Found: C, 57.71; H, 5.64; N, 3.67.

4-(3, 4-Chlorobenzyloxy)-4-(4-fluorophenyl)-piperidinium chloride (27bi, TAV-45)




General procedure C: This compound was obtained as a white solid (200 mg, 95%).

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.40-7.43 (m, 2H), 7.23-7.26 (m, 2H), 6.97-7.01 (m, 4H), 4.03 (s, 3H), 3.14 (t, $J=11.6\text{Hz}$, 2H), 2.92 (d, $J=12.0\text{Hz}$, 2H), 2.10 (d, $J=12.0\text{Hz}$, 2H), 1.86-1.93 (m, 2H), 1.64 (s, NH).

$^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 36.5, 42.5, 63.1, 76.1, 115.3, 115.5, 127.8, 129.2, 134.8, 141.2, 161.1, 163.4.

Anal. Calcd for $\text{C}_{18}\text{H}_{20}\text{Cl}_2\text{FNO}$. H_2O : C, 62.19; H, 5.81; N, 3.74 Found: C, 62.17; H, 5.87; N, 3.70.

4-Benzyloxy-4-(4-chlorophenyl)-piperidinium chloride (27ca, TAV-25)




General procedure C: This compound was obtained as a white solid (295 mg, 87%).

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.25-7.42 (m, 9H), 4.09 (s, 2H), 4.05 (s, 2H), 3.15 (t, $J=11.6\text{Hz}$, 2H), 2.93 (d, $J=12.0\text{Hz}$, 2H), 2.12 (d, $J=12.8\text{Hz}$, 2H), 1.85-1.93 (m, 2H), 1.71 (s, NH).

^{13}C NMR (100 MHz, CDCl_3): δ 36.48, 42.46, 63.9, 76.1, 127.5, 127.6, 127.7, 128.5, 128.8, 133.3, 139.0, 144.2.

Anal. Calcd for $\text{C}_{18}\text{H}_{21}\text{Cl}_2\text{NO} \cdot 3/4\text{H}_2\text{O}$: C, 63.91; H, 6.26; N, 4.14 Found: C, 63.26; H, 6.05; N, 4.10.

4-(4-Fluorobenzoyloxy)-4-(4-chlorophenyl)-piperidinium chloride (27cb, TAV-29)




General procedure C: This compound was obtained as a white solid (185 mg, 82%).

^1H NMR (400 MHz, CDCl_3): δ 7.32-7.39 (m, 4H), 7.23-7.27 (m, 2H), 6.97-7.03 (m, 2H), 4.04 (s, 2H), 3.10-3.16 (m, 2H), 2.92-2.96 (m, 2H), 2.10 (d, $J=8.0\text{Hz}$, 2H), 1.85-1.92 (m, 2H), 1.62 (s, NH).

^{13}C NMR (100 MHz, CDCl_3): δ 36.4, 42.4, 63.3, 76.2, 115.4, 127.6, 129.2, 133.3, 134.7, 144.0, 161.1, 163.5.

Anal. Calcd for $\text{C}_{19}\text{H}_{20}\text{ClFNO} \cdot 2/3\text{H}_2\text{O}$: C, 58.72; H, 5.84; N, 3.80 Found: C, 58.70; H, 5.61; N, 3.93.

4-(4-Methylbenzyloxy)-4-(4-chlorophenyl)-piperidinium chloride (27cc, TAV-34)




General procedure C: This compound was obtained as a white solid (172 mg, 78%).

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.41-7.45 (m, 2H), 7.19 (d, $J=8.0\text{Hz}$, 2H), 7.13 (d, $J=7.6\text{Hz}$, 2H), 7.03-7.07 (m, 2H), 4.03 (s, 2H), 3.15 (t, $J=11.2\text{Hz}$, 2H), 2.92-2.95 (m, 2H), 2.33 (s, 3H), 2.12 (d, $J=13.2\text{Hz}$, 2H), 1.85-1.92 (m, 2H), 1.70 (s, 1H).

$^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 21.3, 36.6, 42.4, 63.7, 75.9, 115.2, 115.5, 127.7, 127.9, 128.0, 129.2, 136.1, 137.2.

Anal. Calcd for $\text{C}_{19}\text{H}_{23}\text{Cl}_2\text{NO} \cdot 1/3\text{H}_2\text{O}$: C, 63.70; H, 6.66; N, 3.91 Found: C, 63.59; H, 6.31; N, 3.98.

4-(4-Trifluoromethylbenzyloxy)-4-(4-chlorophenyl)-piperidinium chloride (27cd, TAV-28)




General procedure C: This compound was obtained as a white solid (198 mg, 90%).

¹H NMR (400 MHz, CDCl₃): δ 7.57 (d, *J*=8.0Hz, 2H), 7.31-7.43 (m, 6H), 4.14 (s, 2H), 3.14 (t, *J*=11.4Hz, 2H), 2.94 (d, *J*=12.0Hz, 2H), 2.10 (d, *J*=11.6Hz, 2H), 1.87-1.94 (m, 2H), 1.67 (s, NH).

¹³C NMR (100 MHz, CDCl₃): 36.3, 42.4, 63.1, 125.4, 127.4, 127.6, 128.9, 129.8, 133.5, 137.3, 143.1, 143.7,

Anal. Calcd for C₁₉H₂₀Cl₂F₃NO. 3/4H₂O: C, 54.36; H, 5.16; N, 3.34 Found: C, 54.30; H, 5.14; N, 3.38.

4-(3,4-Dichlorobenzyloxy)-4-(4-chlorophenyl)-piperidinium chloride (27ce, TAV-26)




General procedure C: This compound was obtained as a white solid (165 mg, 76%).

¹H NMR (400 MHz, CDCl₃): δ 7.32-7.40 (m, 5H), 7.10 (d, *J*=8.0Hz, 2H), 4.08-3.14 (t, *J*=12.4Hz, 2H), 2.93-2.96 (m, 2H), 2.07-2.11 (d, *J*=13.2Hz, 2H), 1.90-1.94 (m, 2H), 1.68 (s, NH).

¹³C NMR (100 MHz, CDCl₃): δ 36.2, 42.4, 62.6, 76.4, 126.6, 127.5, 128.9, 129.2, 130.4, 131.3, 132.6, 133.5, 139.3, 143.5.

Anal. Calcd for C₁₈H₁₉Cl₄NO: C, 53.10; H, 4.70; N, 3.44 Found: C, 53.02; H, 4.95; N, 3.42.

4-(2-Fluorobenzyloxy)-4-(4-chlorophenyl)-piperidinium chloride (27cf, TAV-61)




General procedure C: This compound was obtained as a white solid (175 mg, 80%).

¹H NMR (400 MHz, CDCl₃): δ 7.46-7.52 (m, 2H), 7.37 (t, *J*=7.6Hz, 2H), 7.22-7.30 (m, 2H), 7.14 (t, *J*=8.4Hz, 1H), 6.99 (t, *J*=9.2Hz, 1H), 4.16 (s, 2H), 3.15 (t, *J*=12.0Hz, 2H), 2.95 (d, *J*=12.4Hz, 2H), 2.15 (d, *J*=12.4Hz, 2H), 1.94 (t, *J*=12.0Hz, 2H), 1.80 (s, NH).

¹³C NMR (100 MHz, CDCl₃): δ 161.8, 159.4, 145.2, 129.8, 129.0, 128.7, 127.5, 126.1, 124.2, 115.1, 76.6, 57.7, 42.4, 36.4.

Anal. Calcd for C₁₈H₂₀Cl₂FNO: C, 60.68; H, 5.66; N, 3.93 Found: C, 60.57; H, 5.81; N, 3.89.

4-(3-Fluoromethylbenzyloxy)-4-(4-chlorophenyl)-piperidinium chloride (27cg, TAV-72)




General procedure C: This compound was obtained as a white solid (182 mg, 84%).

¹H NMR (400 MHz, CDCl₃): δ 7.46 (d, *J*= 7.2Hz, 2H), 7.37 (t, *J*=8.0Hz, 2H), 7.24-7.30 (m, 2H), 7.07 (t, *J*= 8.4Hz, 2H), 4.01 (s, 2H), 3.13-3.20 (m, 2H), 2.94-2.98 (m, 2H), 2.14 (d, *J*=12.0Hz, 2H), 1.92-1.99 (m, 2H), 1.81 (s, 2H).

^{13}C NMR (100 MHz, CDCl_3): δ 36.3, 42.4, 63.1, 76.5, 114.1, 114.2, 122.7, 126.1, 128.7, 142.0, 142.0, 145.1, 161.9, 164.

Anal. Calcd for $\text{C}_{18}\text{H}_{21}\text{Cl}_2\text{FNO} \cdot \text{H}_2\text{O}$: C, 60.54; H, 6.16; N, 4.05 Found: C, 60.42; H, 6.20; N, 3.91.

4-(3, 4-Difluorobenzoyloxy)-4-(4-chlorophenyl)-piperidinium chloride (27ch, TAV-63)




General procedure C: This compound was obtained as a white solid (180 mg, 84%).

^1H NMR (400 MHz, CDCl_3): δ 7.63 (d, $J=8.4\text{Hz}$, 2H), 7.56 (d, $J=8.0\text{Hz}$, 2H), 7.24-7.30 (m, 1H), 7.03-7.07 (m, 2H), 6.91-6.96 (m, 1H), 4.09 (s, 4H), 3.26 (s, 2H), 2.15 (d, $J=12.0\text{Hz}$, 2H), 1.93 (s, 2H), 1.48 (s, NH).

^{13}C NMR (100 MHz, CDCl_3): δ 164.3, 161.9, 155.1, 148.6, 126.5, 122.7, 114.2, 114.5, 79.8, 76.2, 63.6, 39.3, 35.7.

Anal. Calcd for $\text{C}_{18}\text{H}_{19}\text{Cl}_2\text{F}_2\text{NO}$: C, 57.77; H, 5.12; N, 3.74 Found: C, 57.96; H, 5.15; N, 3.64.

4-(4-Chlorobenzoyloxy)-4-(4-chlorophenyl)-piperidinium chloride (27ci, TAV-64)




General procedure C: This compound was obtained as a white solid (200 mg, 95%).

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.40-7.43 (m, 2H), 7.23-7.26 (m, 2H), 6.97-7.01 (m, 4H), 4.03 (s, 3H), 3.14 (t, $J=11.6\text{Hz}$, 2H), 2.92 (d, $J=12.0\text{Hz}$, 2H), 2.10 (d, $J=12.0\text{Hz}$, 2H), 1.86-1.93 (m, 2H), 1.64 (s, NH).

$^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 36.5, 42.5, 63.1, 76.1, 115.3, 115.5, 127.8, 129.2, 134.8, 141.2, 161.1, 163.4.

Anal. Calcd for $\text{C}_{18}\text{H}_{20}\text{Cl}_3\text{NO} \cdot 3/4\text{H}_2\text{O}$: C, 63.20; H, 5.93; N, 3.17 Found: C, 63.17; H, 6.13; N, 3.06.

4-Benzyloxy-4-(4-trifluoromethylphenyl)-piperidinium chloride (27da, TAV-37)




General procedure C: This compound was obtained as a white solid (170 mg, 78%).

¹H NMR (100 MHz, CDCl₃): δ 7.58-7.65 (m, 4H), 7.25-7.36 (m, 5H), 4.12 (s, 2H), 3.20 (t, *J*=12.0Hz, 2H), 2.96 (d, *J*=11.6Hz, 2H), 2.14 (d, *J*=12.4Hz, 2H), 1.90-1.97 (m, 2H), 1.70 (s, NH).

¹³C NMR (100 MHz, CDCl₃): δ 36.4, 42.3, 64.1, 76.4, 125.6, 126.5, 127.6, 128.6, 129.5, 129.8, 138.8, 149.8, 161.1

Anal. Calcd for C₁₉H₂₁ClF₃NO: C, 61.37; H, 5.69; N, 3.77 Found: C, 61.10; H, 5.72; N, 3.73.

4-(4-Fluorobenzyloxy)-4-(4-trifluoromethylphenyl)-piperidinium chloride (27db, TAV-40)




General procedure C: This compound was obtained as a white solid (175mg, 84%).

¹H NMR (400 MHz, CDCl₃): δ 7.64 (d, *J*=8.4Hz, 2H), 7.57 (d, *J*=8.4Hz, 2H), 7.25-7.29 (m, 2H), 7.01 (t, *J*=8.8Hz, 2H), 4.06 (s, 2H), 3.13-3.19 (t, *J*=12.0Hz, 2H), 2.96 (s, *J*=12.0Hz, 2H), 2.13 (d, *J*=12.0Hz, 2H), 1.93 (t, *J*=12.4Hz, 2H) 1.72 (s, NH).

¹³C NMR (100 MHz, CDCl₃): δ 163.6, 161.1, 149.6, 134.5, 129.2, 126.5, 125.7, 115.5, 115.3, 76.5, 63.4, 42.3, 36.3.

Anal. Calcd for C₁₉H₂₀ClF₄NO: C, 58.54; H, 5.17; N, 3.59 Found: C, 58.25; H, 5.23; N, 3.66.

4-(4-Trifluoromethylbenzyloxy)-4-(4-trifluoromethylphenyl)-piperidinium chloride (27dd, TAV-39)




General procedure C: This compound was obtained as a white solid (200mg, 92%).

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.55-7.63 (m, 6H), 7.43 (d, $J=8.0\text{Hz}$, 2H), 4.16 (s, 2H), 3.15 (t, $J=12.0\text{Hz}$, 2H), 2.98 (d, $J=11.6\text{Hz}$, 2H), 2.14 (d, $J=12.4\text{Hz}$, 2H), 1.95 (t, $J=12.0\text{Hz}$, 2H), 1.80 (s, NH).

$^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 36.3, 42.3, 63.3, 76.7, 123.4, 125.4, 125.6, 125.8, 126.4, 127.4, 129.9, 130.0, 142.9, 149.3.

Anal. Calcd for $\text{C}_{20}\text{H}_{20}\text{ClF}_6\text{NO}$: C, 54.62; H, 4.58; N, 3.18 Found: C, 54.52; H, 4.57; N, 3.12.

4-(3, 4-Dichlorobenzoyloxy)-4-(4-trifluoromethylphenyl)-piperidinium chloride (27de, TAV-38)



General procedure C: This compound was obtained as a white solid (182 mg, 81%).

¹H NMR (400 MHz, CDCl₃): δ 7.58-7.64 (m, 3H), 7.21 (d, *J*=8.4Hz, 2H), 7.15 (d, *J*=8.0Hz, 2H), 4.07 (s, 2H), 3.15 (m, 2H), 2.96 (d, *J*=12.0Hz, 2H), 2.34 (s, 3H), 2.113 (d, *J*=12.0Hz, 2H), 1.88-1.96 (m, 2H), 1.64 (s, NH).

¹³C NMR (100 MHz, CDCl₃): δ 21.3, 36.4, 42.3, 64.0, 76.3, 125.6, 126.6, 127.7, 128.6, 129.3, 129.5, 129.8, 133.3, 135.8, 137.3, 149.9

Anal. Calcd for C₁₉H₁₉Cl₃F₃NO: C, 51.78; H, 4.45; N, 3.81 Found: C, 51.59; H, 4.53; N, 2.91.

1.8. References

1. Substance Abuse and Mental Health Services Administration, Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration, **2013**.
2. <http://wyoming.methproject.org/documents/Meth%20Impact%20%20National%20Statistics%20Final.pdf>.
3. Elkashef, A.; Vocci, F.; Hanson, G.; White, J.; Wickes, W.; Tiihonen, J. Pharmacotherapy of methamphetamine addiction: An Update. *Subst. Abuse* **2008**, *29*, 31-49
4. Nichols, D. E. Medicinal chemistry and structure-activity relationships. In Amphetamine and its analogs: Psychopharmacology, toxicology and abuse. Cho, A.K. and Segal, D. S. (Eds). Academic Press, San Diego, 1994, pp. 3-41.
5. Negus, S. S.; Mello, N. K.; Blough, B. E.; Baumann, M. H.; Rothman, R. B. Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as a

- candidate agonist medication for cocaine dependence. *J. Pharmacol. Exp. Ther.* **2007**, *320*, 627-36.
6. Howell, L.L.; Carroll, F.I.; Votaw, J. R.; Goodman, M.M.; Kimmel, H. L. Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration. *J. Pharmacol. Exp. Ther.* **2007**, *320*, 757-65.
 7. http://www.cnsforum.com/educationalresources/imagebank/substance_abuse/mao_cocaine.
 8. <http://chekhovsgun.blogspot.com/2010/05/psychosis-among-substance-users.html>.
 9. Runyon, S. P.; Carroll, F. I. Dopamine transporter ligands: Recent developments and therapeutic potential. *Curr. Top. Med. Chem.* **2006**, *6*, 1825.
 10. Runyon, S. P.; Carroll, F. I. In *Dopamine Transporters: Chemistry Biology and Pharmacology*; Trudell, M. L., Izenwasser, S., Eds.; John Wiley & Sons, Inc.: Hoboken, 2008, pp. 125-170.
 11. Shoptaw, S.; Heinzerling, K.; Rotheram-Fuller, E.; Steward, T.; Swanson, A.N.; DeLa Garza, R.; Newton, T.; Ling, W. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. *Drug Alcohol Depend.* **2008**, *96*, 222-32.
 12. Shearer, J.; Drake, S.; Rodgers, C.; Slade, T.; vanBeek, I.; Lewis, J.; Brady, D.; McKetin, R.; Mattic, R. P.; Woodak, A. A double-blind, placebo controlled trial of modafinil for methamphetamine dependence. *Addiction* **2009**, *104*, 224-233
 13. Newton, T.F.; Reid, M.S.; DeLaGraza, R.; Mahoney, J. J.; Abad, A.; Condos, R.; Palamar, J.; Halkitis, P.N.; Mojisak, J.; Anderson, A.; Li, S. H.; Elkashef, A. Evaluation of the subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. *Int. J. Neuropsychopharmacol.* **2008**, *11*, 1037-45.

14. Urschel, H.C.; Hanselka, L.L.; Baron, M. A controlled trial of flumazenil, gabapentin and hydroxyzine in the treatment of methamphetamine dependence. CPDD 70th annual meeting, Puerto Rico, June 2008: 56
15. Takamatsu, Y.; Yamamoto, H.; Ogai, Y.; Hagino, Y.; Markou, A.; Ikeda, K. Fluoxetine as a Potential pharmacotherapy for methamphetamine dependence studies in mice. *Ann. N.Y. Acad. Sci.* **2006**, *1074*, 295–302.
16. Munzar, P.; Baumann, M.H.; Shoaib, M.; Goldberg, S.R. effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats. *Psychopharmacology* **1999**, *141*, 287-96.
17. Batki, S.L.; Moon, J.; Bradley, M.; Hersh, D.; Smolar, S.; Mengis, M.; Delucchi, K.; Sexe, D.; Bennett, S.; Lefkowitz, E.; Chu, W.; Morello, L.; Jacob, P. III; Jones, R.T. Fluoxetine in methamphetamine dependence. A controlled preliminary analysis. *CPDD 61st Annual Meeting, Acapulco*, 1999, Abstr. 235.
18. Batki, S.L.; Moon, J.; Delucchi, K.; Bradley, M.; Hersh, D.; Smolar, S.; Mengis, M.; Lefkowitz, E.; Sexe, D.; Morello, L.; Everhart, T.; Jacob, P. III; Jones, R.T. 3rd Methamphetamine quantitative urine concentrations during a controlled trial of fluoxetine treatment. *Ann. NY Acad. Sci.* **2000**, *909*, 260-3.
19. Piaseki, M.P.; Steinagel, G.M.; Thienhaus, O.J.; Kohlenberg, B. S.; An exploratory study: the use of paroxetine for methamphetamine craving. *J. Psychoactive Drugs*, **2002**, *34*, 301
20. Zorick, T.; Sugar, C.A.; Helleman, G.; Shoptaw, S.; London, E.D. Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine. *Drug Alcohol Depend.* **2011**, *118*, 500-3.

21. Rothman, R. B.; Partilla, J. S.; Baumann, M. H.; Dersch, C. M.; Carroll, F. I.; Rice, K. C. Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse. *Synapse*, **2000**, *35*, 222-227.
22. Vocci, F. J.; Appel, N. M. Approaches to the development of medications for the treatment of methamphetamine dependence. *Addiction*, **2007**, *102* (Supp. 1), 96-106.
23. Baumann, M. H.; Clark, R. D.; Woolverton, W. L.; Wee, S.; Blough, B. E.; Rothman, R. B. In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. *J. Pharmacol. Exp. Ther.* **2011**, *337*, 218-25
24. Lomenzo, S. A.; Rhoden, J.; Izenwasser, S.; Wade, D.; Kopajtic, T.; Katz, J. L.; Trudell, M. L. Synthesis and biological evaluation of meperidine analogues at monoamine transporters. *J. Med. Chem.* **2005**, *48*, 1336.
25. Rhoden, J.; Bouvet, M.; Izenwasser, S.; Wade, D.; Lomenzo, S. A.; Trudell, M. L. Structure-Activity studies of 3',4'-dichloromeperidine analogues at dopamine and serotonin transporters. *Bioorg. Med. Chem.* **2005**, *13*, 5623-29.
26. Gu, X.; Izenwasser, S.; Wade, D.; Housman, A.; Gulasey, G.; Savoie, C. D.; Mobley, D. L.; Lomenzo, S. A.; Trudell, M. L. Synthesis and structure-activity studies of benzyl ester meperidine and normeperidine derivatives as selective Serotonin transporter ligands. *Bioorg. Med. Chem.* **2010**, *18*, 8356-8365.
27. Zhang, S.; Izenwasser, S.; Wade, D.; Xu, L.; Trudell, M. L. Synthesis of Dopamine Transporter Selective 3-(Diarylmethoxymethyl)-8-alkylaryl-8-azabicyclo[3.2.1]octane Derivatives. *Bioorg. Med. Chem.* **2006**, *14*, 7943.

28. Chen, Z.; Skolnick, P. Triple uptake inhibitors: Therapeutic potential and beyond. *Exp. Opin. Invest. Drugs* **2007**, *16*, 1365-77.
29. Skolnick, P.; Kreiter, P.; Tizzano, J.; Popik, P.; Czobor, P.; Lippa, A. Preclinical and clinical pharmacology of DOV216,303, a triple uptake inhibitor. *CNS Drug Rev.* **2006**, *12*, 123.
30. Kaur, H.; Izenwasser, S.; Verma, A.; Wade, D.; Housman, A.; Gulasey, G.; Trudell, M. L. Synthesis And Monoamine Transporter Affinity Of 3-Aryl-3-Arylmethoxtropane Derivatives. 73rd Cpdd Meeting, Hollywood, Fl, 2011. Abstr. 64
31. Lomenzo, S. A.; Izenwasser, S.; Gerdes, R. M.; Katz, J. L.; Kopajtic, T.; Trudell, M. L. Synthesis, dopamine and serotonin binding affinities of novel analogues of meperidine. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 3273-3276.
32. Kaur, H.; Izenwasser, S.; Verma, A.; Wade, D.; Housman, A.; Stevens, E. D.; Mobley, D. L.; Trudell, M. L. Synthesis and Monoamine Transporter Affinity of 3 α -Arylmethoxy-3 β -arylnortropanes. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 6865.
33. Thaxton, A.; Izenwasser, S.; Wade, D.; Wade, D.; Stevens, E. D.; Mobley, D. L.; Jaber, V.; Lomenzo, S. A.; Trudell, M. L. 3-Aryl-3-arylmethoxyazetidines. A new class of high affinity ligands for monoamine transporters. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 4404-4407.

Chapter 2: Design, synthesis and pharmacological evaluation of 3-aryl-3-aryl pyrrolidines as monoamine transporter ligands

2.1. Abstract

We have designed a novel pyrrolidine pharmacophore by combining structural features of previously active pharmacophore (i.e. piperidine and azetidine pharmacophore). The target compounds were prepared via a four step procedure from 1-Boc-pyrrolidin-3-ol.

2.2. Introduction

The dual acting affinity of piperidine^{1,2} and azetidine³ series on monoamine transporters prompted an investigation to explore the pharmacophore by replacing azetidine or piperidine ring with pyrrolidine ring.¹⁻⁴





Figure 2.1. Design of pyrrolidine pharmacophore.

A novel pyrrolidine pharmacophore (**Pharmacophore 3**) was designed with aryl and arylmethoxy substitution on 3 position of ring. A variety of substituents on the aromatic ring would provide a potent and selective dual acting agent at monoamine transporter.⁵⁻⁷


2.3. Results and discussion

Synthesis of target compounds

The commercially available 1-Boc-pyrrolidin-3-ol was used for the synthesis of the target molecules. The substrate was oxidized using Dess–Martin periodinane to furnish corresponding ketone in excellent yields (**Scheme 2.1**).⁸




Scheme 2.1. Synthesis of Boc-pyrrolidin-3-one



Scheme 2.2. Synthesis of tert-alcohol using aryl lithium reagent.


The ketone was further reacted with a pre-formed aryl lithium reagent that was synthesized in-situ using *n*-Butyl lithium and substituted bromobenzenes to produce tertiary alcohol in moderate

to good yields. A variety of substituents were installed on the aryl moiety to furnish intermediates **4a-4c** (Scheme 2.2).



Scheme 2.3. Alkylation of alcohol using substituted benzyl bromides.

The alcohols **4a-4c** were alkylated using variety of substituted benzyl bromides. The alkylation was performed using sodium hydride and dimethylformamide to furnish intermediates **6aa-6ci** in excellent yields (Scheme 2.3).



Scheme 2.4. Deprotection of Boc-group

Removal of the N-Boc group was performed using hydrochloric acid in methanol to give quantitative yield of the pyrrolidines as the hydrochloride salts **7aa-7ci** (Table 2.1, Scheme 2.4).

Cmpd^a	code	R₁	R₂
7aa	TAV-91	H	H
7ab	TAV-85	H	4-F
7ac	TAV-103	H	4-CH ₃
7ad	TAV-84	H	3,4-Cl ₂
7ae	TAV-130	H	2-F
7af	TAV-104	H	3,5-F ₂
7ag	TAV-87	H	4-Cl
7ah	TAV-132	H	3-Cl
7ba	TAV-94	4-F	H
7bb	TAV-100	4-F	4-F
7bc	TAV-108	4-F	4-CH ₃
7bd	TAV-106	4-F	3, 4-Cl ₂
7ca	TAV-114	4-Cl	H
7cb	TAV-124	4-Cl	4-F
7cf	TAV-122	4-Cl	4-CH ₃
7cd	TAV-120	4-Cl	3,4-Cl ₂
7cg	TAV-126	4-Cl	3,5-F ₂
7cc	TAV-116	4-Cl	4-Cl
7ci	TAV-136	4-Cl	3-Cl

^aAll compounds were synthesized as the HCl salts.

Table 2.1. Final pyrrolidine derivatives.

All the compounds will be tested as hydrochloride salts. Binding affinities for the dopamine, serotonin and norepinephrine transporters will be determined by the ability of the drug to displace the radiolabeled ligands [³H] WIN35,428, [³H] Citalopram, and [³H] nisoxetine respectively, from the monoamine transporters in rat brain tissue using previously reported assays.

All the compounds synthesized in this study are in the process of biological evaluation. The potency and efficacy that is determined for these compounds will provide the direction for further studies with these novel tropane derivatives. All the biological studies will be reported in due course.

2.5. Conclusion

We have synthesized 3-aryl-3-arylmethoxy pyrrolidines using 1-Boc-3-pyrrolidinol using a 4 step synthesis methods. All the final compounds were synthesized with 15-45% of overall yields. We will perform the screening of these compounds on monoamine transporters and study the structure activity relationship in future.

2.6. Experimental

All chemicals were purchased from Aldrich Chemical Company and used as received unless otherwise noted. Anhydrous Ethyl ether (Et₂O), Dimethylformamide (DMF), Methanol (MeOH), Dichloromethane (DCM) was purchased from Mallinckrodt Baker. Inc. Thin layer chromatography (TLC) 20×20 cm aluminium plates precoated with silica gel purchased from EMD Millipore USA and used to monitor reactions via visualization with short-wave UV light. ¹H NMR (400 MHz) and ¹³C NMR (400 MHz) spectra were recorded on a Varian 400 MHz NMR spectrometer at ambient temperature in CDCl₃. ¹H NMR chemical shifts are reported as δ values (ppm) relative to tetramethylsilane. ¹³C NMR chemical shifts are reported as δ values (ppm) relative to CDCl₃ (77.0 ppm). Atlantic Microlab, Inc., Norcross, GA performed all CHN microanalyses.

Synthesis of *tert*-butyl 3-oxopyrrolidine-1-carboxylate

To a clean dry flask was added tert-butyl-3-hydroxypyrrolidine-1-carboxylate (10.7 mmol, 1 equiv.) in dry methanol (20 ml). To the reaction mixture was then added Dess–Martin periodinane (16.1 mmol, 1.5 equiv.) in portions. The reaction mixture was stirred for 3 h at room temperature. After the completion of reaction, the solvent was evaporated under reduced pressure and the crude mixture was diluted with water and extract with ethyl ether (3×20ml). The organic extract was dried over anhydrous sodium sulphate and the solvent was evaporated under reduced pressure to get final product as white solid. (Yield : 1.85g, 90%)


¹H NMR (400 MHz, CDCl₃): 4.32 (d, *J* = 12.8, 2H), 4.12 (s, 2H), 2.71 (d, *J* = 12.4, 2H), 1.40 (s, 9H)

¹³C NMR (100 MHz, CDCl₃): 28.7, 27.5, 37.0, 56.7, 79.5, 159.0, 192.5

General procedure A. Synthesis of tertiary alcohols (4a-4c)

In a clean, dry round-bottom flask was added substituted benzenes (2 equiv.) (**3a-3c**) in dry ethyl ether (20 ml). The solution of n-Butyl lithium (2.1 equiv.) was added to the solution dropwise at 0°C. The solution of 1-(Boc) 4-pyrrolidinone (1 equiv.) (**2**) in diethyl ether was added to the solution at -78°C. The solution was warmed to room temperature and stirred for 2h. The reaction mixture was diluted with ammonium chloride solution. The reaction mixture was extracted with ethyl ether (3×30 ml). The organic extract was washed with brine solution (30 ml) and dried over sodium sulphate. The solvent was evaporated under reduced pressure. The crude mixture was purified using column chromatography to obtain compounds **4a-4c**.

Tert-butyl-3-hydroxy-3-phenylpyrrolidine-1-carboxylate




General procedure A: This compound was obtained as a colorless liquid (2.2 g, 70%).

¹H NMR (400 MHz, CDCl₃): 7.47 (d, *J* = 7.6Hz, 2H), 7.36 (t, *J* = 8.0Hz, 2H), 7.28 (t, *J* = 7.2Hz, 1H), 3.52-3.67 (m, 4H), 3.12 (brs, 1H), 2.12-2.23 (m, 2H), 1.42 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.7, 44.4, 44.8, 64.5, 77.9, 79.7, 126.7, 126.8, 128.6, 128.9, 155.0

Tert-butyl-3-(4-fluorophenyl)-3-hydroxypyrrolidine-1-carboxylate




General procedure A: This compound was obtained as a colorless liquid (1.8g, 55%).

¹H NMR (400 MHz, CDCl₃): 7.42-7.45 (m, 2H), 7.06-7.12 (m, 2H), 3.42-3.65 (m, 4H), 3.18 (brs, 1H), 2.15-2.21 (m, 2H), 1.41 (s, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.7, 44.4, 44.8, 65.9, 75.3, 79.6, 115.6, 127.7, 128.7, 136.1, 154.8.

Tert-butyl-3-(4-chlorophenyl)-3-hydroxypyrrolidine-1-carboxylate



General procedure A: This compound was obtained as a colorless liquid (2.1g, 62%).


^1H NMR (400 MHz, CDCl_3): 7.30 (m, 2H), 7.42 (m, 2H), 3.30-3.92 (m, 4H), 3.12 (brs, 1H), 2.15-2.30 (m, 2H), 1.39 (s, 9H)

^{13}C NMR (100 MHz, CDCl_3): 28.7, 44.4, 44.8, 66.0, 76.3, 79.6, 128.3, 129.0, 134.2, 138.4, 154.7.

General procedure B. Benzylation of alcohols (6aa-6ch)

The solution of compounds **4a-4c** was stirred in dimethylformamide at 0°C . To the solution was added sodium hydride (2.2 equiv.) at 0°C . Variety of benzyl bromides (1.2 equiv.) (**5a-5h**) was added to the solution and the reaction was stirred for 2 h. The reaction was quenched with water and extracted with ethyl acetate (3×20 ml). The organic solvent was washed with brine solution and dried over sodium sulphate. The crude product was purified using column chromatography to obtain compounds **6aa-6ch**.

N-(tert-Butoxycarbonyl)-3-(phenylmethoxy)-3-phenylpyrrolidine (**6aa**, TAV-82)




General procedure B: This compound was obtained as a colorless liquid (280 mg, 75%).

¹H NMR (400 MHz, CDCl₃): 7.24-7.748 (m, 10H), 3.93-4.26 (m, 3H), 3.52-3.73 (m, 3H), 2.51-2.52 (m, 1H), 2.12-2.27 (m, 1H), 1.49 (d, *J*=11.2Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.7, 34.0, 36.5, 44.2, 44.6, 54.8, 56.9, 66.0, 79.8, 85.0, 86.2, 126.8, 127.6, 127.7, 128.5, 128.6, 128.9, 138.9, 140.6, 154.8.

N-(*tert*-Butoxycarbonyl)-3-[(4-fluorophenyl)methoxy]-3-phenyl-pyrrolidine (6ab, TAV-83)




General procedure B: This compound was obtained as a colorless liquid (270 mg, 65%).

¹H NMR (400 MHz, CDCl₃): 7.34-7.45 (m, 5H), 7.16-7.20 (m, 2H), 6.94-6.97 (m, 2H), 3.91-4.20 (m, 3H), 3.51-3.63 (m, 3H), 2.48-2.52 (m, 1H), 2.17-2.27 (m, 1H), 1.49 (d, *J*=11.2Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.7, 33.9, 36.5, 44.4, 44.8, 53.8, 55.9, 65.3, 79.6, 85.0, 86.0, 115.5, 126.8, 128.9, 129.3, 134.4, 140.0, 154.8, 161.2, 163.6.

N-(*tert*-Butoxycarbonyl)-3-[(4-methylphenyl)methoxy]-3-phenyl-pyrrolidine (6ac, TAV-101)




General procedure B: This compound was obtained as a colorless liquid (285 mg, 75%).

¹H NMR (400 MHz, CDCl₃): 7.35-7.49 (m, 5H), 7.14 (m, 4H), 3.94-4.22 (m, 3H), 3.56-3.74 (m, 3H), 2.51-2.54 (m, 1H), 2.34 (s, 3H) 2.23-2.26 (m, 1H), 1.52 (d, *J*=11.6Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 21.3, 38.8, 33.9, 36.5, 44.5, 44.9, 54.0, 56.1, 65.9, 79.5, 84.9, 85.8, 126.8, 127.8, 128.3, 128.8, 129.2, 135.7, 137.3, 140.3, 155.0.

N-(*tert*-Butoxycarbonyl)-3-[(3,4-dichlorophenyl)methoxy]-3-phenyl-pyrrolidine (6ad, TAV-82)




General procedure B: This compound was obtained as a colorless liquid (255 mg, 55%).

¹H NMR (400 MHz, CDCl₃): 7.30-7.41 (m, 6H), 7.00-7.05 (m, 1H), 3.88-4.18 (m, 3H), 3.52-3.69 (m, 3H), 2.46-2.51 (m, 1H), 2.18-2.28 (m, 1H), 1.47 (d, *J*=9.2Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.7, 33.9, 36.4, 44.4, 44.8, 53.7, 55.9, 64.5, 79.7, 85.3, 86.2, 126.7, 126.8, 128.6, 128.9, 129.3, 130.4, 131.3, 132.5, 139.0, 139.6, 155.0.

N-(*tert*-Butoxycarbonyl)-3-[(3-fluorophenyl)methoxy]-3-phenyl-pyrrolidine (6ae, TAV-129)




General procedure B: This compound was obtained as a colorless liquid (270 mg, 70%).

¹H NMR (400 MHz, CDCl₃): 7.31-7.46 (m, 6H), 7.21-7.22 (m, 1H), 7.07-7.12 (m, 1H), 6.94-6.99 (m, 1H), 4.28 (t, *J*=12.4Hz, 1H), 4.146 (t, *J*=12.0Hz, 1H), 3.96 (d, *J*=12.4Hz, 1H), 3.51-3.65 (m, 3H), 2.50-2.51 (m, 1H), 2.20-2.25 (m, 1H), 1.48 (d, *J*=13.2Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.7, 33.9, 35.9, 44.4, 44.8, 54.4, 56.1, 59.6, 79.5, 85.1, 86.0, 115.1, 115.3, 124.2, 124.3, 126.7, 128.4, 128.8, 129.3, 129.9, 139.8, 155.6

N-(*tert*-Butoxycarbonyl)-3-[(3,5-difluorophenyl)methoxy]-3-phenyl-pyrrolidine (7af, TAV-102)




General procedure B: This compound was obtained as a colorless liquid (250 mg, 55%).

¹H NMR (400 MHz, CDCl₃): 7.25-7.41 (m, 5H), 6.61-6.74 (m, 3H), 4.04-4.21 (m, 2H), 3.68 (d, *J*=11.2Hz, 1H), 3.52-3.69 (m, 3H), 2.47-2.51 (m, 1H), 2.18-2.28 (m, 1H), 1.48 (d, *J*=8.0Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.6, 33.9, 36.5, 44.4, 44.8, 53.6, 55.8, 64.7, 79.7, 85.3, 86.2, 115.7, 126.6, 128.5, 129.3, 132.5, 135.5, 138.9, 154.7, 163.9.

N-(*tert*-Butoxycarbonyl)-3-[(4-chlorophenyl)methoxy]-3-phenyl-pyrrolidine (6ag, TAV-86)




General procedure B: This compound was obtained as a colorless liquid (275 mg, 65%).

¹H NMR (400 MHz, CDCl₃): 7.32-7.44 (m, 5H), 7.24-7.27 (m, 2H), 7.13-7.16 (m, 2H), 4.06-4.21 (m, 2H), 3.90 (d, *J*=11.6Hz, 1H), 3.51-3.71 (m, 3H), 2.47-2.51 (m, 1H), 2.17-2.25 (m, 1H), 1.48 (d, *J*=11.2Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.7, 34.0, 36.5, 44.4, 44.9, 53.8, 55.9, 65.2, 79.6, 85.1, 86.0, 126.7, 126.8, 128.4, 128.5, 128.6, 133.3, 133.4, 137.2, 137.3, 139.9, 140.0, 154.8

N-(*tert*-Butoxycarbonyl)-3-[(3-chlorophenyl)methoxy]-3-phenyl-pyrrolidine (6ah, TAV-131)




General procedure B: This compound was obtained as a colorless liquid (250 mg, 50%).

¹H NMR (400 MHz, CDCl₃): 7.33-7.42 (m, 5H), 7.19-7.26 (m, 3H), 7.07-7.10 (m, 1H), 3.91-4.21 (m, 3H), 3.52-3.70 (m, 3H), 2.49-2.51 (m, 1H), 2.18-2.21 (m, 1H), 1.49 (d, *J*=9.4Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.7, 33.9, 36.4, 44.4, 44.9, 53.8, 56.0, 65.1, 79.6, 85.1, 86.1, 125.5, 126.8, 127.5, 127.7, 128.5, 128.9, 129.7, 134.3, 139.8, 140.7, 154.8

N-(*tert*-Butoxycarbonyl)-3-phenylmethoxy-3-(4-fluorophenyl)-pyrrolidine (6ba, TAV-93)




General procedure B: This compound was obtained as a colorless liquid (280 mg, 68%).

¹H NMR (400 MHz, CDCl₃): 7.42-7.45 (m, 2H), 7.22-7.33 (m, 4H), 7.06-7.12 (m, 2H), 3.92-4.24 (m, 3H), 3.51-3.68 (m, 3H), 2.49-2.53 (m, 1H), 2.16-2.22 (m, 1H), 1.50 (d, *J*=9.6Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.7, 34.0, 36.4, 44.4, 44.8, 54.1, 56.1, 65.9, 79.6, 84.5, 85.4, 115.6, 127.6, 127.7, 128.7, 136.1, 138.6, 154.8, 161.4, 163.9.

N-(*tert*-Butoxycarbonyl)-3-[(4-fluorophenyl)methoxy]-3-(4-fluorophenyl)pyrrolidine (6bb, TAV-99)




General procedure B: This compound was obtained as a colorless liquid (265 mg, 62%).

¹H NMR (400 MHz, CDCl₃): 7.38-7.43 (m, 2H), 7.14-7.18 (m, 2H), 7.06-7.11 (m, 2H), 6.94-7.00 (m, 2H), 3.87-4.18 (m, 3H), 3.49-3.67 (m, 3H), 2.45-2.50 (m, 1H), 2.14-2.24 (m, 1H), 1.47 (d, *J*=9.6Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.7, 34.0, 36.6, 44.4, 44.8, 53.9, 56.0, 65.3, 79.7, 84.5, 85.4, 115.3, 115.8, 128.6, 129.4, 134.2, 136.0, 154.9, 161.4, 163.9.

N-(tert-Butoxycarbonyl)-3-[(4-methylphenyl)methoxy]-3-(4-fluorophenyl)-pyrrolidine (6bc, TAV-107)




General procedure B: This compound was obtained as a colorless liquid (282 mg, 78%).

¹H NMR (400 MHz, CDCl₃): 7.41-7.45 (m, 2H), 7.06-7.12 (m, 6H), 4.04-4.20 (m, 2H), 3.93 (d, *J*=11.6Hz, 1H), 3.51-3.65 (m, 3H), 2.48-2.52 (m, 1H), 2.32 (s, 3H), 2.15-2.21 (m, 1H), 1.50 (d, *J*=10.0Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 21.3, 28.7, 34.04, 36.4, 44.4, 44.8, 54.2, 56.1, 65.8, 79.6, 84.4, 85.3, 115.6, 127.7, 128.6, 129.2, 136.2, 137.3, 154.8, 161.4, 163.9.

N-(tert-Butoxycarbonyl)-3-[(3,4-dichlorophenyl)methoxy]-3-(4-fluorophenyl)-pyrrolidine (6bd, TAV-105)




General procedure B: This compound was obtained as a colorless liquid (278 mg, 72%).

¹H NMR (400 MHz, CDCl₃): 7.25-7.39 (m, 4H), 6.99-7.09 (m, 3H), 4.00-4.16 (m, 2H), 3.87 (d, *J*=11.6Hz, 1H), 3.50-3.64 (m, 3H), 2.44-2.49 (m, 1H), 2.15-2.24 (m, 1H), 1.46 (d, *J*=8.4Hz, 9H).

^{13}C NMR (100 MHz, CDCl_3): 28.7, 34.0, 36.4, 44.4, 44.8, 53.8, 55.9, 64.5, 79.7, 84.7, 85.7, 115.7, 126.6, 128.5, 130.5, 131.4, 132.5, 135.5, 138.9, 154.7, 161.5, 163.9.

N-(*tert*-Butoxycarbonyl)-3-[(2-fluorophenyl)methoxy]-3-(4-fluorophenyl)-pyrrolidine (6be, TAV-111)




General procedure B: This compound was obtained as a colorless liquid (280mg, 84%).

^1H NMR (400 MHz, CDCl_3): 7.31-7.43 (m, 3H), 7.21-7.25 (m, 1H), 6.93-7.11 (m, 4H), 3.88-4.27 (m, 3H), 3.46-3.65 (m, 3H), 2.49-2.52 (m, 1H), 2.16-2.27 (m, 1H), 1.45-1.47 (d, $J=9.6\text{Hz}$, 9H).

^{13}C NMR (100 MHz, CDCl_3): 28.7, 33.9, 35.9, 44.4, 44.8, 54.5, 56.1, 59.6, 79.6, 84.6, 85.5, 115.8, 124.2, 124.3, 125.5, 128.5, 129.3, 129.9, 135.8, 154.7, 161.4, 163.9.

N-(*tert*-Butoxycarbonyl)-3-[(3,5-difluorophenyl)methoxy]-3-(4-fluorophenyl)-pyrrolidine (6bf, TAV-109)




General procedure B: This compound was obtained as a colorless liquid (264 mg, 62%).

¹H NMR (400 MHz, CDCl₃): 7.34-7.39 (m, 2H), 7.02-7.07 (m, 2H), 6.59-6.71 (m, 3H), 4.00-4.18 (m, 2H), 3.88 (d, *J*=11.6Hz, 1H), 3.51-3.59 (m, 3H), 2.43-2.48 (m, 1H), 2.14-2.20 (m, 1H), 1.44 (d, *J*=6.4Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.6, 34.0, 36.4, 44.3, 44.8, 53.8, 55.8, 64.6, 79.7, 84.8, 85.7, 102.7, 109.8, 115.7, 128.5, 135.5, 142.7, 154.7, 161.8, 164.3.

N-(*tert*-Butoxycarbonyl)-3-[(4-chlorophenyl)methoxy]-3-(4-fluorophenyl)-pyrrolidine (6bg, TAV-95)




General procedure B: This compound was obtained as a colorless liquid (270 mg, 68%).

¹H NMR (400 MHz, CDCl₃): 7.37-7.40 (m, 2H), 7.21-7.24 (m, 2H), 7.12 (d, *J*=8.0Hz, 2H), 7.03- 7.08 (m, 2H), 3.87-4.17 (m, 3H), 3.50-3.64 (m, 3H), 2.45-2.48 (m, 1H), 2.13-2.23 (m, 1H), 1.46 (d, *J*=9.6Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.7, 34.0, 36.4, 44.4, 44.8, 54.0, 55.9, 65.1, 79.6, 84.6, 85.5, 115.8, 128.6, 128.9, 133.4, 135.8, 137.1, 154.9, 161.4, 163.9

N-(*tert*-Butoxycarbonyl)-3-phenylmethoxy-3-(4-chlorophenyl)-pyrrolidine (6ca, TAV-113)




General procedure B: This compound was obtained as a colorless liquid (284 mg, 86%).

¹H NMR (400 MHz, CDCl₃): 7.21-7.38 (m, 9H), 4.04-4.23 (m, 2H), 3.91(d, *J*=11.6Hz, 1H), 3.52-3.68 (m, 3H), 2.47-2.48 (m, 1H), 2.15-2.18 (m, 1H), 1.49 (d, *J*=9.6Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.7, 34.1, 36.5, 44.4, 44.8, 54.0, 55.9, 66.0, 79.6, 84.5, 85.4, 127.6, 127.6, 128.2, 128.3, 128.5, 129.0, 134.2, 138.4, 138.9, 154.7.

N-(*tert*-Butoxycarbonyl)-3-[(4-fluorophenyl)methoxy]-3-(4-chlorophenyl)-pyrrolidine (6cb, TAV-123)




General procedure B: This compound was obtained as a colorless liquid (272 mg, 64%).

¹H NMR (400 MHz, CDCl₃): 7.36-7.37 (m, 4H), 7.15-7.18 (m, 2H), 6.94-6.99 (m, 2H), 4.01-4.18 (m, 2H), 3.87 (d, *J*=11.6Hz, 1H), 3.50-3.61 (m, 3H), 2.46-2.49 (m, 1H), 2.13-2.20 (m, 1H), 1.45 (d, *J*=9.6Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.7, 34.0, 36.6, 44.4, 44.8, 53.8, 55.8, 65.4, 79.7, 84.5, 85.5, 115.5, 128.2, 129.1, 129.4, 134.2, 138.6, 154.7, 161.2, 163.6.

N-(*tert*-Butoxycarbonyl)-3-[(4-methylphenyl)methoxy]-3-(4-chlorophenyl)-pyrrolidine (6cc, TAV-121)




General procedure B: This compound was obtained as a colorless liquid (265 mg, 60%).

¹H NMR (400 MHz, CDCl₃): 7.39-7.29 (m, 4H), 7.12 (d, *J*=0.8Hz, 4H), 4.03-4.20 (m, 2H), 3.90 (d, *J*=11.6Hz, 1H), 3.49-3.68 (m, 3H), 2.48-2.50 (m, 1H), 2.33 (s, 3H), 2.16-2.21 (m, 1H), 1.48 (d, *J*=10.4Hz, 9H).

¹³C NMR (400 MHz, CDCl₃): 21.3, 28.7, 34.0, 36.6, 44.4, 44.8, 53.9, 56.0, 66.0, 79.6, 84.4, 85.4, 128.3, 129.0, 129.2, 129.3, 134.2, 135.4, 137.6, 139.0, 154.8

N-(tert-Butoxycarbonyl)-3-[(3,4-dichlorophenyl)methoxy]-3-(4-chlorophenyl)-pyrrolidine (6cd, TAV-119)




General procedure B: This compound was obtained as a colorless liquid (285 mg, 84%).

¹H NMR (400 MHz, CDCl₃): 7.25-7.36 (m, 6H), 6.99-7.03 (m, 1H), 3.99-4.16 (m, 2H), 3.84 (d, *J*=11.6Hz, 1H), 3.50-3.64 (m, 3H), 2.44-2.47 (m, 1H), 2.13 (s, 1H), 1.46(d, *J*=8.4Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.7, 34.0, 36.4, 44.3, 44.7, 53.7, 55.7, 64.6, 79.8, 84.8, 85.7, 126.6, 128.1, 129.1, 129.3, 130.4, 131.5, 132.6, 134.5, 138.3, 138.7, 154.7.

N-(tert-Butoxycarbonyl)-3-[(3,5-difluorophenyl)methoxy]-3-(4-chlorophenyl)-pyrrolidine
(6ce, TAV-133)




General procedure B: This compound was obtained as a colorless liquid (260 mg, 61%).

¹H NMR (400 MHz, CDCl₃): 7.33 (m, 4H), 6.60-6.72 (m, 4H), 3.85-4.19 (m, 3H), 3.51-3.63 (m, 3H), 2.46-2.47 (m, 1H), 2.14-2.20 (m, 1H), 1.45 (d, *J*=6.0Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.6, 34.0, 36.5, 44.3, 44.8, 53.6, 55.7, 64.8, 79.8, 84.8, 85.7, 102.8, 109.8, 127.7, 127.8, 128.1, 129.1, 134.4, 138.2, 142.7, 154.6, 161.9

N-(tert-Butoxycarbonyl)-3-[(3,5-difluorophenyl)methoxy]-3-(4-chlorophenyl)-pyrrolidine
(6cf, TAV-125)




General procedure B: This compound was obtained as a colorless liquid (270 mg, 65%).

¹H NMR (400 MHz, CDCl₃): 7.31-7.37 (m, 4H), 7.19-7.21 (m, 1H), 7.05-7.10 (m, 1H), 6.93-6.97 (m, 1H), 4.21 (t, *J*=11.2Hz, 1H), 4.10-4.16 (t, *J*=11.2Hz, 1H), 3.90 (d, *J*=11.6Hz, 1H), 3.48-3.64 (m, 3H), 2.47-2.50 (m, 1H), 2.10-2.19 (m, 1H), 1.45 (d, *J*=8.0Hz, 9H).

^{13}C NMR (100 MHz, CDCl_3): 28.7, 33.9, 35.9, 44.3, 44.7, 54.4, 55.9, 59.7, 79.7, 84.6, 85.5, 115.4, 124.2, 128.2, 129.0, 129.3, 129.9, 134.2, 138.5, 154.7.

N-(*tert*-Butoxycarbonyl)-3-[(4-chlorophenyl)methoxy]-3-(4-chlorophenyl)-pyrrolidine (6cg, TAV-115)




General procedure B: This compound was obtained as a colorless liquid (275 mg, 72%).

^1H NMR (400 MHz, CDCl_3): 7.34 (d, $J=3.6\text{Hz}$, 4H), 7.23-7.26 (m, 2H), 7.12-7.14 (m, 2H), 4.00-4.18 (m, 2H), 3.86 (d, $J=12.0\text{Hz}$, 1H), 3.48-3.65 (m, 3H), 2.44-2.47 (m, 1H), 2.13-2.19 (m, 1H), 1.46 (d, $J=9.6\text{Hz}$, 9H).

^{13}C NMR (100 MHz, CDCl_3): 28.7, 34.1, 36.5, 44.4, 44.8, 53.8, 55.8, 65.3, 79.7, 84.6, 85.6, 125.5, 127.4, 128.1, 128.2, 129.1, 134.4, 138.4, 142.6, 154.7

N-(*tert*-Butoxycarbonyl)-3-[(3-chlorophenyl)methoxy]-3-(4-chlorophenyl)-pyrrolidine (6ch, TAV-135)



General procedure B: This compound was obtained as a colorless liquid (290 mg, 81%).


¹H NMR (400 MHz, CDCl₃): 7.31-7.32 (m, 4H), 7.15-7.17 (m, 3H), 7.03-7.05 (m, 1H), 3.98-4.16 (m, 2H), 3.86 (d, *J*=11.2Hz, 1H), 3.49-3.62 (m, 3H), 2.42-2.45 (m, 1H), 2.14-2.17 (m, 1H), 1.44 (d, *J*=8.0Hz, 9H).

¹³C NMR (100 MHz, CDCl₃): 28.7, 33.9, 36.3, 44.3, 44.7, 53.9, 55.8, 65.2, 79.7, 84.6, 85.6, 125.4, 127.5, 127.7, 127.8, 128.2, 129.1, 129.8, 134.3, 138.4, 140.5, 154.

General procedure C. Synthesis of hydrochloride salts (7aa-7eh)

To the solution of **6aa-6ch** in methanol (15ml) was added to conc. HCl (2 ml) and stirred for 1h. The solvent was evaporated under reduced pressure. To the crude product was added water (20ml) at 0°C. The solid formed was filtered and dried under vacuum to get hydrochloride salt of compounds **7aa-7ch**.

3-(Benzyloxy)-3-phenylpyrrolidine hydrochloride (7aa, TAV-91)




General procedure C: This compound was obtained as a white solid (182 mg, 81%).

¹H NMR (400 MHz, CDCl₃): 7.23-7.41 (m, 10H), 4.10-4.20 (m, 2H), 3.43 (d, *J*=12.0Hz, 1H), 3.26-3.30 (m, 1H), 3.10 (s, 1H), 2.91-2.94 (m, 1H), 2.37-2.48 (m, 2H), 2.10-2.18 (m, 1H)

¹³C NMR (100 MHz, CDCl₃): 36.1, 46.2, 58.2, 65.8, 88.0, 127.5, 127.7, 128.5, 128.6, 128.8, 133.6, 138.8, 140.1.

Anal. Calcd for C₁₇H₂₀ClNO: C, 70.46; H, 6.96; N, 4.83 Found: C, 69.80; H, 6.79; N, 4.87.

3-(4-Fluorobenzyloxy)-3-phenylpyrrolidine hydrochloride (7ab, TAV-85)




General procedure C: This compound was obtained as a white solid (190 mg, 88%).

¹H NMR (400 MHz, CDCl₃): 7.33-7.39 (m, 5H), 7.17-7.20 (m, 2H), 6.96-7.00 (m, 2H), 4.05-4.14 (m, 2H), 3.41 (dd, *J*=1.2Hz, 12.0Hz, 1H), 3.26-3.29 (m, 1H), 3.09-3.11 (m, 1H), 2.91 (d, *J*=12.4Hz, 1H), 2.38-2.41 (m, 2H), 2.12-2.18 (m, 1H).

¹³C NMR (100 MHz, CDCl₃): 36.1, 46.1, 58.1, 65.1, 88.1, 115.3, 128.5, 128.9, 129.2, 129.3, 133.7, 134.5, 140.0.

Anal. Calcd for C₁₇H₁₉ClFNO. 1/4H₂O: C, 65.38; H, 6.12; N, 4.54 Found: C, 65.46; H, 6.23; N, 4.62.

3-(4-Methylbenzyloxy)-3-phenylpyrrolidine hydrochloride (7ac, TAV-103)




General procedure C: This compound was obtained as a white solid (186 mg, 85%).

¹H NMR (400 MHz, CDCl₃): 7.33-7.40 (m, 5H), 7.12-7.25 (m, 4H), 4.05-4.15 (m, 2H), 3.41 (d, *J*=12.0Hz, 1H), 3.24-3.31 (m, 1H), 3.05-3.11 (m, 1H), 2.90 (d, *J* =12.4Hz, 1H), 2.35-2.42 (m, 2H), 2.32 (s, 3H), 2.13-2.16 (m, 1H).

¹³C NMR (100 MHz, CDCl₃): 21.3, 36.1, 46.1, 58.1, 65.7, 87.9, 127.6, 128.5, 128.8, 129.3, 133.6, 135.7, 137.4, 140.1.

Anal. Calcd for C₁₈H₂₂ClNO. 1/3H₂O: C, 69.79; H, 7.37; N, 4.52 Found: C, 69.43; H, 7.11; N, 4.65.

3-(3,4-Dichlorobenzoyloxy)-3-phenylpyrrolidine hydrochloride (7ad, TAV-84)




General procedure C: This compound was obtained as a white solid (175mg, 80%).

¹H NMR (400 MHz, CDCl₃): 7.33-7.35 (m, 6H), 7.03 (d, *J*=8.4Hz, 2H), 4.04-4.12 (m, 2H), 3.43 (d, *J*=11.6Hz, 1H), 3.27 (brs, 1H), 2.97-3.12 (m, 2H), 2.35-2.38 (m, 1H), 2.13-2.19 (s, 1H).

¹³C NMR (100 MHz, CDCl₃): 35.9, 45.9, 57.7, 64.4, 88.2, 126.6, 128.4, 129.0, 129.2, 130.5, 132.5, 133.6, 134.0, 139.0, 139.4.

Anal. Calcd for C₁₇H₁₈Cl₃NO. 2H₂O: C, 56.92; H, 5.05; N, 3.90 Found: C, 51.72; H, 5.57; N, 3.58.

3-(2-Fluorobenzoyloxy)-3-phenylpyrrolidine hydrochloride (7ae, TAV-130)




General procedure C: This compound was obtained as a white solid (190 mg, 89%).

¹H NMR (400 MHz, CDCl₃): 7.35-7.39 (m, 4H), 7.10 (t, *J*=7.6Hz, 2H), 6.96-7.00 (t, *J*=9.2Hz, 1H), 4.14-4.23 (m, 2H), 3.43-3.46 (d, *J*=12.4Hz, 1H), 3.24-3.31 (m, 1H), 3.05-3.11 (m, 1H), 2.90-2.93 (d, *J*=12.0Hz, 1H), 2.37-2.43 (m, 2H), 2.10-2.17 (m, 1H).

^{13}C NMR (100 MHz, CDCl_3): 36.1, 46.1, 58.0, 59.7, 88.1, 115.3, 124.3, 128.5, 128.8, 129.4, 129.9, 130.5, 133.7, 138.9 139.7.

Anal. Calcd for $\text{C}_{17}\text{H}_{19}\text{ClFNO}$: C, 66.34; H, 6.22; N, 4.55 Found: C, 66.05; H, 6.28; N, 4.72.

3-(3,5-Difluorobenzyloxy)-3-phenylpyrrolidine hydrochloride (7af, TAV-104)




General procedure C: This compound was obtained as a white solid (182 mg, 79%).

^1H NMR (400 MHz, CDCl_3): 7.32-7.39 (m, 4H), 7.21-7.25 (m, 1H), 7.10 (t, $J=7.6\text{Hz}$, 2H), 6.96-7.00 (t, $J=8.8\text{Hz}$, 1H), 4.14-4.23 (m, 2H), 3.43-3.46 (d, $J=12.4\text{Hz}$, 1H), 3.24-3.31 (m, 1H), 3.05-3.11 (m, 1H), 2.90-2.93 (d, $J=12.0\text{Hz}$, 1H), 2.37-2.43 (m, 2H), 2.10-2.17 (m, 1H).

^{13}C NMR (100 MHz, CDCl_3): 36.1, 46.1, 58.0, 59.7, 88.1, 115.3, 124.3, 128.5, 128.8, 129.4, 129.9, 133.7, 139.7.

Anal. Calcd for $\text{C}_{17}\text{H}_{18}\text{ClF}_2\text{NO}$: C, 62.67; H, 5.57; N, 4.30 Found: C, 62.40; H, 5.53; N, 4.39.

3-(4-Chlorobenzyloxy)-3-phenylpyrrolidine hydrochloride (7ag, TAV-87)




General procedure C: This compound was obtained as a white solid (174 mg, 78%).

¹H NMR (400 MHz, CDCl₃): 7.32-7.37 (m, 5H), 7.26 (d, *J*=8.4Hz, 2H), 7.15 (d, *J*=8.4Hz, 2H), 4.05-4.15 (m, 2H), 3.41 (d, *J*=12.1Hz, 1H), 3.26-3.28 (m, 1H), 3.09 (brs, 1H), 2.91-2.93 (m, 2H), 2.34-2.40 (m, 1H), 2.10-2.17 (m, 1H).

¹³C NMR (100 MHz, CDCl₃): 36.1, 46.1, 58.1, 65.0, 128.4, 128.7, 128.8, 128.9, 133.4, 133.8, 137.3, 139.8.

Anal. Calcd for C₁₇H₁₉Cl₂NO · 3/4H₂O: C, 62.97; H, 5.91; N, 4.32 Found: C, 62.68; H, 6.00; N, 4.37.

3-(3-Chlorobenzyloxy)-3-phenylpyrrolidine hydrochloride (7ah, TAV-132)




General procedure C: This compound was obtained as a white solid (188mg, 83%).

¹H NMR (400 MHz, CDCl₃): 7.35-7.39 (m, 5H), 7.25-7.27 (m, 2H), 7.20 (t, *J*=8.4Hz, 2H), 4.05-4.15 (m, 2H), 3.42 (d, *J*=12.4Hz, 2H), 3.27 (m, 1H), 2.91-2.93 (m, 2H), 2.38-2.40 (m, 1H), 2.10-2.17 (m, 1H).

¹³C NMR (100 MHz, CDCl₃): 36.1, 46.1, 58.1, 65.0, 88.1, 115.3, 128.4, 128.7, 128.8, 128.9, 131.2, 133.4, 133.8, 137.3, 139.7.

Anal. Calcd for C₁₇H₁₉Cl₂NO: C, 60.45; H, 6.12; N, 4.15 Found: C, 60.15; H, 5.38; N, 4.63.

3-(Benzyloxy)-3-(4-fluorophenyl)-pyrrolidine hydrochloride (7ba, TAV-94)




General procedure C: This compound was obtained as a white solid (180 mg, 83%).

¹H NMR (400 MHz, CDCl₃): 7.23-7.41 (m, 5H), 7.17-7.20 (m, 2H), 6.96-7.00 (m, 2H), 4.10-4.20 (m, 2H), 3.43 (d, *J*=12.0Hz, 1H), 3.26-3.30 (m, 1H), 3.10 (s, 1H), 2.91-2.94 (m, 1H), 2.37-2.48 (m, 2H), 2.10-2.18 (m, 1H)

¹³C NMR (100 MHz, CDCl₃): 36.1, 46.2, 58.2, 65.8, 88.0, 127.5, 127.7, 128.5, 128.6, 128.8, 133.6, 138.8, 140.1.

Anal. Calcd for C₁₇H₁₉ClFNO. 3/4H₂O: C, 63.55; H, 6.43; N, 4.36 Found: C, 63.70; H, 6.37; N, 4.66.

3-(4-Fluorobenzoyloxy)-3-(4-fluorophenyl)pyrrolidine hydrochloride (7bb, TAV-100)




General procedure C: This compound was obtained as a white solid (176 mg, 80%).

¹H NMR (400 MHz, CDCl₃): 7.33-7.39 (m, 4H), 7.20-7.24 (m, 2H), 6.96-7.00 (m, 2H), 4.05-4.14 (m, 2H), 3.41 (dd, *J*=1.2Hz, 11.6Hz, 1H), 3.26-3.29 (m, 1H), 3.09-3.11 (m, 1H), 2.91 (d, *J*=12.4Hz, 1H), 2.38-2.41 (m, 2H), 2.12-2.18 (m, 1H).

¹³C NMR (100 MHz, CDCl₃): 36.1, 46.1, 58.1, 65.1, 88.1, 115.3, 128.5, 128.9, 129.2, 129.3, 133.7, 134.5, 140.0.

Anal. Calcd for C₁₇H₁₈ClF₂NO. 1/2H₂O: C, 60.99; H, 5.72; N, 4.18 Found: C, 61.11; H, 5.55; N, 4.34.

3-(4-Methylbenzyloxy)-3-(4-fluorophenyl)-pyrrolidine hydrochloride (7bc, TAV-108)




General procedure C: This compound was obtained as a white solid (195 mg, 90%).

¹H NMR (400 MHz, CDCl₃): 7.33-7.40 (m, 4H), 7.09-7.29 (m, 4H), 4.05-4.15 (m, 2H), 3.41 (d, *J*=12.0Hz, 1H), 3.24-3.31 (m, 1H), 3.05-3.11 (m, 1H), 2.90 (d, *J*=12.4Hz, 1H), 2.35-2.42 (m, 2H), 2.32 (s, 3H), 2.13-2.16 (m, 1H).

¹³C NMR (100 MHz, CDCl₃): 21.3, 36.1, 46.1, 58.1, 65.7, 87.9, 127.6, 128.5, 128.8, 129.3, 133.6, 135.7, 137.4, 140.1.

Anal. Calcd for C₁₇H₂₁ClFNO.2/3H₂O: C, 64.79; H, 6.74; N, 4.20 Found: C, 64.48; H, 6.44; N, 4.45.

3-(3,4-Dichlorobenzoyloxy)-3-(4-fluorophenyl)-pyrrolidine hydrochloride (7bd, TAV-106)




General procedure C: This compound was obtained as a white solid (185 mg, 81%).

¹H NMR (400 MHz, CDCl₃): 7.33-7.35 (m, 2H), 7.25-7.27 (m, 2H), 7.20 (t, *J*=8.4Hz, 2H), 7.03 (d, *J*=8.4Hz, 1H), 4.04-4.12 (m, 2H), 3.43 (d, *J*=11.6Hz, 1H), 3.27 (brs, 1H), 2.97-3.12 (m, 2H), 2.35-2.38 (m, 1H), 2.13-2.19 (s, 1H).

¹³C NMR (100 MHz, CDCl₃): 35.9, 45.9, 57.7, 64.4, 88.2, 126.6, 128.4, 129.0, 129.2, 130.5, 132.5, 133.6, 134.0, 139.0, 139.4.

Anal. Calcd for C₁₇H₁₇Cl₃FNO: C, 54.21; H, 4.55; N, 3.72 Found: C, 53.95; H, 4.44; N, 3.71.

3-(Benzyloxy)-3-(4-chlorophenyl)-pyrrolidine hydrochloride (7ca, TAV-114)




General procedure C: This compound was obtained as a white solid (172 mg, 79%).

¹H NMR (400 MHz, CDCl₃): 7.23-7.41 (m, 9H), 4.10-4.20 (m, 2H), 3.43 (d, *J*=12.0Hz, 1H), 3.26-3.30 (m, 1H), 3.10 (s, 1H), 2.91-2.94 (m, 1H), 2.37-2.48 (m, 2H), 2.10-2.18 (m, 1H)

¹³C NMR (100 MHz, CDCl₃): 36.1, 46.2, 58.2, 65.8, 88.0, 127.5, 127.7, 128.5, 128.6, 128.8, 133.6, 138.8, 140.1

Anal. Calcd for C₁₇H₁₉Cl₂NO: C, 62.97; H, 5.91; N, 4.32 Found: C, 62.72; H, 5.74; N, 4.27.

3-(4-Fluorobenzyloxy)-3-(4-chlorophenyl)-pyrrolidine hydrochloride (7cb, TAV-124)




General procedure C: This compound was obtained as a white solid (190 mg, 87%).

¹H NMR (400 MHz, CDCl₃): 7.33-7.39 (m, 4H), 7.17-7.20 (m, 2H), 6.96-7.00 (m, 2H), 4.05-4.14 (m, 2H), 3.41 (dd, *J*=1.2Hz, 12.0Hz, 1H), 3.26-3.29 (m, 1H), 3.09-3.11 (m, 1H), 2.91 (d, *J*=12.4Hz, 1H), 2.38-2.41 (m, 2H), 2.12-2.18 (m, 1H).

¹³C NMR (100 MHz, CDCl₃): 36.1, 46.1, 58.1, 65.1, 88.1, 115.3, 128.5, 128.9, 129.2, 129.3, 133.7, 134.5, 140.0.

Anal. Calcd for C₁₇H₁₈Cl₂FNO: C, 59.66; H, 5.30; N, 4.09 Found: C, 59.38; H, 5.40; N, 4.06.

3-(4-Methylbenzyloxy)-3-(4-chlorophenyl)-pyrrolidine hydrochloride (7cc, TAV-122)




General procedure C: This compound was obtained as a white solid (198 mg, 91%).

¹H NMR (400 MHz, CDCl₃): 7.33-7.40 (m, 4H), 7.12-7.25 (m, 4H), 4.05-4.15 (m, 2H), 3.41 (d, *J*=12.0Hz, 1H), 3.24-3.31 (m, 1H), 3.05-3.11 (m, 1H), 2.90 (d, *J* =12.4Hz, 1H), 2.35-2.42 (m, 2H), 2.32 (s, 3H), 2.13-2.16 (m, 1H).

¹³C NMR (100 MHz, CDCl₃): 21.3, 36.1, 46.1, 58.1, 65.7, 87.9, 127.6, 128.5, 128.8, 129.3, 133.6, 135.7, 137.4, 140.1.

Anal. Calcd for C₁₈H₂₁Cl₂NO · H₂O: C, 60.88; H, 6.51; N, 3.93 Found: C, 59.58; H, 6.26; N, 3.97.

3-(3,4-Dichlorobenzoyloxy)-3-(4-chlorophenyl)-pyrrolidine hydrochloride (7cd, TAV-120)




General procedure C: This compound was obtained as a white solid (184mg, 81%).

¹H NMR (400 MHz, CDCl₃): 7.33-7.35 (m, 6H), 7.03 (d, *J*=8.4Hz, 1H), 4.04-4.12 (m, 2H), 3.43 (d, *J*=11.6Hz, 1H), 3.27 (brs, 1H), 2.97-3.12 (m, 2H), 2.35-2.38 (m, 1H), 2.13-2.19 (s, 1H).

¹³C NMR (100 MHz, CDCl₃): 35.9, 45.9, 57.7, 64.4, 88.2, 126.6, 128.4, 129.0, 129.2, 130.5, 132.5, 133.6, 134.0, 139.0, 139.4.

Anal. Calcd for C₁₇H₁₇Cl₄NO. 1/4H₂O: C, 51.35; H, 4.44; N, 3.52 Found: C, 51.68; H, 4.40; N, 3.53.

3-(3,5-Difluorobenzoyloxy)-3-(4-chlorophenyl)-pyrrolidine hydrochloride (7cf, TAV-126)




General procedure C: This compound was obtained as a white solid (188 mg, 84%).

¹H NMR (400 MHz, CDCl₃): 7.32-7.39 (m, 4H), 7.21-7.25 (m, 1H), 7.10 (t, *J*=7.6Hz, 1H), 6.96-7.00 (t, *J*=8.8Hz, 1H), 4.14-4.23 (m, 2H), 3.43-3.46 (d, *J*=12.4Hz, 1H), 3.24-3.31 (m, 1H), 3.05-3.11 (m, 1H), 2.90-2.93 (d, *J*=12.0Hz, 1H), 2.37-2.43 (m, 2H), 2.10-2.17 (m, 1H).

¹³C NMR (100 MHz, CDCl₃): 36.1, 46.1, 58.0, 59.7, 88.1, 115.3, 124.3, 128.5, 128.8, 129.4, 129.9, 133.7, 139.7.

Anal. Calcd for C₁₇H₁₇Cl₂F₂NO: C, 56.68; H, 4.76; N, 3.89 Found: C, 56.38; H, 4.81; N, 3.89.

3-(4-Chlorobenzoyloxy)-3-(4-chlorophenyl)-pyrrolidine hydrochloride (7cg, TAV-116)




General procedure C: This compound was obtained as a white solid (175 mg, 79%).

¹H NMR (400 MHz, CDCl₃): 7.32-7.37 (m, 4H), 7.26 (d, *J*=8.4Hz, 2H), 7.15 (d, *J*=8.4Hz, 2H), 4.05-4.15 (m, 2H), 3.41 (d, *J*=12.1Hz, 1H), 3.26-3.28 (m, 1H), 3.09 (brs, 1H), 2.91-2.93 (m, 2H), 2.34-2.40 (m, 1H), 2.10-2.17 (m, 1H).

¹³C NMR (100 MHz, CDCl₃): 36.1, 46.1, 58.1, 65.0, 128.4, 128.7, 128.8, 128.9, 133.4, 133.8, 137.3, 139.8.

Anal. Calcd for C₁₇H₁₈Cl₃NO: C, 56.92; H, 5.05; N, 3.90 Found: C, 56.88; H, 5.21; N, 3.92.

3-(3-Chlorobenzoyloxy)-3-(4-chlorophenyl)-pyrrolidine hydrochloride (7ch, TAV-136)



General procedure C: This compound was obtained as a white solid (190 mg, 87%).

¹H NMR (400 MHz, CDCl₃): 7.32-7.37 (m, 4H), 7.25-7.27 (m, 2H), 7.15 (t, *J*=8.4Hz, 2H), 4.05-4.15 (m, 2H), 3.42 (d, *J*=12.4Hz, 2H), 3.27 (m, 1H), 2.91-2.93 (m, 2H), 2.38-2.40 (m, 1H), 2.10-2.17 (m, 1H).

¹³C NMR (100 MHz, CDCl₃): 36.1, 46.1, 58.1, 65.0, 88.1, 115.3, 128.4, 128.7, 128.8, 128.9, 131.2, 133.4, 133.8, 137.3, 139.7.

Anal. Calcd for C₁₇H₁₈Cl₃NO: C, 56.92; H, 5.06; N, 3.90 Found: C, 56.62; H, 5.09; N, 3.93.

2.7. References

1. Kaur, H.; Izenwasser, S.; Verma, A.; Wade, D.; Housman, A.; Gulasey, G.; Trudell, M. L. Synthesis And Monoamine Transporter Affinity Of 3-Aryl-3-Arylmethoxtropane Derivatives. 73rd CPDD Meeting, Hollywood, Fl, 2011. Abstr. 64
2. Kaur, H.; Izenwasser, S.; Verma, A.; Wade, D.; Housman, A.; Stevens, E, D.; Mobley, D. L.; Trudell, M. L. Synthesis and Monoamine Transporter Affinity of 3 α -Arylmethoxy-3 β -arylnortropans. *Bioorg. Med. Chem. Lett.* 2009, 19, 6865–6868.
3. Thaxton, A.; Izenwasser, S.; Wade, D.; Stevens, E, D.; Mobley, D. L.; Jaber V.; Lomenzo, S. A.; Trudell, M. L. 3-Aryl-3-arylmethoxyazetidines. A new class of high affinity ligands for monoamine transporters. *Bio. Org. Med. Chem. Lett.* 2013, 23, 4404-4407.
4. Runyon, S. P.; Carroll, F. I. Dopamine transporter ligands: Recent developments and therapeutic potential. *Curr. Top. Med. Chem.* 2006, 6, 1825.
5. Runyon, S. P.; Carroll, F. I. In *Dopamine Transporters: Chemistry Biology and Pharmacology*; Trudell, M. L., Izenwasser, S., Eds.; John Wiley & Sons, Inc.: Hoboken, 2008, pp. 125-170.
6. Zhang, S.; Izenwasser, S.; Wade, D.; Xu, L.; Trudell, M. L. Synthesis of Dopamine Transporter Selective 3-(Diarylmethoxymethyl)-8-alkylaryl-8-azabicyclo[3.2.1]octane Derivatives. *Bioorg. Med. Chem.* 2006, 14, 7943.
7. Skolnick, P.; Kreiter, P.; Tizzano, J.; Popik, P.; Czobor, P.; Lippa, A. Preclinical and clinical pharmacology of DOV216,303, a triple uptake inhibitor. *CNS Drug Rev.* 2006, 12, 123.
8. Kaur, H.; Izenwasser, S.; Verma, A.; Wade, D.; Housman, A.; Gulasey, G.; Trudell, M. L. Synthesis and monoamine transporter affinity of 3-aryl-3-arylmethoxtropane derivatives. 73rd cpdd meeting, Hollywood, fl, 2011. Abstr. 64.

Chapter 3. Application of Iridium catalyzed N-heterocyclization for synthesis of Natural products.

3.1. Abstract

The focus of these studies has been toward the development of new synthetic methods and procedures for the synthesis of novel compounds with unique biological properties. This research has led to the development of new synthetic strategy for the construction of pyridine alkaloids such as Nicotine and Anabasine. The developed method utilizes microwave condition and water as solvent for the reaction. The protocol is efficient, facile and short as compare to the previous methods reported for synthesis for these compounds. The key step involves the aqueous microwave-assisted, iridium-catalyzed N-heterocyclization reaction of pyridinylbutane-1, 4-diols and pyridinylpentane- 1, 5-diols with various amines. The microwave-assisted N-heterocyclization furnishes derivatives of nicotine and anabasine in good yields (50–75%) with overall yields ranging from 30–50%.

3.2. Introduction

Our group has been working on iridium catalyzed N-alkylation reaction of amines with alcohols over last 5 years. We have been utilizing iridium catalyzed methods for the total synthesis of medicinally important natural products.

In recent years many transition metals have been used for synthesis of substituted amines such as hydroamination of alkenes or alkynes, and amination of aryl halides have been developed. The traditional method of synthesis of substituted amines includes N-alkylation of amines with alkyl halides and reductive amination using carbonyl compounds. However, these conventional reaction conditions have some disadvantages from environmental point of view because they

generate equimolar amounts of wasteful salts as co-products. Moreover, the reaction with alkyl halides and reducing agent is undesirable. Similarly, the N-heterocyclization of amines has been performed for synthesis of nitrogen heterocycles such as pyrrolidine, piperidine, and morpholine using hydroamination and ring closing metathesis which requires drastic reaction conditions and generates harmful byproduct at the end of reaction.

3.3. Pyridine alkaloids

Nicotine and anabasine are pyridine alkaloids commonly found in the solanaceae plant family such as *Nicotina tabacum* and *Nicotina rustica*.¹ Nicotine alkaloids modulate neuronal acetylcholine receptors, which affect the central nervous system (**Figure 3.1**).²





Figure 3.1. Pyridine alkaloids- Nicotine derivatives

The pharmacological action of nicotine alkaloids and related derivatives on the central nervous system has attracted considerable attention as potential therapeutic targets for the variety of disease states and pathological conditions mediated by nicotinic acetylcholine receptors.²⁻⁵ However, toxicity and abuse potential has limited the use of nicotine related drugs for central nervous system disorders.² Therefore, new analogues of nicotine with unique nicotinic acetylcholine receptor subtype selectivity remain important pharmacological targets for the

development of novel therapeutics with improved safety profiles. Nicotine has also been used for synthesis of Altinicline (SIB-1508Y), a preclinical drug candidate for Parkinson's disease. Benzo-fused nicotine derivative has found to shown similar binding affinity as nicotine. To this end, considerable effort has been focused on the development of new synthetic methods for the construction nicotine derivatives.⁶⁻⁸ Although a variety of methods have been reported; there is still a need for versatile and practical methods for the synthesis of nicotine-related derivatives. In the past, we have described the application of the iridium catalyzed N-heterocyclization reaction for the synthesis of nicotine related compounds, and the first total synthesis of the alkloid, Noranabasamine.^{9, 10} Further studies by Zhao and co-workers showed that N-heterocyclization of simple amine/alcohol systems proceeded under solvent free, base-free microwave-assisted conditions.¹¹ Based on the past findings, it was of interest to explore the further application of these conditions for the green synthesis of nicotine and anabasine-related analogues.


3.4. Application of iridium catalysis

N-Alkylation or N-heterocyclization of amines with alcohols or diols has been attracted considerable attention because the product of the reaction can be obtained from easily available starting materials in one step without generation of any harmful by products (**Scheme 3.1**).¹²



Scheme 3.1. N-alkylation of primary amines with primary alcohol in the presence of Iridium catalyst

Alcohols or diols are more readily available than corresponding halides or carbonyl compounds in many cases. The reaction also works efficiently by the employment of equimolar amounts of starting materials, generating high atom economical system. Although, variety of catalytic system for N-alkylation or N-heterocyclization have been utilized using ruthenium and other transition metal catalysts but the requirement of high temperature and excess of use of alcohols or diols preclude use of these catalyst system for practical synthesis of nitrogen heterocycles and N-substituted amines.



Scheme 3.2. N-heterocyclization of amines with alcohols using iridium catalyst¹²

Fujita and co-workers reported the use of (pentamethylcyclopentadienyl) iridium dichloride dimer ($[\text{Cp}^* \text{IrCl}_2]_2$) for N-alkylation of amines with alcohols and N-heterocyclization of amines with diols by primary amines (**Scheme 3.2**).¹² The method works by hydrogen borrowing concept, which involves catalytic transfer of hydrogen from alcohol to form in-situ aldehydes or ketones. A possible mechanism for the $\text{Cp}^* \text{Ir}$ -catalyzed N-heterocyclization of primary amines with primary and secondary alcohols is shown in **Figure 3.2**.





Figure 3.2. Mechanism of iridium catalysis


3.5. Results and discussion

We utilized approach using methodology already developed in our laboratory for the synthesis of 1-(3-pyridinyl) diols. 3-bromopyridine or 5-bromo-2-methoxypyridine was treated with *n*-butyllithium at -78°C in diethyl ether. Butyrolactone or valerolactone was then added to the resulting lithiated pyridine derivatives to afford the corresponding hydroxyl ketones in high yields. Further, subsequent reduction with sodium borohydride in methanol afforded the required intermediate diols in good to excellent yields (**Scheme 3.3**).¹³




Scheme 3.3. Synthesis of 1,4 and 1,5- pyridine diols.

Similarly, 3-bromoquinoline and butyrolactone was used for synthesis of 3-quinoline-1, 4-diol using a two step synthesis procedure (**Scheme 3.4**).¹³



Scheme 3.4. Synthesis of quinoline butan-1, 4-diol

Initially, we decided to explore and optimize the reaction conditions for the synthesis of N-benzylornicotine. The reaction of the diol and benzyl amine was performed under reflux and microwave assisted conditions. When the reaction was performed in the absence of a base and solvent compound was formed in low yields. Even using a base and toluene as the solvent did not improve substantially the yields of product. The highly polar nature and poor solubility of the diols in toluene encouraged us to explore the use of water as solvent for this transformation. It was found that reaction yield was considerably improved when water was used as the solvent under reflux conditions (Scheme 3.5, Table 3.1).




Scheme 3.5. Development of method for synthesis of N-benzyl nor-nicotine derivatives.

Entry	Solvent	Base	Conditions	Yields (%)
1	-	-	Reflux, 17h	10
2	-	-	Microwave, 2h	15
3	Toluene	NaHCO ₃	Reflux, 17h	10
4	Toluene	NaHCO ₃	Microwave, 2h	20
5	H ₂ O	NaHCO ₃	Reflux, 17h	50
6	H ₂ O	NaHCO ₃	Microwave, 2h	60
7	H ₂ O	NaOAc	Microwave, 2h	65
8	H ₂ O	Na ₂ CO ₃	Microwave, 2h	75
9	H ₂ O	K ₂ CO ₃	Microwave, 2h	35

Table 3.1. Optimization of the N-Heterocyclization Reaction.

Further, optimization was base showed that sodium carbonate was superior base than sodium bicarbonate, sodium acetate and potassium carbonate. And let to an optimized yield of 75%.¹³

To check scope and limitations of the developed method, we performed N-heterocyclization of 1,4-butandiol and 1, 5-pentandiol under optimized aqueous conditions to prepare series of nicotine and anabasine derivatives (Table 3.2, Scheme 3.6).¹³



Scheme 3.6. Synthesis of N-substituted nor-nicotine derivatives

Diol	Amine	Product	Yield (%) [*]
 8a	CH ₃ NH ₂ (9a)	 10a	50
 8a	 9b	 10b	75
 8b	 9b	 10c	73

















Diol	Amine	Product	Yield (%) [*]
 8a	 9c	 10d	78
 8b	 9c	 10e	75
 8c	 9b	 10f	70
 8c	 9c	 10g	75
 8d	 9b	 10h	78

Table 3.2. Synthesis of nor-nicotine derivatives, *Yields of isolated product

To check scope and limitations of the developed method, we performed N-heterocyclization of 1, 4-butandiol and 1, 5-pentandiol under optimized aqueous conditions to prepare series of nicotine and anabasine derivatives. As provided in **Table 3.2**, the reaction of 1, 4-butandiol with methylamine gave a modest yield of nicotine. The lower than expected yield is believed to be due to the high volatility of methylamine in water at elevated temperatures of the microwave conditions. The reaction of benzyl amine and 4-methoxy amine with 1, 4-diol and 1, 5-diol provided good yields of the corresponding cyclization products.


We also synthesized quinoline derivative in good yields using developed N-heterocyclization method from its corresponding diol (**Figure 3.3**).



10h

Figure 3.3. Quinoline analogue of Benzyl-nornicotine¹³

Further, to demonstrate utility of this approach, we performed transformation of one of the benzyl nor-nicotine derivative to its debenzylated analogue. The hydrogenolysis was performed using palladium on carbon at 55°C afforded in 75% yield (**Scheme 3.7**).¹³



Scheme 3.7. Synthesis of Nicotine from its N-benzyl derivative

3.6 Conclusion

To conclude this chapter, we have devised an efficient three step methodology for the synthesis of nicotine and anabasine derivatives from readily available starting materials. The key step involves the aqueous microwave assisted, iridium-catalyzed N-heterocyclization reaction of 1, 4-diols and 1, 5-diols with various amines.


3.7. Experimental

All chemicals were purchased from Aldrich Chemical Company and used as received unless otherwise noted. Microwave-assisted N-heterocyclization reactions were carried out using a StartSYNTH multicavity instrument with start rotor from Milestone. The maximum microwave power was 1200 W and the reaction temperature was monitored by an internal infrared sensor. All the reactions were performed in glass reactor tubes with a maximum working pressure of 15 bars and maximum temperature of 230 °C. Thin-layer chromatography (TLC) was performed on silica gel plates (250 mm) purchased from Sorbent Technologies. Compounds were made visual with UV light, iodine or phosphomolybdic acid. Chromatography was accomplished with silica gel 60 Å (230–400 mesh) purchased from Sorbent Technologies. ¹H NMR (400 MHz) and ¹³C NMR (100 MHz) spectra were recorded on a Varian 400 MHz NMR spectrometer at ambient temperature in CDCl₃. ¹H NMR chemical shifts are reported as δ values (ppm) relative to tetramethylsilane. ¹³C NMR chemical shifts are reported as δ values (ppm) relative to CDCl₃ (77.0 ppm). Atlantic Microlab, Inc., Norcross, GA performed all CHN microanalyses.

Hydroxy Ketones: General Procedure

Under an N₂ atm, bromopyridine (**5b**) (1 equiv) was added to anhyd Et₂O (20 mL) and cooled to -78 °C. A soln of *n*-BuLi (2.5 M in hexane, 1.2 equiv) was added dropwise, and the mixture was stirred for 15 min. A solution of gamma-butyrolactone (**6a**) or delta-valerolactone (**6b**) (1.1 equiv) in Et₂O (5 mL) was added and the mixture was stirred for 2 h. The mixture was allowed to warm to R.T. and brine (20 mL) was added. The mixture was extracted with Et₂O (3 × 20 mL) and the combined organic layers dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (CH₂Cl₂-MeOH, 92:8) to afford the hydroxy ketones as oils.

4-Hydroxy-1-(pyridine-3-yl) butan-1-one (**7a**)




The title product was prepared from 3-bromopyridine (**5b**) (2 g, 12.5 mmol), gamma-butyrolactone (**6a**) (1.2 g, 13.9 mmol) and *n*-BuLi (6 mL, 15 mmol, 2.5 M in hexane) in anhyd Et₂O (30 mL). Purification by flash chromatography afforded the product as yellow oil; Yield: 1.4 g (65%). The spectroscopic data were consistent with those reported previously for this compound.¹⁰

¹H NMR (400 MHz, CDCl₃): δ = 9.03 (s, 1 H), 8.61 (d, *J* = 3.6 Hz, 1 H), 8.14 (d, *J* = 8.0 Hz, 1 H), 7.34–7.30 (m, 1 H), 3.91 (br s, 1 H), 3.63 (t, *J* = 6.0 Hz, 2 H), 3.04 (t, *J* = 7.2 Hz, 2 H), 1.92–1.89 (m, 2H).

¹³C NMR (100 MHz, CDCl₃): δ = 199.3, 153.3, 149.5, 135.8, 132.4, 124.0, 61.5, 35.6, 26.8.

4-Hydroxy-1-(6-methoxypyridin-3-yl) butan-1-one (**7b**)




The title product was prepared from 5-bromo-2-methoxypyridine (**5a**) (2g, 10.6 mmol), gamma-butyrolactone (**6a**) (1g, 11.7 mmol) and *n*-BuLi (5.1 mL, 12.7 mmol, 2.5 M in hexane) in anhyd Et₂O (30 mL). Purification by flash chromatography afforded the product as yellow oil; yield: 1.5 g (70%). The spectroscopic data were consistent with those reported previously for this compound.¹⁰

¹H NMR (400 MHz, CDCl₃): δ = 8.80 (d, *J* = 2.4 Hz, 1 H), 8.13 (dd, *J* = 8.8, 2.4 Hz, 1 H), 6.77 (d, *J* = 8.8 Hz, 1 H), 3.99 (s, 3 H), 3.74–3.73 (m, 2 H), 3.07 (t, *J* = 7.2 Hz, 2 H), 2.02–1.97 (m, 2 H).

¹³C NMR (100 MHz, CDCl₃): δ = 198.4, 166.4, 149.1, 138.3, 126.7, 111.1, 61.7, 54.1, 35.0, 27.0.

5-Hydroxy-1-(pyridin-3-yl) pentan-1-one (**7c**)



The title product was prepared from 3-bromopyridine (**5b**) (2g, 12.5 mmol), delta-valerolactone (**6b**) (1.4 g, 13.9 mmol) and *n*-BuLi (6 mL, 15 mmol, 2.5 M in hexane) in anhyd Et₂O (30 mL). Purification by flash chromatography afforded the product as yellow oil; yield: 1.7 g (65%). The spectroscopic data were consistent with those reported previously for this compound.¹⁰


¹H NMR (400 MHz, CDCl₃): δ = 9.14 (d, *J* = 4.0 Hz, 1 H), 8.73 (dd, *J* = 8.0, 4.0 Hz, 1 H), 8.22 (dd, *J* = 8.0, 4.0 Hz, 1 H), 7.41–7.39 (m, 1 H), 3.67 (t, *J* = 4.8 Hz, 2 H), 3.05–3.01 (m, 2 H), 1.87–1.82 (m, 2 H), 1.67–1.63 (m, 2 H).

^{13}C NMR (100 MHz, CDCl_3): $\delta = 199.2, 153.2, 149.4, 135.7, 132.3, 123.9, 61.9, 38.6, 32.1, 20.3$.

Diols 6a, b and 7; General Procedure

Powdered NaBH_4 (1.5 equiv) was added to a well stirred soln of hydroxy ketone **7a**, **7b** or **7c** (1 equiv) in anhyd MeOH at 0 °C. After 2 h, NaHCO_3 was added to the reaction mixture and the solvent was removed under reduced pressure. The residue was purified by flash chromatography to afford the diols **8a**, **8b** or **8c** as viscous oils.

1-(Pyridin-3-yl) butane-1, 4-diol (**8a**)




The title product was prepared from (**7a**) (1g, 6.0 mmol) and NaBH_4 (0.34 g, 9 mmol) in anhyd MeOH (20 mL). Purification by flash chromatography (CH_2Cl_2 -MeOH, 92:8) afforded colorless oil; yield: 0.96 g (95%). The spectroscopic data were consistent with those reported previously for this compound.¹⁴

^1H NMR (400 MHz, CDCl_3): $\delta = 8.47$ (d, $J = 4.0$ Hz, 1 H), 8.38 (dd, $J = 8.0, 4.0$ Hz, 1 H), 7.72 (d, $J = 8.0$ Hz, 1 H), 7.24 (dd, $J = 8.0, 4.0$ Hz, 1 H), 4.95 (brs, 1 H), 4.73 (t, $J = 6.4$ Hz, 1 H), 3.69 (br s, 1 H), 3.68–3.64 (m, 2 H), 1.87–1.82 (m, 2 H), 1.68–1.62 (m, 2 H).

^{13}C NMR (100 MHz, CDCl_3): $\delta = 148.3, 147.6, 140.8, 134.2, 123.8, 71.8, 62.6, 36.7, 29.1$

1-(6-Methoxypyridin-3-yl) butane-1, 4-diol (**8b**)




The title product was prepared from (**7b**) (1g, 5.2 mmol) and NaBH₄ (0.30 g, 7.77 mmol) in anhyd MeOH (20 mL). Purification by flash chromatography afforded colorless oil; yield: 0.9 g (90%).

¹H NMR (400 MHz, CDCl₃): δ = 7.89 (s, 1 H), 7.46 (d, *J* = 0.8 Hz, 1 H), 6.59 (d, *J* = 8.4 Hz, 1 H), 5.06 (br s, 1 H), 4.48 (t, *J* = 6.4 Hz, 1 H), 4.43 (br s, 1 H), 3.76 (s, 3 H), 3.47–3.43 (m, 2 H), 1.70–1.61 (m, 2 H), 1.52–1.43 (m, 2 H).

¹³C NMR (100 MHz, CDCl₃): δ = 163.7, 144.5, 137.1, 133.3, 110.8, 71.4, 62.2, 53.7, 36.0, 29.0.

Anal. Calcd for C₁₀H₁₅NO₃: C, 60.90; H, 7.67; N, 7.10. Found: C, 60.75; H, 7.55; N, 6.99.

1-(pyridine-3-yl) pentane-1, 5-diol (**8c**)




The title product was prepared from (**7c**) (1g, 5.2 mmol) and NaBH₄ (0.3g, 7.8 mmol) in anhyd MeOH (20 mL). Purification by flash chromatography afforded colorless oil; yield: 0.9g (95%).

¹H NMR (400 MHz, CDCl₃): δ = 8.44 (d, *J* = 1.6 Hz, 1 H), 8.38 (dd, *J* = 6.4, 1.2 Hz, 1 H), 7.70–7.69 (m, 1 H), 7.26–7.23 (m, 1 H), 4.68 (t, *J* = 5.6 Hz, 1 H), 3.58 (t, *J* = 6.4 Hz, 2 H), 1.82–1.70 (m, 2 H), 1.71–1.65 (m, 2 H), 1.45–1.36 (m, 2 H).

¹³C NMR (100 MHz, CDCl₃): δ = 148.3, 147.6, 141.0, 134.27, 123.8, 71.8, 62.6, 38.8, 32.4, 22.1.

Anal. Calcd for C₁₀H₁₅NO₂: C, 66.27; H, 8.34; N, 7.73. Found: C, 66.22; H, 8.45; N, 7.67.

1-(Quinolin-3-yl) butane-1, 4-diol (**8d**)



Under an N₂ atm, 3-bromoquinoline (**5c**) (2.0 g, 9.6 mmol) was added to anhydrous Et₂O (30 mL) and the resulting soln cooled to -78 °C. A solution of *n*-BuLi (4.6 mL, 11.4 mmol, 2.5 M in hexane) was added dropwise and the mixture stirred for 15 min. A solution of gamma-butyrolactone (**6a**) (0.95 g, 10.5 mmol) in Et₂O (5 mL) was added and the mixture was stirred for 2 h. The mixture was allowed to warm to RT and brine (20 mL) was added. The mixture was extracted with Et₂O (3 × 20 mL) and the combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to furnish ketone (**7d**) as light yellow oil. The crude ketone **8** was dissolved in anhydrous MeOH (20 mL) and cooled to 0 °C. Powdered NaBH₄ (0.52 g, 14.22 mmol) was added in one portion and the mixture was stirred for 2 h. Purification by flash chromatography (10% MeOH- CH₂Cl₂) afforded as yellow oil; overall yield over two steps: 1.1g (50%).

¹H NMR (400 MHz, CDCl₃): δ = 8.77 (d, *J* = 2.0 Hz, 1 H), 8.06 (s, 1 H), 7.98 (d, *J* = 8.4 Hz, 1 H), 7.70 (d, *J* = 8.0 Hz, 1 H), 7.63–7.57 (m, 1 H), 7.46 (t, *J* = 8.0 Hz, 1 H), 4.87 (t, *J* = 6.0 Hz, 1 H), 3.69–3.60 (m, 3 H), 1.92–1.87 (m, 2 H), 1.71–1.01 (m, 2 H).


¹³C NMR (100 MHz, CDCl₃): δ = 149.5, 147.2, 138.0, 133.1, 129.6, 128.7, 128.1, 127.1, 110.5, 72.0, 62.5, 36.7, 29.2.

Anal. Calcd for C₁₃H₁₅NO₂: C, 71.87; H, 6.96; N, 6.45. Found: C, 71.59; H, 7.03; N, 6.11.

Microwave-Assisted N-Heterocyclization; General Procedure

The diol (1 equiv) was added to a well stirred soln of [Cp*IrCl₂]₂ (5 mol%) and Na₂CO₃ (1.1 equiv), in H₂O (5 mL), in a microwave reactor tube under an N₂ atm. The amine (1 equiv) was added to the soln and the mixture was irradiated at 110 °C for 2 h. The mixture was extracted with EtOAc (3 × 10 mL) and the combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (3% MeOH–CH₂Cl₂) to afford the cyclic amine.

(±)-Nicotine (10a)




The title product was prepared from **6a** (100 mg, 0.6 mmol), [Cp*IrCl₂]₂ (12 mg, 0.015 mmol), Na₂CO₃ (1.3 mg, 0.015 mmol) and 40% aq. MeNH₂ soln (**9a**) (0.050 mL, 0.6 mmol). Purification by flash chromatography afforded brown oil; yield: 48 mg (50%). The spectroscopic data were consistent with a commercial sample and those reported previously for this compound.¹⁵

¹H NMR (400 MHz, CDCl₃): δ = 8.52 (d, *J* = 2.0 Hz, 1 H), 8.49 (dd, *J* = 4.8, 1.6 Hz, 1 H), 7.69 (d, *J* = 8.0 Hz, 1 H), 7.26 (t, *J* = 6.8 Hz, 1 H), 3.25 (t, *J* = 7.6 Hz, 1 H), 3.09 (t, *J* = 8.0 Hz, 1 H), 2.35–2.29 (m, 1 H), 2.24–2.16 (m, 4 H), 2.00–1.74 (m, 3 H).

¹³C NMR (100 MHz, CDCl₃): δ = 153.5, 149.7, 135.8, 124.0, 75.8, 61.9, 35.7, 29.9, 26.8.

3-(1-Benzylpyrrolidin-2-yl) pyridine (10b)




The title product was prepared from **8a** (100 mg, 0.6 mmol), $[\text{Cp}^*\text{IrCl}_2]_2$ (12 mg, 0.015 mmol), Na_2CO_3 (1.3 mg, 0.015 mmol) and BnNH_2 (64 mg, 0.60 mmol) (**9b**) in H_2O (5 mL). Purification by Flash chromatography afforded colorless oil; yield: 105 mg, (75%). The spectroscopic data were consistent with those reported previously for this compound.¹⁶

^1H NMR (400 MHz, CDCl_3): δ = 8.63 (s, 1 H), 8.48 (d, J = 3.6 Hz, 1 H), 7.83 (d, J = 8.0 Hz, 1 H), 7.33–7.18 (m, 6 H), 3.81 (d, J = 13.2 Hz, 1 H), 3.44–3.40 (m, 1 H), 3.13–3.09 (m, 2 H), 2.28–2.18 (m, 2 H), 1.89–1.68 (m, 3 H).

^{13}C NMR (100 MHz, CDCl_3): δ = 149.9, 148.8, 135.2, 128.8, 128.7, 128.4, 127.2, 123.9, 67.2, 58.3, 53.7, 35.5, 22.7.

5-(1-Benzylpyrrolidin-2-yl)-2-methoxypyridine (**10c**)




The title product was prepared from (**8b**) (100 mg, 0.5 mmol), $[\text{Cp}^*\text{IrCl}_2]_2$ (12 mg, 0.012 mmol), Na_2CO_3 (1.1 mg, 0.012 mmol) and BnNH_2 (**9b**) (0.053 g, 0.5 mmol). Purification by flash chromatography afforded colorless oil; yield: 100 mg (78%).

¹H NMR (400 MHz, CDCl₃): δ = 8.15–8.14 (d, *J* = 2.4 Hz, 1 H), 7.75 (dd, *J* = 8.8, 2.4 Hz, 1 H), 7.29–7.20 (m, 5 H), 6.76 (d, *J* = 8.8 Hz, 1 H), 3.94 (s, 3 H), 3.80 (d, *J* = 12.0 Hz, 1 H), 3.33–3.31 (m, 1 H), 3.08–3.06 (m, 2 H), 2.19–2.14 (m, 2 H), 1.89–1.86 (m, 1 H), 1.80–1.69 (m, 2 H).

¹³C NMR (100 MHz, CDCl₃): δ = 163.9, 146.3, 139.7, 138.2, 132.0, 128.4, 127.0, 111.3, 66.6, 58.1, 53.5, 35.1, 22.5.

Anal. Calcd for C₁₇H₂₀N₂O: C, 76.09; H, 7.51; N, 10.44. Found: C, 76.00; H, 7.73; N, 10.28.

3-[1-(4-Methoxybenzyl) pyrrolidin-2-yl] pyridine (10d)




The title product was prepared from (**8a**) (100 mg, 0.6 mmol), [Cp*IrCl₂]₂ (12 mg, 0.015 mmol), Na₂CO₃ (1.3 mg, 0.015 mmol) and 4-methoxybenzylamine (**9c**) (82 mg, 0.6 mmol). Purification by flash chromatography afforded colorless oil; yield: 110 mg (73%).

The spectroscopic data were consistent with those reported previously for this compound.¹⁶

¹H NMR (400 MHz, CDCl₃): δ = 8.63 (d, *J* = 1.6 Hz, 1 H), 8.49 (dd, *J* = 4.4, 1.6 Hz, 1 H), 7.81 (d, *J* = 8.0 Hz, 1 H), 7.25 (dd, *J* = 8.0 Hz, 1 H), 7.25 (dd, *J* = 8.0, 4.4 Hz, 1 H), 7.14 (d, *J* = 8.0 Hz, 2 H), 6.81 (d, *J* = 8.0 Hz, 2 H), 3.78 (s, 3 H), 3.73 (d, *J* = 12.8 Hz, 2 H), 3.38 (t, *J* = 8.0 Hz, 1 H), 3.10–3.02 (m, 2 H), 2.64–2.19 (m, 2 H), 1.77–1.67 (m, 3 H).

¹³C NMR (100 MHz, CDCl₃): δ = 158.8, 149.8, 148.8, 139.7, 135.2, 129.6, 123.8, 114.0, 113.8, 67.0, 57.6, 55.4, 53.5, 35.5, 22.7.

2-Methoxy-5-[1-(4-methoxybenzyl) pyrrolidin-2-yl] pyridine (10e)




The title product was prepared from **(8b)** (100 mg, 0.5 mmol), [Cp*IrCl₂]₂ (12 mg, 0.012 mmol), Na₂CO₃ (1.1 mg, 0.012 mmol) and 4-methoxybenzylamine **(9c)** (69 mg, 0.5 mmol). Purification by flash chromatography afforded colorless oil; yield: 110 mg (75%).

¹H NMR (400 MHz, CDCl₃): δ = 8.13 (d, *J* = 1.6 Hz, 1 H), 7.72 (dd, *J* = 8.0, 1.6 Hz, 1 H), 7.15 (d, *J* = 8.0 Hz, 2 H), 6.82 (d, *J* = 8.0 Hz, 2 H), 6.76 (d, *J* = 8.4 Hz, 1 H), 3.93 (s, 3 H), 3.77 (s, 3 H), 3.73 (d, *J* = 12.8 Hz, 1 H), 3.28 (t, *J* = 8.0 Hz, 1 H), 3.05 (t, *J* = 8.0 Hz, 1 H), 2.98 (d, *J* = 12.8 Hz, 1 H), 2.22–2.10 (m, 2 H), 1.89–1.65 (m, 3 H).

¹³C NMR (100 MHz, CDCl₃): δ = 163.9, 158.7, 146.2, 138.2, 132.0, 131.7, 130.0, 113.7, 111.3, 66.4, 57.3, 55.4, 53.6, 53.4, 35.1, 22.4.

Anal. Calcd for C₁₈H₂₂N₂O₂: C, 72.46; H, 7.43; N, 9.39. Found: C, 72.40; H, 7.52; N, 9.11.

3-(1-Benzylpiperidin-2-yl) pyridine (10f)¹⁷




The title product was prepared from **(8c)** (100 mg, 0.55 mmol), [Cp*IrCl₂]₂ (14 mg, 0.013 mmol), Na₂CO₃ (1.2 mg, 0.013 mmol) and BnNH₂ (**5b**) (55 mg, 0.55 mmol). Purification by flash chromatography afforded colorless oil; yield: 100 mg, (70%).

¹H NMR (400 MHz, CDCl₃): δ = 8.65 (d, *J* = 1.6 Hz, 1 H), 8.48 (dd, *J* = 4.8, 1.6 Hz, 1 H), 7.83 (d, *J* = 8.0 Hz, 1 H), 7.34–7.18 (m, 6 H), 3.70 (d, *J* = 13.6 Hz, 1 H), 3.16 (dd, *J* = 11.2, 2.8 Hz, 1 H), 2.99 (d, *J* = 11.6 Hz, 1 H), 2.85 (d, *J* = 13.6 Hz, 1 H), 1.99–1.92 (m, 2 H), 1.81–1.75 (m, 2 H), 1.65–1.42 (m, 2 H), 1.42–1.37 (m, 1 H).

¹³C NMR (100 MHz, CDCl₃): δ = 149.7, 148.9, 141.2, 139.5, 135.1, 128.8, 128.4, 127.1, 124.0, 66.7, 60.3, 53.5, 37.2, 26.0, 25.2.

Anal. Calcd for C₁₇H₂₀N₂: C, 80.91; H, 7.99; N, 11.10. Found: C, 80.77; H, 8.21; N, 11.00.

3-[1-(4-Methoxybenzyl) piperidin-2-yl] pyridine (**12b**)




The title product was prepared from **(8c)** (100 mg, 0.55 mmol), [Cp*IrCl₂]₂ (14 mg, 0.013 mmol), Na₂CO₃ (1.2 mg, 0.013 mmol) and 4-methoxybenzylamine (**5c**) (75 mg, 0.55 mmol). Purification by flash chromatography afforded colorless oil; yield: 129 mg (75%).

¹H NMR (400 MHz, CDCl₃): δ = 8.63 (s, 1 H), 8.48 (dd, *J* = 4.8, 1.6 Hz, 1 H), 7.80 (d, *J* = 7.6 Hz, 1 H), 7.26–7.24 (m, 1 H), 7.12 (d, *J* = 8.4 Hz, 2 H), 6.81 (d, *J* = 8.4 Hz, 2 H), 3.78 (s, 3 H), 3.61 (d, *J* = 13.6 Hz, 1 H), 3.15 (dd, *J* = 7.2, 2.4 Hz, 1 H), 2.98 (d, *J* = 11.6 Hz, 1 H), 2.79 (d, *J* = 13.6 Hz, 1 H), 1.96–1.89 (m, 1 H), 1.80–1.72 (m, 2 H), 1.63–1.50 (m, 3 H), 1.41–1.30 (m, 1 H).

^{13}C NMR (100 MHz, CDCl_3): δ = 158.7, 149.7, 148.8, 141.3, 135.1, 131.3, 130.0, 123.9, 113.7, 66.6, 59.3, 55.4, 53.3, 37.3, 26.0, 25.2.

Anal. Calcd for $\text{C}_{18}\text{H}_{22}\text{N}_2\text{O}$: C, 76.56; H, 7.85; N, 9.92. Found: C, 76.50; H, 7.91; N, 9.78.

3-(1-Benzylpyrrolidin-2-yl) quinoline (13)




The title product was prepared from **(8d)** (100 mg, 0.5 mmol), $[\text{Cp}^*\text{IrCl}_2]_2$ (12 mg, 0.012 mmol), Na_2CO_3 (1.1 mg, 0.012 mmol) and BnNH_2 (**5b**) (53 mg, 0.5 mmol). Purification by flash chromatography afforded colorless oil; yield: 100 mg (78%).

^1H NMR (400 MHz, CDCl_3): δ = 9.05 (s, 1 H), 8.17 (s, 1 H), 8.12 (d, J = 8.8 Hz, 1 H), 7.83 (d, J = 8.0 Hz, 1 H), 7.67 (t, J = 7.2 Hz, 1 H), 7.56 (t, J = 7.2 Hz, 1 H), 7.34–7.19 (m, 5 H), 3.85 (d, J = 12.8 Hz, 1 H), 3.59 (t, J = 7.6 Hz, 1 H), 3.15 (d, J = 12.8 Hz, 1 H), 2.34–2.27 (m, 2 H), 2.01–1.81 (m, 4 H).

^{13}C NMR (100 MHz, CDCl_3): δ = 151.6, 148.1, 139.5, 137.0, 134.4, 129.5, 129.2, 129.0, 128.6, 128.4, 127.8, 127.1, 126.8, 67.5, 58.5, 53.7, 35.5, 22.9.

Anal. Calcd for $\text{C}_{20}\text{H}_{20}\text{N}_2$: C, 83.30; H, 6.99; N, 9.71. Found: C, 83.29; H, 7.08; N, 9.53.

2-Methoxy-5-(pyrrolidin-2-yl) pyridine (11)



5-(1-Benzylpyrrolidin-2-yl)-2-methoxypyridine (**10c**) (100 mg, 0.37 mmol,) and 10% Pd/C (10 mg) were stirred in EtOH under H_2 (1 atm) for 2 h at 55 °C. After the reaction was complete

(TLC), the mixture was filtered through Celite. The solvent was removed under reduced pressure to afford the normicotine derivative as a light yellow oil; yield: 51 mg (75%).

¹H NMR (400 MHz, CDCl₃): δ = 8.19 (d, J = 4.0 Hz, 1 H), 7.79 (dd, J = 4.8, 2.4 Hz, 1 H), 6.72 (d, J = 4.8 Hz, 1 H), 5.73 (br s, 1 H, NH), 4.37 (t, J = 6.8 Hz, 1 H), 3.88 (s, 3 H), 3.36–3.34 (m, 1 H), 3.21–3.16 (m, 1 H), 2.16–2.14 (m, 1 H), 2.10–2.01 (m, 3 H).

¹³C NMR (100 MHz, CDCl₃): δ = 164.8, 147.0, 138.4, 123.8, 111.5, 60.8, 53.8, 45.1, 31.6, 24.0.

Anal. Calcd for C₁₀H₁₄N₂O: C, 67.39; H, 7.92; N, 15.72. Found: C, 67.12; H, 8.15; N, 15.67.

3.8. References

1. (a) Leete, E. In *Alkaloids, Chemical and Biological Perspectives*; Vol. 1; Pelletier, S. W., Ed.; John Wiley & Sons: New York, **1983**, 85. (b) Strunz, G. M.; Findlay, J. A. In *The Alkaloids, Chemistry and Pharmacology*; Vol. 26; Brossi, A., Ed.; Academic Press: Orlando, **1985**, 89.
2. Holladay, M. W.; Dart, M. J.; Lynch, J. K. Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery *J. Med. Chem.* **1997**, *40*, 4169.
3. *Neuronal Nicotinic Receptors*; Arneric, S. P.; Brioni, J. D., Eds.; John Wiley & Sons: New York, **1999**.
4. Romanelli, M. N.; Gualtieri, F. Cholinergic nicotinic receptors: Competitive ligands, allosteric modulators, and their potential applications. *Med. Res. Rev.* **2003**, *60*, 393.
5. Gundisch, D.; Eibl, C. Nicotinic acetylcholine receptor ligands, a patent review. *Expt. Opin. Ther. Pat.* **2011**, *21*, 1867.
6. Ghandi, M.; Taheri, A.; Abbasi, A. Diastereoselective synthesis of nicotine derivatives via 1, 3-dipolar cycloaddition reactions. *J. Heterocycl. Chem.* **2010**, *47*, 611.
7. Wagner, F. F.; Comins, D. L. Recent advances in the synthesis of nicotine and its derivatives *Tetrahedron* **2007**, *63*, 8065.
8. Ayers, J.; Xu, R.; Dwoskin, L. P.; Crooks, P. A general procedure for the enantioselective synthesis of the minor tobacco alkaloids nornicotine, anabasine, and anatabine. *AAPS J.* **2005**, *7*, E752.
9. Miao, L.; DiMaggio, S. C.; Shu, H.; Trudell, M. L. Enantioselective Syntheses of Both Enantiomers of Noranabasamine. *Org. Lett.* **2009**, *11*, 1579.

10. Miao, L.; DiMaggio, S. C.; Trudell, M. L. Hydroxyarylketones via Ring-Opening of Lactones with Aryllithium Reagents: An Expedient Synthesis of (\pm)-Anabasamine. *Synthesis* **2010**, 91.
11. Zhang, W.; Dong, X.; Zhao, W. Microwave-Assisted Solventless Reaction of Iridium-Catalyzed Alkylation of Amines with Alcohols in the Absence of Base. *Org. Lett.* **2011**, *13*, 5386.
12. Fujita, K.; Fuji, T.; Yamaguchi, R. Cp*Ir Complex-Catalyzed *N*-Heterocyclization of Primary Amines with Diols: A New Catalytic System for Environmentally Benign Synthesis of Cyclic Amines. *Org. Lett.* **2004**, *6*, 3525.
13. Apsunde, T. D.; Trudell, M. L. Microwave-Assisted Iridium-Catalyzed Synthesis of Nicotine and Anabasine Derivatives. *Synthesis*, **2013**, *45*, 2120-2124.
14. Viatcheslav, S.; Melvin, D. J.; Morgarita, O.; Kun, H. A new and efficient approach to the synthesis of nicotine and anabasine analogues. *J. Heterocycl. Chem.* **2009**, *46*, 1252
15. SDBSWeb: <http://riodb01.ibase.aist.go.jp/sdbs/> (National Institute of Advanced Industrial Science and Technology, 12/19/12).
16. Baxendale, I. R.; Brusotti, G.; Matsuoka, M.; Ley, S. V. Synthesis of nornicotine, nicotine and other functionalised derivatives using solid-supported reagents and scavengers. *J. Chem. Soc., Perkin Trans. 1* **2002**, 143.

Chapter 4: Solvent free, base free microwave mediated iridium catalyzed N-alkylation of amides with alcohols

4.1. Abstract

Solvent-free, base-free microwave mediated $(Cp^*IrCl_2)_2$ catalyzed conditions for the N-alkylation of amides with alcohols have been developed. A series of primary and secondary alcohols have been shown to produce high yields of N-alkyl arylamides and N-alkyl alkylamides.

4.2. Introduction


Importance of N-substituted amides

The N-substituted amide is an important functional group found in natural products as well as non-natural compounds and materials. The N-substituted amide also plays important role in synthetic chemistry as a protecting group for amines and carboxylic acid derivatives.¹ There has been variety of reports that describe methods for the preparation of N-substituted amides.^{2,3}

Recently, transition metals have been used to catalyze the formation of C-N bonds using alcohols as environmentally benign equivalents of alkyl halides.⁴⁻⁷ These reactions work on the hydrogen borrowing concept which involves generation of only water as a by-product. Previous reports on N-alkylation of amides with alcohols have been shown that high reaction temperatures (>180 °C) are required.^{8,9}


Literature report of N-alkylation of primary amide

The first example of N-alkylation of amides with alcohols using an iridium complex was reported by Fujita coworkers.¹⁰ This process required refluxing toluene for 17 h in the presence of base (**Scheme 4.1**).



Scheme 4.1. N-alkylation of primary amides with primary alcohol using iridium catalysis

Subsequent studies by Xu and co-workers had demonstrated that solvent-free conditions could be employed for N-alkylation of amides with primary alcohols using a variety of transition metal catalyst systems (Rh, Ru, Ir).¹¹ However, these systems typically required long reaction times and high reaction temperatures. Williams and coworkers reported the use of ruthenium catalysis under solvent-free microwave mediated conditions to affect N-alkylation of amides with alcohols (Scheme 4.2).¹²



Scheme 4.2. N-alkylation of primary amides using primary alcohol with Ruthenium catalysis

However, despite the success of the metal catalyzed N-alkylation of amides, these reports were limited to use of only primary alcohols as alkylation agents.




Figure 4.3. N-alkylation of primary amides using primary alcohol with copper catalysis

Consequently, there has remained a need for the development of a suitable method with wide substrate tolerance that exploited solvent-free microwave mediated conditions. Our interest in

iridium-based catalytic systems for the formation of C-N bonds prompted us to investigate the potential application of iridium catalyzed amide alkylation under solvent-free and microwave conditions.¹³ Herein we wish to report the first solvent-free, base-free microwave mediated iridium catalyzed N-alkylation of amides with both primary and secondary alcohols.

The developed method under microwave condition for synthesis of nicotine and anabasine derivatives prompted us to investigate the use of iridium catalyzed N-alkylation of amides under microwave conditions.¹⁴ The microwave approach would provide N-alkylated product in shorter time period than the conventional reflux times for these reactions.


4.3. Result and discussion

Optimization of conditions

Initially, we examined the conditions for N-alkylation of benzyl alcohol with benzamide with microwave irradiation to heat the reaction mixture. We found that the solvent free system using 1 equiv. of alcohol and sodium acetate afforded a modest yield of N-benzylbenzamide (Table 1, Entry1). Further, we found that use of potassium carbonate showed slight improvement of yield, while switching to stronger base diminished the yield to only trace amount of product (Table 1, entry 2).¹⁵

Serendipitously, it was discovered that if the base was omitted from the reactant mixture, the reaction still gave N-alkylation products, albeit in low yield (Table 1, entry 4). However, this result was encouraging since it revealed that a base was not essential to the catalytic cycle in order to affect the N-alkylation of amides. It was subsequently determined that by increasing the quantity of the alcohol **2a** to three equivalents (Table 1, entry 6) and raising the reaction temperature to 160 °C (Table 1, entry 8) the yield of **3aa** (85%) under base-free conditions could be significantly improved. It was determined that the solvent-free, base-free microwave mediated

conditions furnished amide yields equivalent to yields reported using conventional methods (Scheme 4.4, Table 4.1).¹⁰



Scheme 4.4. Development of methodology for N-alkylation of amides using microwave strategy











Entry	2a (equiv)	(Cp*IrCl ₂) ₂ (mol %)	Base	T (°C)	Yield [%]
1	1	5	NaOAc	160	40
2	1	5	K ₂ CO ₃	160	51
3	1	5	KOtBu	160	<10
4	1	5	-	140	10
5	2	5	-	140	25
6	3	5	-	140	50
7	3	5	-	150	80
8	3	5	-	160	85
9	3	5	-	165	84
10	3	2.5	-	160	60
11	3	1.25	-	160	35










Table 4.1. Reaction optimization for N-alkylation of benzamide with benzyl alcohol

Further evaluation of the solvent-free base-free microwave mediated conditions revealed that there was no improvement in yields with an increase of reaction temperature above 160 °C (Table 4.1, entry 9), while a decrease in yield was observed with a reduction in catalyst loading below 5 mol% (Table 4.1, entries 10-11). Having established optimized conditions for the N-alkylation of benzamide (**1a**, Table 4.1, entry 8) it was of interest to explore the scope and limitations of the method.¹⁵

Examination of scope of developed method

As summarized in **Table 4.2**, substituted benzyl alcohols afforded good yields of the corresponding N-substituted benzyl amides (**3aa–3ai**). Benzyl alcohols substituted with electron-donating groups, electron-withdrawing groups and halogen were equally tolerant of the solvent-free, base-free reaction conditions. Only the 4-nitrobenzyl alcohol (**2f**) failed to give a good yield of the amide **3f**, affording only an intractable mixture of material. In addition to benzyl alcohols, the primary alkanols, 1-pentanol (**2j**) and 1-hexanol (**2k**) furnished the N-alkyl amides **3aj** and **3ak** in 70% yield and 72% yield, respectively. Acetamide (**1b**) and the substituted benzamides (**1c–1f**) also gave good yields of the corresponding N-benzyl benzamide derivatives (**3ba–3fa**) under the solvent-free, base-free conditions.

Entry ^a	Amide	Alcohol	Product, Yield 3 (%) ^b
1	 1a	 2a	3aa, 85
2	 1a	 2b	3ab, 85
3	 1a	 2c	3ac, 72
4	 1a	 2d	3ad, 75
5	 1a	 2e	3ae, 77

Entry ^a	Amide	Alcohol	Product, Yield 3 (%) ^b
6	 <p>1a</p>	 <p>2f</p>	3af, IM ^[c]
7	 <p>1a</p>	 <p>2g</p>	3ag, 65
8	 <p>1a</p>	 <p>2h</p>	3ah, 68
9	 <p>1a</p>	 <p>2i</p>	3ai, 60
10	 <p>1a</p>	<p>CH₃(CH₂)₄-OH</p> <p>2j</p>	3aj, 72












Entry ^a	Amide	Alcohol	Product, Yield 3 (%) ^b
11	 1a	$\text{CH}_3(\text{CH}_2)_5\text{-OH}$ 2k	3ak, 70
12	$\text{CH}_3\text{-NH}_2$ 1b	 2a	3ba, 68
13	 1c	 2a	3ca, 76
14	 1d	 2a	3da, 75
15	 1e	 2a	3ea, 70
16	 1f	 2a	3fa, 78

Table 4.2. Reaction of variety of amides with various substituted primary alcohols

As summarized in Table 4.2, substituted benzyl alcohols afforded good yields of the corresponding N-substituted benzyl amides **3aa** – **3fa**. Benzyl alcohols substituted with electron-donating groups, electron-withdrawing groups and halogen were equally tolerant of the solvent-free, base-free reaction conditions. Only the 4-nitrobenzyl alcohol (**2f**, entry 6) failed to give a good yield of the amide **3af**, affording only an intractable mixture of material. However, the poor yield obtained with **2f** was consistent with the sluggish reactivity previously reported for the nitro derivative in other systems.^{16, 17}

In addition to benzyl alcohols, the primary alkanols, 1-pentanol (**2j**, Table 4.2, entry 10) and 1-hexanol (**2k**, Table 4.3, entry 11) furnished the N-alkyl amides **3aj** and **3ak** in 70% yield and 72% yield, respectively. Acetamide (**1b**, entry 12) and the substituted benzamides (**1c-1f**, entries 13-16) also gave good yields of the corresponding N-benzyl benzamide derivatives (**3ba-3fa**) under the solvent-free, base-free conditions.¹⁵

The success of the solvent-free, base-free microwave mediated conditions with primary alcohols prompted a further investigation of the suitability of the reaction conditions for the N-alkylation of benzamide (**1a**) with secondary alcohols. A variety of acyclic and cyclic secondary alcohols (**4**) were investigated as substrates for the N-alkylation reaction.¹⁵



Scheme 4.6. Reaction of benzamide with secondary alcohols















Entry	Alcohol	Product, Yield (%)
1	 2l	 3al, 68%
2	 2m	 3am, 72%
3	 2n	 3an, 65%
4	 2o	 3ao, 78%
5	 2p	 3ap, 76%
6	 2q	 3aq, 65%
7	 2r	 3ar, 65%

Table 4.3. Reaction of benzamide with secondary alcohols

It was satisfying to observe that the solvent free, base-free microwave mediated reaction conditions developed for the primary alcohols were applicable to secondary alcohols as well. The acyclic alcohols (entries 1-3) and cyclic alcohols (entries 4-5) coupled with benzamide to furnish the N-alkylated products in 65-78% yield. Even the sterically hindered benzhydrol derivatives (entry 6 and 7) afforded the N-benzhydryl amides **3aq** and **3ar** in good yield.¹⁵

4.4. Conclusion

In summary, we have devised a solvent-free, base free, micro-wave mediated process for the iridium-catalyzed alkylation of amides with alcohols. This environmentally benign method furnished a variety of structurally diverse N-alkyl and N-arylalkyl amides from both primary and secondary alcohols. The reaction conditions were tolerant of a variety of functional groups, employed short reaction times and provided good to high yields of the corresponding highly functionalized N-alkylated amides.¹⁵

4.5. Experimental


All chemicals were purchased from Aldrich Chemical Company and used as received unless otherwise noted. Microwave-assisted N-alkylation of amides were carried out using a StartSYNTH multicavity instrument with start rotor from Milestone. The maximum microwave power was 1200 W and the reaction temperature was monitored by an internal infrared sensor. Thin layer chromatography (TLC): silica gel (250 m). Visualization with UV light, iodine or phosphomolybdic acid, Chromatography: silica gel 60 Å (230-400 mesh). ¹H NMR (400 MHz) and ¹³C NMR (100 MHz) were recorded on a Varian-400 MHz nuclear magnetic resonance

spectrometer at ambient temperature in CDCl_3 . ^1H NMR chemical shifts are reported as δ values (ppm) relative to tetramethylsilane. ^{13}C NMR chemical shifts are reported as δ values (ppm) relative to chloroform-*d* (77.0 ppm). Atlantic Microlab, Inc., Norcross, GA performed all CHN microanalyses.

N-Alkylation of Amides with Alcohols

General Procedure The amide (100 mg, 1 equiv), alcohol (3 equiv.) and $(\text{Cp}^*\text{IrCl}_2)_2$ (2.5 mol %) were added to a microwave reactor tube. The reaction mixture was microwaved at 160°C for 3h. The reaction mixture was allowed to cool to room temperature and water (10 mL) was added. The mixture was extracted with EtOAc (3×10 mL). The combined organic layers were dried over Na_2SO_4 and filtered. The solvent was removed under reduced pressure and the residue was purified using flash silica gel chromatography with DCM: CH_3OH (95:5) to furnish the N-alkyl amide.

N-Benzylbenzamide (3aa)¹⁸




The title product was prepared according to the general method using **1a** (100 mg, 0.83 mmol), $(\text{Cp}^*\text{IrCl}_2)_2$ (16 mg, 0.021 mmol) and benzyl alcohol (270 mg, 2.5 mmol). Purification by flash chromatography afforded a white solid; yield: 149 mg (85%); mp $105\text{-}106^\circ\text{C}$ [Lit. $103\text{-}104^\circ\text{C}$].

^1H NMR (400 MHz, CDCl_3): δ 7.79 (d, $J = 7.2$ Hz, 2H), 7.52-7.30 (m, 8H), 6.39 (brs, 1H), 4.65 (d, $J = 5.6$ Hz, 2H).

^{13}C NMR (100 MHz, CDCl_3): δ 44.3, 127.2, 127.8, 128.1, 128.8, 129.0, 131.7, 134.6, 138.4, 167.6.

N-(4-Methylbenzyl) benzamide (3ab) ¹⁹




The final compound was prepared according to the general method using **1a** (100 mg, 0.83 mmol), (Cp*IrCl₂)₂ (16 mg, 0.021 mmol) and **2b** (305 mg, 2.5 mmol). Purification by flash chromatography afforded a white solid; yield: 159 mg (85%); mp 138-140 °C [Lit. 137 °C].

¹H NMR (400 MHz, CDCl₃): δ 7.80 (d, *J* = 7.6 Hz, 2H), 7.49 (t, *J* = 7.2 Hz, 1H), 7.41 (t, *J* = 7.6 Hz, 2H), 7.24 (d, *J* = 8.0 Hz, 2H), 7.16 (d, *J* = 7.6 Hz, 2H), 6.41 (brs, 1H), 4.59 (d, *J* = 5.6 Hz, 2H), 2.34 (s, 3H).

¹³C NMR (100 MHz, CDCl₃): δ 21.3, 44.1, 127.3, 128.2, 128.8, 129.7, 131.7, 134.6, 135.3, 137.6, 167.5.

N-(4-Methoxybenzyl) benzamide (3ac) ¹⁸




The final compound was prepared according to the general method using **1d** (100 mg, 0.83 mmol), (Cp*IrCl₂)₂ (16 mg, 0.021 mmol) and **2c** (350 mg, 2.5 mmol). Purification by flash chromatography afforded a white solid; yield: 144 mg (72%); mp 94-96 °C [Lit. 97-98 °C].

¹H NMR (400 MHz, CDCl₃): δ 7.76 (d, *J* = 8.4 Hz, 2H), 7.48 (t, *J* = 7.2 Hz, 1H), 7.41 (t, *J* = 7.6 Hz, 2H), 7.27 (d, *J* = 8.4 Hz, 2H), 6.87 (d, *J* = 8.4, 2H), 6.40 (brs, 1H), 4.57 (d, *J* = 5.2 Hz, 2H), 3.79 (s, 3H).

^{13}C NMR (100 MHz, CDCl_3): δ 43.8, 55.5, 114.3, 127.1, 128.8, 129.5, 130.4, 131.7, 134.6, 159.3, 167.4.

N-4-Methylthiobenzyl benzamide (3ad)




The final compound was Prepared according to the general method using **1a** (100 mg, 0.83 mmol), $(\text{Cp}^*\text{IrCl}_2)_2$ (16 mg, 0.021 mmol) and **2d** (390 mg, 2.5 mmol). Purification by flash chromatography afforded a white solid; yield: 160 mg (75%); mp 109-110 °C.

^1H NMR (400 MHz, CDCl_3): δ 7.77 (d, $J = 7.6$ Hz, 2H), 7.49 (t, $J = 7.2$ Hz, 1H), 7.40 (t, $J = 7.2$ Hz, 2H), 7.21-7.28 (m, $J = 7.2$ Hz, 2H), 6.47 (brs, 1H), 4.58 (d, $J = 5.6$ Hz, 2H), 2.46 (s, 3H).

^{13}C NMR (100 MHz, CDCl_3): δ 16.1, 43.8, 127.1, 127.2, 128.7, 128.8, 131.8, 134.5, 135.2, 128.0, 167.6.

Anal. Calcd. for $\text{C}_{15}\text{H}_{15}\text{NOS}$: C, 70.01; H, 5.87; N, 5.44. Found: 69.88; H, 5.71; 5.20.

N-4-Trifluoromethylbenzyl benzamide (3ae).²⁰




The final compound was prepared according to the general method using **1a** (100 mg, 0.83 mmol), $(\text{Cp}^*\text{IrCl}_2)_2$ (16 mg, 0.021 mmol) and **2e** (440 mg, 2.5 mmol). Purification by flash chromatography afforded a white solid 179 mg (77%); mp 134-135 °C [Lit.131-134 °C].

¹H NMR (400 MHz, CDCl₃): δ 7.79 (d, *J* = 7.2 Hz, 2H), 7.55 (d, *J* = 8.4 Hz, 2H), 7.48-7.52 (m, 1H), 7.41 (d, *J* = 6.4 Hz, 2H), 7.37-7.38 (m, 2H), 6.91 (brs, 1H), 4.64 (d, *J* = 5.6 Hz, 2H).

¹³C NMR (100 MHz, CDCl₃): δ 43.6, 125.8, 125.9, 127.2, 128.1, 128.8, 132.0, 134.2, 142.6, 167.9.

N-4-Chlorobenzyl benzamide (3ag)¹³




The final compound was prepared according to the general method using **1a** (100 mg, 0.83 mmol), (Cp*IrCl₂)₂ (16 mg, 0.021 mmol) and **2g** (350 mg, 2.5 mmol). Purification by flash chromatography afforded a white solid; yield: 132 mg, (65%); mp 140-142 °C [Lit. 140-143 °C];

¹H NMR (400 MHz, CDCl₃): δ 7.77 (d, *J* = 7.6 Hz, 2H), 7.49 (t, *J* = 7.2 Hz, 1H), 7.39 (t, *J* = 7.6 Hz, 2H), 7.22-7.28 (m, 4H), 6.78 (brs, 1H), 4.55 (d, *J* = 6.0 Hz, 2H).

¹³C NMR (100 MHz, CDCl₃): δ 43.5, 127.2, 128.8, 129.0, 129.3, 131.9, 133.5, 134.3, 137.0, 167.7.

N-(4-Bromobenzyl) benzamide (3ah)²¹




The final compound was prepared according to the general method using **1a** (100 mg, 0.83 mmol), (Cp*IrCl₂)₂ (16 mg, 0.021 mmol) and **2h** (470 mg, 2.5 mmol). Purification by flash chromatography afforded a white solid; yield: 163 mg (68%); mp 140-142 °C [Lit. 144-145 °C].

¹H NMR (400 MHz, CDCl₃): δ 7.76 (d, *J* = 7.2 Hz, 2H), 7.49 (t, *J* = 6.8 Hz, 1H), 7.36-7.42 (m, 4H), 7.16 (d, *J* = 8.0 Hz, 2H), 6.88 (brs, 1H), 4.51 (d, *J* = 6.0 Hz, 2H).

^{13}C NMR (400 MHz, CDCl_3): δ 43.5, 115.5, 121.5, 127.2, 128.8, 129.6, 131.9, 134.3, 137.6, 167.8

***N*-(4-Phenylbenzyl) benzamide (3ai)** ²²




The final compound was prepared according to the general method using **1a** (100 mg, 0.83 mmol), $(\text{Cp}^*\text{IrCl}_2)_2$ (16 mg, 0.021 mmol) and **2i** (220 mg, 2.5 mmol). Purification by flash chromatography afforded a white solid; yield: 143 mg (60%); mp 166-167 °C [Lit. 166.9 – 168.3 °C].

^1H NMR (400 MHz, CDCl_3): δ 7.82 (d, $J = 6.8$ Hz, 2H), 7.59 – 7.52 (m, 4H), 7.49 – 7.35 (m, 6H), 7.33 (d, $J = 7.2$ Hz, 2H), 6.57 (s, 1H), 4.68 (d, $J = 5.6$ Hz, 2H).

^{13}C NMR (100 MHz, CDCl_3): δ 44.1, 127.2, 127.3, 127.6, 127.8, 128.6, 128.8, 129.1, 131.8, 134.6, 137.5, 140.9, 141.0, 167.7.

***N*-Pentylbenzamide (3aj)** ²¹




The final compound was prepared according to the general method using **1a** (100 mg, 0.83 mmol), $(\text{Cp}^*\text{IrCl}_2)_2$ (16 mg, 0.021 mmol) and **2j** (220 mg, 2.5 mmol). Purification by flash chromatography afforded a colorless liquid; yield: 114 mg (72%).

^1H NMR (400 MHz, CDCl_3): δ 7.74 (d, $J = 7.6$ Hz, 2H), 7.44 (t, $J = 7.2$ Hz, 1H), 7.35 (t, $J = 7.6$ Hz, 2H), 6.64 (brs, 1H), 3.35-3.40 (m, 2H), 1.53-1.60 (m, 2H), 1.26-1.31 (m, 4H), 0.86 (t, $J = 6.8$ Hz, 3H).

^{13}C NMR (100 MHz, CDCl_3): δ 14.2, 22.6, 29.3, 29.5, 40.3, 127.1, 128.6, 131.4, 135.0, 167.8.

N-Hexylbenzamide (3ak)²³




The final compound was prepared according to the general method using **1a** (100 mg, 0.83 mmol), $(\text{Cp}^*\text{IrCl}_2)_2$ (16 mg, 0.021 mmol) and **2k** (260 mg, 2.5 mmol). Purification by flash chromatography afforded a white solid; yield: 119 mg (70%); mp 44-45 °C.

^1H NMR (400 MHz, CDCl_3): δ 7.74 (d, J = 8.0 Hz, 2H), 7.43 (t, J = 6.0 Hz, 1H), 7.33-7.41 (m, 2H), 6.64 (brs, 1H), 3.35-3.40 (m, 2H), 1.52-1.59 (m, 2H), 1.26-1.33 (m, 6H), 0.83 (t, J = 6.8 Hz, 3H).

^{13}C NMR (100 MHz, CDCl_3): δ 14.2, 22.7, 26.9, 29.8, 31.7, 40.3, 127.1, 128.6, 131.4, 135.0, 167.8.

N-Benzylacetamide (3ba)²⁴




The final compound was prepared according to the general method using **1b** (100 mg, 1.7 mmol), $(\text{Cp}^*\text{IrCl}_2)_2$ (32 mg, 0.041 mmol) and **2a** (550 mg, 5.1 mmol). Purification by flash chromatography afforded a white solid; yield: 172 mg (68%); mp 58-60 °C [Lit. 61 °C].

^1H NMR (400 MHz, CDCl_3): δ 7.23-7.32 (m, 5H), 6.27 (brs, 1H), 4.35 (d, J = 5.6 Hz, 2H), 1.95 (s, 3H).


^{13}C NMR (100 MHz, CDCl_3): δ 23.3, 43.8, 127.6, 128.0, 128.8, 138.5, 170.4.

N-Benzyl 4-methylbenzamide (3ca)²⁵




The final compound was prepared according to the general method using **1c** (100 mg, 0.74 mmol), (Cp*IrCl₂)₂ (14 mg, 0.019 mmol) and **2a** (240 mg, 2.2 mmol). Purification by flash chromatography afforded a white solid; yield: 133 mg (80%); mp 133-135 °C [Lit. 133-135 °C].
¹H NMR (400 MHz, CDCl₃): δ 7.68 (d, *J* = 8.0 Hz, 2H), 7.25-7.35 (m, 5H), 7.18 (d, *J* = 7.6 Hz, 2H), 6.71 (brs, 1H), 4.58 (d, *J* = 5.6 Hz, 2H), 2.37 (s, 3H).
¹³C NMR (100 MHz, CDCl₃): δ 21.6, 44.21, 127.2, 127.7, 128.0, 128.9, 129.4, 131.7, 138.6, 142.1, 167.6.

N-Benzyl 4-methoxybenzamide (**3da**)²⁶



The final compound was prepared according to the general method using **1d** (100 mg, 0.66 mmol), (Cp*IrCl₂)₂ (13 mg, 0.017 mmol) and **2a** (216 mg, 2.0 mmol). Purification by flash chromatography afforded a white solid; yield: 119 mg (75%); mp 126-128 °C [Lit. 126-128 °C].
¹H NMR (400 MHz, CDCl₃): δ 7.75 (d, *J* = 8.8 Hz, 2H), 7.25-7.33 (m, 5H), 7.88 (d, *J* = 8.8 Hz, 2H), 6.52 (brs, 1H), 4.59 (d, *J* = 5.6 Hz, 2H), 3.82 (s, 3H).
¹³C NMR (100 MHz, CDCl₃): δ 44.2, 55.6, 113.9, 126.8, 127.7, 128.1, 128.9, 129.0, 138.6, 162.4, 167.1.

N-Benzyl-4-chlorobenzamide (**3ea**)²⁵




The final compound was prepared according to the general method using **1e** (100 mg, 0.65 mmol), (Cp*IrCl₂)₂ (12 mg, 0.016 mmol) and **2a** (216 mg, 2.0 mmol). Purification by flash chromatography afforded a white solid; yield: 121 mg (76%); mp 162-164 °C [Lit. 162 °C].

¹H NMR (400 MHz, CDCl₃): δ 7.72 (dd, *J* = 6.4 Hz, *J* = 2.0 Hz, 2H), 7.27-7.40 (m, 7H), 6.47 (brs, 1H), 4.62 (d, *J* = 5.6 Hz, 2H).

¹³C NMR (100 MHz, CDCl₃): δ 44.5, 127.9, 128.6, 129.0, 132.9, 138.0, 138.1, 166.5.

N-Benzyl-3, 5-dimethoxybenzamide (3fa) ²⁶




The final compound was prepared according to the general method using **1f** (100 mg, 0.55 mmol), (Cp*IrCl₂)₂ (11 mg, 0.014 mmol) and **2a** (180 mg, 2.5 mmol). Purification by flash chromatography afforded a white solid; yield: 117 mg (78%); mp 125-126 °C.

¹H NMR (400 MHz, CDCl₃): δ 7.25-7.33 (m, 5H), 6.91 (d, *J* = 2.0 Hz, 2H) 6.59 (brs, 1H), 6.55 (t, *J* = 2.0 Hz, 1H), 4.59 (d, *J* = 6.0 Hz, 2H), 3.78 (s, 6H).

¹³C NMR (100 MHz, CDCl₃): δ 44.3, 55.7, 103.8, 105.1, 127.8, 128.1, 132.8, 136.8, 138.3, 161.1, 167.4.

N-(Pentan-2-yl) benzamide (3al) ²⁷




The final compound was prepared according to the general method using **1a** (100 mg, 0.83 mmol), (Cp*IrCl₂)₂ (16 mg, 0.021 mmol) and **2l** (220 mg, 2.5 mmol). Purification by flash chromatography afforded a colorless liquid; yield: 108 mg (68%).

¹H NMR (400 MHz, CDCl₃): δ 7.74 (d, *J* = 7.2 Hz, 2H), 7.42 (t, *J* = 7.2 Hz, 1H), 7.35 (t, *J* = 7.2 Hz, 2H), 6.58 (brs, 1H), 3.42 (q, *J* = 6.0 Hz, 2H), 1.59-1.64 (m, 1H), 1.45 (q, *J* = 6.4 Hz, 2H), 0.88-0.90 (m, 6H).

¹H NMR (100 MHz, CDCl₃): δ 22.7, 26.1, 38.6, 38.6, 127.1, 128.6, 131.4, 135.0, 167.8

N-(1-Phenylpropan-2-yl) benzamide (3am) ²⁹




The final compound was prepared according to the general method using **1a** (100 mg, 0.83 mmol), (Cp*IrCl₂)₂ (16 mg, 0.021 mmol) and **2m** (340 mg, 2.5 mmol). Purification by flash chromatography afforded a white solid; yield: 143 mg (72%); mp 127-129 °C.

¹H NMR (400 MHz, CDCl₃): δ 7.68 (d, *J* = 8.0 Hz, 2H), 7.48 (d, *J* = 7.2 Hz, 1H), 7.40 (d, *J* = 7.6 Hz, 2H), 7.31 (t, *J* = 7.2 Hz, 2H), 7.24 (t, *J* = 7.6 Hz, 3H), 5.91 (brs, 1H), 4.46-4.49 (m, 1H), 2.83-2.97 (m, 2H), 1.21 (d, *J* = 6.8 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃): δ 20.2, 42.5, 46.6, 126.7, 126.9, 128.6, 128.7, 129.7, 131.5, 135.0, 138.0, 166.9.

N-(1-Phenylbutan-3-yl) benzamide (3an) ³¹




The final compound was prepared according to the general method using **1a** (100 mg, 0.83 mmol), (Cp*IrCl₂)₂ (16 mg, 0.021 mmol) and **2n** (375 mg, 2.5 mmol). Purification by flash chromatography afforded a white solid; yield: 136 mg (65%); mp 117-119 °C.

¹H NMR (400 MHz, CDCl₃): δ 7.68 (d, *J* = 7.6 Hz, 2H), 7.46-7.49 (t, *J* = 8.0 Hz, 1H), 7.40 (t, *J* = 7.6 Hz, 2H), 7.27 (t, *J* = 7.6 Hz, 2H), 7.18 (t, *J* = 6.8 Hz, 3H), 5.93 (brs, 1H), 4.26-4.30 (m, 1H), 2.70-2.74 (m, 2H), 1.86-1.92 (m, 2H), 1.28 (d, *J* = 6.8 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃): δ 21.3, 32.7, 38.8, 45.9, 126.2, 127.0, 128.6, 128.7, 131.5, 135.1, 141.9, 167.0.

N-(Cyclopentyl) benzamide (3ao)²⁸




The final compound was prepared according to the general method using **1a** (100 mg, 0.83 mmol), (Cp*IrCl₂)₂ (16 mg, 0.021 mmol) and **2o** (215 mg, 2.5 mmol). Purification by flash chromatography afforded a white solid; yield: 122 mg (78%); mp 158-160°C [Lit. 160-162 °C].

¹H NMR (400 MHz, CDCl₃): δ 7.73 (d, *J* = 7.2 Hz, 2H), 7.46 (t, *J* = 8.0 Hz, 1H), 7.40 (d, *J* = 8.0 Hz, 2H), 6.53 (brs, 1H), 4.37-4.41 (m, 1H), 2.06-2.10 (m, 2H), 1.63-1.77 (m, 4H), 1.47-1.64 (m, 2H).

¹³C NMR (100 MHz, CDCl₃): δ 24.0, 33.4, 51.9, 127.0, 128.7, 131.4, 135.1, 167.4.

N-Cyclohexylbenzamide (5ap)³³




The final compound was prepared according to the general method using **1a** (100 mg, 0.83 mmol), (Cp*IrCl₂)₂ (16 mg, 0.021 mmol) and **2p** (250 mg, 2.5 mmol). Purification by flash chromatography afforded a white solid; yield: 128 mg (76%); mp 152-154 °C [Lit. 152-154 °C].

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ = 7.74 (d, J = 7.2 Hz, 2H), 7.47 (t, J = 7.2 Hz, 1H), 7.40 (t, J = 7.2 Hz, 2H), 5.98 (brs, 1H), 3.95-3.99 (m, 1H), 2.05-2.04 (m, 2H), 1.63-1.77 (m, 4H), 1.18-1.47 (m, 5H).

$^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ = 25.1, 25.7, 33.4, 48.9, 127.0, 128.7, 131.4, 135.3, 166.8.

N-[(4-Chlorophenyl) (phenyl) methyl]-benzamide (3aq)³⁴




The final compound was prepared according to the general method using **1a** (100 mg, 0.83 mmol), $(\text{Cp}^*\text{IrCl}_2)_2$ (16 mg, 0.021 mmol) and **2q** (545 mg, 2.5 mmol). Purification by flash chromatography afforded a white solid; yield: 173 mg (65%)

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.78 (d, J = 7.6 Hz, 2H), 7.50 (t, J = 7.6 Hz, 1H), 7.41 (t, J = 8.0 Hz, 2H), 7.21-7.35 (m, 8H), 6.80 (d, J = 7.6 Hz, 1H), 6.38 (d, J = 7.6 Hz, 1H).

$^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 57.1, 115.5, 127.3, 127.8, 128.0, 128.8, 129.0, 129.0, 129.1, 132.0, 134.2, 140.2, 141.1, 166.8.

N-Bis (4-fluorophenyl) methylbenzamide (3ar)²⁵



The final compound was prepared according to the general method using **1a** (100 mg, 0.83 mmol), $(\text{Cp}^*\text{IrCl}_2)_2$ (16 mg, 0.021 mmol) and **2r** (550 mg, 2.5 mmol). Purification by flash chromatography afforded a white solid; yield: 174 mg (65%); mp 177-179 °C.

¹H NMR (400 MHz, CDCl₃): δ 7.79 (d, *J* = 8.0 Hz, 2H), 7.52 (t, *J* = 8.0 Hz, 1H), 7.42 (t, *J* = 7.6 Hz, 2H), 7.22-7.05 (m, 4H), 7.02 (t, *J* = 8.4 Hz, 4H), 6.65 (brs, 1H), 6.39 (d, *J* = 7.6 Hz, 2H). **¹³C NMR (100 MHz, CDCl₃):** δ 56.4, 115.8, 116.0, 127.2, 128.9, 129.3, 129.3, 132.1, 134.1, 137.2, 137.2, 163.6

4.6. References

- (1) Greene, T. W.; Wuts, P. G. M. *Greene's Protective Groups in Organic Synthesis*, 4th Ed.; John Wiley & Sons, Inc.: Hoboken, NJ, **2007** and references cited therein.
- (2) Valeur, E.; Bradley, M. Amide bond formation: beyond the myth of coupling reagents *Chem. Soc. Rev.* **2009**, *38*, 606.
- (3) Montalbetti, C. A. G. N.; Falque, V. Amide bond formation and peptide coupling *Tetrahedron*, **2005**, *61*, 10827.
- (4) Dobereiner, G. E.; Crabtree, R. H. Dehydrogenation as a substrate-activating strategy in homogeneous transition-metal catalysis *Chem. Rev.* **2010**, *110*, 681.
- (5) Guillena, G.; Ramon, D. J.; Yus, M. Alcohols as electrophiles in C-C bond-forming reactions: The hydrogen autotransfer process. *Angew. Chem. Int. Ed.* **2007**, *46*, 2358.
- (6) Guillena, G. Ramon, D. J.; Yus, M. Dehydrogenation as a Substrate-Activating Strategy in Homogeneous Transition-Metal Catalysis. *Chem. Rev.* 2010, *110*, 681.
- (7) Nixon, T. D.; Whittlesey, M. K.; Williams, J. M. J. Transition metal catalysed reactions of alcohols using borrowing hydrogen methodology. *Dalton Trans.* **2009**, *38*, 753.
- (8) Watanabe, Y.; Ohta, T.; Tsuji, Y. Ruthenium catalyzed N-alkylation of amides with alcohols. *Bull. Chem. Soc. Jpn.* **1983**, *56*, 2647-2651.
- (9) Jenner, G. Ruthenium catalyzed N-alkylation of amides with alcohols. *J. Mol. Catal.* **1989**, *55*, 241.
- (10) Fujita, K.; Komatsubara, A.; Yamaguchi, R. N-alkylation of carbamates and amides with alcohols catalyzed by a Cp*Ir complex. *Tetrahedron* **2009**, *65*, 3624.

- (11) Liu, C.; Liao, S.; Li, Q.; Feng, S.; Sun, Q.; Yu, X.; Xu, Q.; Discovery and mechanistic studies of a general air-Promoted Metal-Catalyzed Aerobic *N*-Alkylation Reaction of Amides and Amines with Alcohols. *J. Org. Chem.* **2011**, *76*, 5759.
- (12) Watson, A. J. A.; Maxwell, A. C.; Williams, J. M. J. Borrowing Hydrogen Methodology for Amine Synthesis under Solvent-Free Microwave Conditions. *J. Org. Chem.* **2011**, *76*, 2328.
- (13) Miao, L.; DiMaggio, S.; Shu, H.; Trudell, M. L. Enantioselective Syntheses of Both Enantiomers of Noranabasamine. *Org. Lett.* **2009**, *11*, 1579.
- (14) Apsunde, T. D.; Trudell, M. L. Microwave-Assisted Iridium-Catalyzed Synthesis of Nicotine and Anabasine Derivatives. *Synthesis* **2013**, *45*, 2120-2114.
- (15) Apsunde, T. D.; Trudell, M. L. Solvent-Free, Base-Free Microwave-Mediated Iridium-Catalyzed *N*-Alkylation of Amides with Alcohols. *Synthesis*, **2014**, *46*, 230-234
- (16) Fujita K.; Li, Z.; Ozeki, N. Yamaguchi, R. *N*-Alkylation of amines with alcohols catalyzed by a Cp*Ir complex. *Tetrahedron Lett.* **2003**, *44*, 2687.
- (17) Fujita, K.; Enoki, Y.; Yamaguchi, R. Cp*Ir-catalyzed *N*-alkylation of amines with alcohols-A versatile and atom economical method for the synthesis of amines. *Tetrahedron* **2008**, *64*, 1943.
- (18) Molander, G. A.; Hiebel, M. A. Synthesis of Amidomethyltrifluoroborates and Their Use in Cross-Coupling Reactions *Org. Lett.* **2010**, *12*, 4876.
- (19) Maki, T.; Ishihara, K.; Yamamoto, H. 4, 5, 6, 7-Tetrachlorobenzo[*d*][1,3,2]dioxaborol-2-ol as an Effective Catalyst for the Amide Condensation of Sterically Demanding Carboxylic Acids. *Org. Lett.* **2006**, *8*, 1431.

- (20) Rubio-Perez L.; Sharma, P.; Perez-Flores, J.; Velasco, L.; Aries, J. L.; Cabrera, A. One-pot stibine modified $\text{Co}_2(\text{CO})_8$ catalyzed reductive N-alkylation of primary amides with carbonyl compounds *Tetrahedron* **2012**, *10*, 2342.
- (21) Melsa, P.; Cajan, M.; Havlas, Z.; Mazal, C.; Substituent Effect on *exo*-Stereoselectivity in the 1,3-Dipolar Cycloaddition Reaction of Tulipalin A with Nitrile ylides. *J. Org. Chem.* **2008**, *73*, 3032.
- (22) Kulkarni, S. S.; Hu, X.;Mantsch, R.; A simple base-mediated amidation of aldehydes with azides. *Syn. Commun.* **2013**, *49*, 119.
- (23) Hicks, J. D.; Hyde, A. M.; Cuezva, A. M.; Buchwald, S. L. Pd-Catalyzed N-Arylation of Secondary Acyclic Amides: Catalyst Development, Scope, and Computational Study. *J. Am. Chem. Soc.* **2009**, *131*, 16720.
- (24) Ishihara, K.; Yano, T. Synthesis of Carboxamides by LDA-Catalyzed Haller–Bauer and Cannizzaro Reactions. *Org. Lett.* **2004**, *6*, 1983
- (25) Al-Musum, M.; Wai, M. C.; Dunnenberg, H. Solvent Free C-Benzoylation and N-Benzoylation Reactions Using Microwave Heating. *Syn. Commun.* **2011**, *41*, 2888.
- (26) Cho, S. J.; Roh, J. S.; Sun, W. S.; Kim S. H.; Park, K. D. *N*-Benzylbenzamides: A new class of potent tyrosinase inhibitors. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 2682.
- (27) Hayashi, S.; Nair, M.; Houser, D. J.; Shechter, H. The behavior of 1-(5-oxazolyl)-1-alkylidenes and 1-(5-isoxazolyl)-1-alkylidenes. *Tetrahedron Lett.* **1979**, *20*, 2961.
- (28) Werry, J.; Stamm, H.; Lin, P. Y.; Falkenstein, R.; Gries, S.; Irngartinger, H. Homolytic aziridine opening (aza variant of cyclopropylcarbinyl-homoallyl rearrangement) by addition of tributyltin radical to N-acylaziridines. Factors contributing to the regioselectivity. *Tetrahedron* **1989**, *45*, 5015.

- (29) Jiang, H.; Liu, B.; Li, Y.; Wang, A.; Huang, H. N-Acyl- β -phenethylamines, and a New Isoquinoline Synthesis. *Org. Lett.* 2011, *13*, 1028.
- (30) Jo, Y.; Ju, J.; Choe, J.; Song, K. H.; Lee, S. The Scope and Limitation of Nickel-Catalyzed Aminocarbonylation of Aryl Bromides from Formamide Derivatives. *J. Org. Chem.* **2009**, *74*, 6358.

VITA

Tushar Apsunde was born in city Nashik, Maharashtra, India on April 25, 1986. He graduated from N.D.M.V.P Samaj's Arts, Science And Commerce College, Nashik, India in June 2003. He received his bachelor in Pharmacy at the M. G.V's Pharmacy college Nashik, India in June 2007. He received his M.S. at National Institute of Pharmaceutical education and Research, Mohali, India in May 2009. He continued his education at the University of New Orleans to pursue a PhD degree in organic synthesis under the supervision of Professor Mark L. Trudell in 2009. He went on to complete the requirements for this degree in August 2014.